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Chapter 1 
 
General introduction 
 
1.1 Biomolecular surface recognition by multivalent abiotic ligands.  
 
Reversible interactions, based on recognition between biological 
macromolecules are essential for the regulation of biochemical processes: 
Inside the cells, proteins rarely act alone, but interact instead with each 
other, assembled in complexes either homo-oligomeric or formed by 
several different components (1). Outside the cell, processes like cell 
recognition, endocytosis or drug internalization are mediated by surface 
recognition on the cell membrane. Therefore studying the principles of 
biomolecular surface interactions allow for both prediction and mimicry of 
molecular recognition and represent an important class of targets for human 
therapeutics (2). 
 
From a physico-chemical point of view biomolecular interactions rely on 
the complementary association between functional groups through 
noncovalent interactions of hydrophobic or electrostatic nature, as well as 
on hydrogen bonds. Based on the site of association two types of 
recognition may be distinguished: one which takes place at the cavity of a 
biological macromolecule, such as the one between an enzyme and its 
substrate, and another which takes place at its surface, like the recognition 
of an antigen by its antibody. The difference between them lies in the fact 
that a substrate -generally highly functionalized- is recognized in a reduced 
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cavity free from solvent molecules, while interactions at protein or 
membrane surfaces have a divergent character and compete against the 
solvent (3). 
 
Nevertheless, the recognition of protein surfaces by designed ligands is 
nowadays a current pursuit in drug discovery (4), and a formidable 
challenge as well, since the lack of characteristic features, the large 
extension, the planarity or the discontinuity of protein surfaces and protein-
protein interfaces, coupled with their conformational flexibility and 
dynamic behavior (5), make it difficult to establish general rules for the 
selective attachment of suitable ligands to the target biomolecules. Still, 
there are a number of strategies that address the rational design of 
molecules capable of recognizing surfaces or disrupting interfaces of 
proteins (6), many of them supported by computational methods (7). 
 
Generally, chemists seek for an optimized matching of non covalent 
interactions between the ligand and the biological target for efficient drug 
design (8). However, a general problem in supramolecular chemistry is that 
molecular recognition is based on noncovalent interactions which in 
contrast to covalent bonds are highly dependent on external parameters 
such as solvent composition, polarity or even temperature. In this context 
water as a solvent is the most challenging parameter. On the one hand, 
electrostatic interactions (H-bonds or ion pairs), which are quite well 
understood and have been extensively used in supramolecular systems, are 
rather weak in this solvent (9). On the other hand, hydrophobic or aromatic 
interactions, which can be rather strong in aqueous solvents, are much more 
difficult to predict by design and to use in artificial receptors (10).  
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Recently, a new concept, multivalency, has gained importance to 
overcome the intrinsic limitations of small noncovalent abiotic surface 
ligands. Multivalency which is the ability of a particle (or molecule) to bind 
another one via multiple simultaneous noncovalent interactions. In this 
case, the valency refers to the number of functional groups of the same type 
that are bound to the same scaffold and participate simultaneously in the 
binding event (Fig. 1.1) (11).  
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: Monovalent vs multivalent complex formation, 
reproduced from ref. 8. 
 
In fact, multivalency is widely represented in nature, where relatively 
weak interactions (e.g. carbohydrate-protein) are converted into strong and 
specific recognition events, which control essential biological processes 
such as the adhesion of cells, viruses/bacteria or antibodies/macrophages to 
the cell surface (12). Moreover, multivalency has several and attractive 
features in common to the supramolecular concepts of self-assembly, 
reversibility, complementarity, molecular recognition, effective molarity, 
monovalent
receptor
monovalent
Ligand
monovalent
complex
multivalent
receptor
multivalent
ligand
multivalent
complex
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and effective concentration (13). Actually, in biomimetic approaches to 
drug design, application of multivalency has already allowed the 
development of therapeutic agents able to neutralize bacterial toxins or to 
prevent viral or bacterial infections (14). Scaffolds of diverse structure, 
flexibility, and valency have been proposed as artificial multivalent ligands 
for these interfaces (Fig. 1.2) (15).  
 
Relevant examples of low valency multivalent scaffolds range from small 
C2 and C4 symmetric porphyrin ligands (16) and calix[4]arenes (see 
chapters 2 and 3) to similar aromatic scaffolds such as anthracenes (17), 
DNA-quadruplex (18), and cyclophanes (19), Fig. 1.2a.  
 
a) 
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b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: Examples of multivalent scaffolds of low (a) and high 
valency (b) designed to allow biological interactions through 
multivalent contacts, from reference 14. 
 
Among the high valency multivalent scaffolds are dendrimers that 
provide promising adherence-inhibition for toxins and other relevant lectins 
(20). In addition, highly flexible supramolecular platforms like rotaxanes 
(21) and polymers (22) have been proposed as challenging alternatives to 
more rigid designs. Finally, even nanoparticles are being exploited for this 
aim as they present important advantages from the biological and synthetic 
points of view (Fig. 1.2b) (23). 
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Besides the topology of the scaffold and the flexibility of the linkers, the 
strength of the noncovalent forces involved and the number of binding 
elements -also called recognition elements (REs)- are key aspects of the 
synergistic recognition event. 
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1.2 The guanidinium group: An efficient recognition element for 
surface association.  
  
Each protein or membrane surface has a unique exterior composed of 
charged, hydrophobic and hydrophilic elements, but all association 
processes are determined by the thermodynamic aspects of the ligand-
surface association and the relative importance of enthalpy, entropy and 
heat capacity effects in stabilizing complex formation (24). Though it is 
accepted that hydrophobic interactions generally provide the key driving 
force for complex formation on water-solvated surfaces, electrostatic 
associations also play an important role, as they often confer specificity to 
the binding process (5a). 
 
Certain amino acid residues, particularly tryptophan (21%), arginine 
(13%), and tyrosine (12%) appear more frequently in hot spots of protein 
surfaces. The enrichment of these surfaces on cationic and aromatic amino 
acid residues is a result of their contribution to the binding energy through 
hydrophobic effects and electrostatic interactions, without a substantial 
entropic penalty, as they have fewer rotable bonds.  
 
In particular, the guanidine functional group is widely spread as mediator 
of specific molecular recognition events in nature (25), some of which are 
shown herein:  
 
Guanidine appears as a carboxylate binding element in the active site of 
enzymes such as carboxypeptidase A (Fig. 1.3) (26), creatine kinase (27), 
fumarate reductase (28), and malate dehydrogenase (29). 
Multivalent guanidinium scaffolds 
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Fig. 1.3 Binding of an inhibitor (benzyl glutamic acid) within 
the active site of carboxypeptidase A. The carboxylate forms an 
ion pair with the Arg145 guanidinium cation. Two additional H-
bonds from Asn144 and Tyr248 further stabilize the complex 
(reproduced from ref. 25b).  
 
Furthermore, it has a major role in the condensation of DNA through 
arginine-rich histones. Part of these arginines stabilize histone-histone 
interactions essential for nucleosome formation, while another part directly 
associates with the phosphodiester groups of DNA, both interactions being 
essential for nucleosome formation (30). Moreover, methylation of 
arginines in the histone core leads to conformational changes which 
ultimately regulate gene expression (31).  
 
Binding of phosphorylated serines via guanidine at arginine side chains, 
further mediates protein-protein heterodimerization processes between 
receptors at the cell membrane (32). A related case is the involvement of 
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the guanidinium group in the cell-cell and cell-matrix adhesion via the 
RGD (arginine-glycine-aspartate) motif, identified in a variety of biological 
processes such as bone mineralization or cancer metastasis (33). Finally, the 
guanidine functional group also constitutes an essential base pairing 
element in nucleic acids, taking into account that guanine is formally an 
acylated guanidine (Fig. 1.4b).  
 
The properties of the guanidinium functional group that, besides the alkyl 
chain, do account for arginines’ importance, rely on high basicity (pKa: 
~13), causing the group to stay protonated throughout a wide pH range. Its 
positive charge is stabilized by delocalization over the three nitrogen atoms 
and four out of the five hydrogen bond donors present in the guanidinium 
group of arginine can complement bidentate oxoanion acceptors, along the 
two available edges (Fig. 1.4a). Thus, both ion-pairing and hydrogen 
bonding account for its high oxoanion binding ability. 
 
 
Fig. 1.4: (a) The guanidnium group of arginine and its two 
possible binding modes. (b) G-C base pairing with highlighted 
acylated guanidinium integrated in guanine structure. 
 
However, as already mentioned, a guanidinium-oxoanion pair is only 
stable in solvents of low polarity while highly unstable in aqueous media, 
Multivalent guanidinium scaffolds 
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unless shielded with an hydrophobic pocket. For example, the lactate-
guanidinium ion pair has a stability of only Ka ≤ 6 M-1 in water (34). 
 
Nevertheless, inspired in nature’s use of arginine, a number of abiotic 
supramolecular host systems based on guanidines have been designed in the 
last decades (35). Examples of receptors for phosphate (36), carboxylates 
(37), and sulfates (38), have paved the way for bioorganic receptors able to 
associate to citrate (Fig. 1.5a) (39), amino acids (Fig. 1.5b) (40), dipeptides 
(41) and even oligopeptides (Fig. 1.5c) (42) in aqueous media.  
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Fig. 1.5: (a) Anslyn’s guanidinium receptor I forms stable 
complexes with citrate II in water, due to the triple ion-pair 
formation. (b) de Mendoza’s bicyclic guanidinium receptor III 
for D-tryptophan. (c) Schmuck’s lead compound IV, from a 
tripeptide based library of cationic guanidiniocarbonyl pyrrole 
receptors, binds the C-terminus tetrapeptide of Aβ (V). 
 
In these examples the substantial decrease of binding in water is 
overcome by increasing the number of recognition elements (multivalency), 
combining different noncovalent interactions (Gulliver effect) or by 
designing more sophisticated ligands with restricted solvent access (43).  
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Initial efforts from supramolecular chemists in the area of surface protein 
recognition concentrated on the design of small molecules able to associate 
to functional side chains located at positions typical of secondary structures 
such as α-helices. Compound VI (Fig. 1.6), represents a concave scaffold 
that orients two guanidinium subunits to interact with two aspartates of 
model peptide VII in i(i + 3) positions (Ka = 2200 M-1 in 10% water-
methanol, NMR titrations) (44). Analogous peptides with aspartates in i(i + 
4) and i(i + 11) positions, gave weaker complexes (Ka = 770 and 390 M-1, 
respectively).  
H
H
NN
N
N
H
H
H
H
HH
N
N H
H
H
H
VI
VII : Ac-Ala-Ala-Gln-Asp-Ala-Ala-Asp-Ala-Ala-Ala-Ala-Ala-Gln-Ala-Ala-Tyr-NH2
 
Fig. 1.6: Compound VI and model peptide VII. 
 
Peptide VII was designed to possess a significant α-helical character, a 
necessary condition to establish ion-pairs with VI, because in this 
conformation the carboxylates are spaced 4-5 Å in an approximate parallel 
arrangement, so they can interact with the guanidinium groups of the 
receptor (Fig. 1.7) (45). 
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Fig. 1.7: Schematic representation of rigid receptor VI binding 
to an α-helical representation of peptide VII (from ref. 45).  
 
Further oligoguanidinium based protein surface ligands synthesized and 
evaluated by the group of de Mendoza and coll. are described in section 2.3. 
Moreover, due to the high density of oxoanions on the cell membrane, 
oligo- and polyguanidiniums constitute a versatile source of cell 
permeabilizing and transfection agents (46). The nature of the scaffold, the 
number and spacing between the guanidine moeities, as well as the 
flexibility and topology of the overall polycationic molecules, are some of 
the parameters that influence cell uptake and are further explained in 
section 4.1.  
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1.3 Objectives of the thesis 
 
The aims of these thesis are rational design of protein surface ligands 
combining guanidine recognition elements with the preassembled 
supramolecular calix[4]arene scaffold, and the methodological proposal of 
a solid-phase synthetic strategy for bicyclic guanidinium oligomers. 
 
1.3.1 Guanidiniocalix[4]arenes for designed protein surface 
interactions  
 
In chapters 2 and 3 we describe the design, synthesis, computational 
modelling, and biophysical evaluation of guanidiniocalix[4]arene ligands 
for two different protein surfaces. 
 
1.3.1.1 Stabilizing ligands for p53TD 
 
Conical ligands 1a and 1b, designed to associate and stabilize the 
tetrameric structure of p53 as well as its mutant p53R337H with deffective 
association properties will be presented in Chapter 2, besides controls 2a 
and 2b (Fig. 1.8). 
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Fig. 1.8: Ligands for p53TD surface described in Chapter 2. 
 
1.3.1.2 Conical molecular blockers of voltage-dependent K+ 
channels 
 
With the aim to identify reversible inhibitors of the voltage dependent K+ 
channel family Kv1, we synthesized the small series of ligands 3-14, with 
cationic, neutral and negatively charged ligands (Fig. 1.9). Their synthesis 
and blocker activity are described in Chapter 3. 
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Fig. 1.9: Small series of potential Kv1 blockers presented in Chapter 3. 
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1.3.2 Solid phase synthesis of bicyclic guanidinium oligomers 
 
In Chapter 4 we describe the development of a solid phase strategy to 
obtain a series of cell vectors based on bicyclic oligoguanidinium scaffolds. 
Several bicyclic guanidinium building blocks (15-20, Fig. 1.10a) as well as 
different resins were employed for this purpose (Fig. 1.10b). 
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b) 
 
 
Fig. 1.10: Bicyclic building blocks (a) and resins (b) described in 
Chapter 4. 
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Chapter 2 
 
Guanidilated calix[4]arene ligands for p53 tetramerization 
domain (p53TD) 
 
 2.1 Multivalent ligands based on calix[4]arenes 
 
Calix[4]arenes have become one of the most popular scaffolds employed 
in the design of ligands for biomolecular recognition and 
bionanotechnology. Calix[n]arenes are synthetic macrocycles derived from 
the condensation of phenol and formaldehyde (1). Its chemistry is well 
established; depending on the experimental conditions, they can be formed 
by four to eight aromatic units arranged cyclically and linked by methylene 
bridges. In their conical conformation, they display basket-like structures 
with wider and narrower edges (upper and lower rims) as shown in Fig. 2.1.  
 
 
 
Fig. 2.1: Calix[n]arenes. The cone conformation is represented at the left. 
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Depending on the reaction conditions and the bulkiness of the O-
substituents at the lower rim, the macrocycles can be freezed in one of their 
conformations, exemplified on calix[4]arenes in Fig. 2.2 (2).  
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Fig. 2.2: Chemical representation of (a) cone, (b) partial cone, 
(c) 1,3 alternate and (d) 1,2 alternate conformation of 
calix[4]arenes. 
 
Traditionally, calix[n]arenes, like cyclodextrins and crown ethers, have 
played a central role in supramolecular chemistry, as hosts or model 
receptors for ions and neutral molecules, or guests (3). Thereafter, they 
have found applications in the construction of electrodes, selective 
membranes, and sensors for analytical applications (4). Moreover, they 
have been applied recently for the solubilization of molecules of 
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biopharmaceutical interest (5), as well as in medical diagnosis (6), and even 
in nuclear waste decontamination (7). 
 
Furthermore, calix[4]arenes have been exploited as multivalent ligands, 
with the upper rim of the conical platform as the main scaffold to bear 
several covalent connections to the peripheral ligating units, also called 
recognition elements (REs). These classical supramolecular molecules 
present several advantages in the multivalent approach towards drug 
design: First, they constitute a scaffold with multiple reactive positions that 
can be functionalized selectively. Second, flexibility of the macrocycle and 
stereochemical orientation of the ligating arms can be tuned by selecting the 
proper calix[n]arene (n = 4-8) and shaping the macrocycle in one of its 
possible conformations (Figs. 2.1 and 2.2). Third, efficient procedures are 
nowadays available to easily functionalize both the lower and the upper rim 
with most of the functional groups usually employed for conjugation of 
RE’s (-NH2, -CHO, -CO2H, -NCS, -C≡C) (8).  
 
In fact, multifunctional calix[4]arenes have already been successfully 
employed as biomimetic receptors for drug encapsulation (9), as building 
blocks for nanostructures or protein inmobilization on microarrays (10), as 
DNA transfection agents (11), and as modulators of several biological 
processes (protein inhibitors and protein surface binders), as summarized in 
Fig. 2.3 (12).  
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Fig. 2.3: Multivalent calixarene ligands in drug 
design and bionanotechnology (ref. 12). 
 
In the context of protein surface recognition (see Chapter 1), extensive 
work has been reported by Hamilton and co-workers. In their search for 
specific ligands for positively charged protein surfaces, they developed 
calix[4]arene ligands for cytochrome C (Cyt C) (13), chymotrypsin (14), 
and platelet derived growth factor (PDGF) (15). They identified a powerful 
pharmacological agent, from a second generation library of multivalent 
calix[4]arene derivatives, which blocks the function of PDGF and VEGF 
(vascular endothelial growth factor), simultaneously inhibiting initiation 
and maintenance of blood vessels around a tumor (16). This conical ligand, 
GFB204, endowed with polar and non polar cyclopeptides, was further 
optimized by replacing its peptidic loops by isophthalate groups with 
similar polarity: GFB111 (Fig. 2.4) (17). Finally, systematic modifications 
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of the number of upper rim elements, the linker to the calixarene scaffold 
and the O-substituents in the narrower edge led to a simplified ligand 
endowed with three isophthalate groups and OH-free phenols (Fig. 2.4) 
(18).  
a) 
 
 
 
 
 
 
 
                        GFB111                                                  GFB204     
b) 
 
 
 
 
 
 
 
 
Fig. 2.4: a) GFB111 structure and systematic modifications on 
GFB204 scaffold. b) Docking between a GFB204-derived 
ligand with diazo linkers, three isophthalate arms and four free 
OH groups, carried out using GOLD (Goldscore fitness 
function). Graph was generated using WebLab Viewer Pro 
(from ref. 18). 
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A series of conical peptidocalix[4]arene regioisomers were conceived by 
Neri et al. to target the surface of transglutaminase, a crucial enzyme in 
Huntington disease (19). Competition assays suggested that inhibitors bind 
to a hot spot of the proteins’ surface, rather than to the active site, thus 
exerting their inhibitory effects either by causing a conformational change 
in the protein or by hindering the approach of the enzyme’s substrate. 
 
Conical and 1,3-alternate calix[n]arenes functionalized with sugars have 
been exploited by the group of Ungaro et al. as scaffolds to target lectins 
(20). These are proteins able to recognize carbohydrates on glycoproteins 
present on the cell surface and responsible for recognition and entry of 
pathogens into cells. Recently, these authors prepared an array of 
calix[n]arenes presenting spacered galactose and lactose moieties and 
analyzed their reactivity towards a plant toxin and several human galectins 
(Fig. 2.5). Interestingly, bioassays revealed difference in selectivity for the 
different galectins and dependence of inhibition on the conformational 
properties of the calix[n]arene scaffold, as well as on the shape and valency 
of the glycoclusters (21). 
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Fig. 2.5: Scheme of one of the series of sugar bound-
calix[4]rene ligands developed for galectin recognition.  
 
Furthermore, in collaboration with Bernardi’s research group, they 
designed a conical calix[4]arene ligand for cholera toxin (CT), the 
pathogenic lectin causing the cholera disease (22). Efficient inhibition 
through adherence (IC50 of 0.048 µM) was obtained through a divalent 
ligand I with two opposite subunits of a mimic of the natural 
pentasaccharide o-GM1 (pseudo o-GM1) recognized by CT and linked to 
the scaffold through a flexible polyethyleneglycol spacer (Fig. 2.6). 
 
Guanidilated calix[4]arene ligands for p53 tetramerization domain (p53TD) 
 32 
 
Fig. 2.6: CT ligand I based on a pseudo o-GM1-attachment to a 
conical calix[4]arene. 
 
 
In an effort to bind tryptase -a key enzyme involved in allergic and 
inflammatory responses- Cunsolo and co-workers synthesized positively 
charged competitive inhibitors of the tetrameric protein. These flexible 
macrocycles based on peptidocalix[8]arenes have shown to bind to aspartic 
residues near the active site (23).  
 
Ligands for heparin, based on the same multivalent scaffold, were also 
developed. Initial lead compounds effectively disrupted the heparin-protein 
binding event underpinning blood coagulation cascade (24). Similar 
macrocycles called calix[n]resorcarenes or resorcinarenes were exploited 
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by the group of Aoyama to target cell specific adhesion and transfection 
through proteoglycan mimicry (25). Calix[4]resorcarenes (cyclic oligomers 
obtained by reacting resorcinol with aldehydes), functionalized with one to 
four chondroitin sulfate polysaccharides on their upper rim, inhibit cell 
adhesion with nanomolar affinity. In addition, lactose functionalized 
macrocycles form glycoclusters of viral size (4-5 nm) and show specific 
targeting of hepatocytes via multiple saccharide-receptor interactions and 
transfection of reporter DNA (luciferase) (26).  
 
Enhanced valency-ligands may be achieved by binding calix[n]arenes or 
resorcinarenes to further multivalent scaffolds. One example of this are 
cyclophane-based resorcinarene oligomers reported by Uchiyama et al.. 
Carboxylic resorcinarenes bound to tetraaza[6,1,6,1]paracyclophane 
skeletons, afforded ligands of pentameric and dodecameric resorcinarene-
valency (Fig. 2.7) (27). In addition to histone binding, these receptors 
carried fluorescent molecules from the bulk aqueous phase to the histone 
surface, allowing a visual discrimination between post-translationally 
modified and non modified histones (28).  
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Fig. 2.7: Cyclophane-based tetra(resorcinarene) II, with 
tetrameric resorcinarene valency as ligands for histones. 
 
In all the above examples, either electrostatic or sugar mediated 
complementarity was searched for, but none of them reports a rational 
designed ligand with spatial, electrostatic and symmetry complementarity 
to a defined protein surface. 
 
Herein we will describe the design, synthesis and evaluation of two 
different series of calix[4]arene ligands which complement and specifically 
bind two defined protein surface targets, namely the tetramerization domain 
of p53 (p53TD) and the voltage dependent potassium channel subfamily 
Kv1 (see Chapter 3). 
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  2.2 Introduction to target protein p53TD 
 
The Genome guardian: P53 
 
P53 is a transcription factor crucial for cell cycle and genomic integrity. It 
is an oligomeric protein able to trigger cell arrest when DNA damage in the 
cell is detected and activate the expression of DNA repair machinery. 
However, once DNA damage or cell senescence is irreversible, p53 induces 
apoptosis (29). Moreover it is a key target for anticancer research due to the 
high frequency of p53 mutations (50%) found in human cancers (30).  
 
The main part of p53 activity comes from its ability to stimulate the 
transcription of various genes which contain a p53-binding element in their 
promoter (palindromic sequence: 5’-PuPuPuCA/TT/AGPyPyPy-3’) (31). 
The transcriptional activity of p53 is tightly controlled by a complex 
feedback-regulated network via the negative-regulator MDM2 in concert 
with its homolog MDM4 (32). It is further regulated through post-
translational modifications (such as phosphorylation, acetylation, 
methylation, etc.), interaction with a variety of signaling proteins and by 
degradation through ubiquitination (Fig. 2.8) (33). 
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Fig. 2.8: Simplified scheme of the core regulatory network of 
the p53 pathway (from ref. 30). 
 
From the structural point of view, p53 is a multidomain protein, active as 
a homotetramer, with four identical chains of 393 residues. A 
transactivation (p53TAD) and a proline-rich domain or SH3-binding site 
(residues 1 to 42 and 61 to 94, respectively) are present at the N-terminus 
and are intrinsically disordered. The DNA-binding domain (p53DBD) is 
located in the middle of the protein (residues 102 to 292) and is responsible 
for sequence-specific DNA binding. This domain is connected, via a 
flexible linker to a short tetramerization domain (p53TD) that regulates the 
oligomerization state of p53 (residues 326-357). Finally, the regulatory 
domain (residues 360-393), an unfolded region rich in basic amino acids 
with non specific binding to DNA, is located at the C-terminus (Fig. 2.9) 
(34).  
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Fig. 2.9: Domains represented on the primary sequence of p53 
(reproduced from ref. 34). 
 
The quaternary structure of p53 consists basically of a folded core and the 
tetramerization domain, linked and flanked by intrinsically disordered 
segments that prevent or difficult structure analysis by x-ray 
crystallography or NMR. However, Fersht et al. recently solved the 
quaternary structure of human p53 in solution, by a combination of small-
angle x-ray scattering (SAXS), which defined the shape, and NMR, which 
identified the core domain interfaces (35). They showed that the folded 
domains had the same structure in the intact protein than when solved 
separately. Thereafter, they combined solution data with 3D electron 
microscopy images of the closed and open forms of the oligomer and 
suggested the structure represented in Fig. 2.10.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.10: Rigid body models of (a) free and (b) DNA-bound 
p53 in solution from small-angle x-ray scattering data. The 
second model is represented in 2 different orientations. The core 
(green and blue) and tetramerization domains (red) are shown 
as cartoon representations. Flexible connecting linkers (grey), 
N-termini (pink), and C-termini (yellow) are shown as 
semitransparent space-fill models. Models of N- and C-termini 
in the free protein are approximations to illustrate the space 
occupied by these flexible regions, rather than representing 
defined conformations. (reproduced from refs. 30 and 35). 
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The fine balance of the p53 pathway can be altered by many factors (Fig. 
2.8). The most common impairment is the direct mutation of p53 gene, 
which in more than 95% of the cases affects the prominent DNA binding 
region (36). Single missense mutations can compromise the structure of the 
protein or modify key residues either directly involved in the interaction 
with other biomolecules or required for post-translational modifications. 
Besides loss-of-function, mutations can also result in a protein with 
undesired oncogenic activity by promoting the transcription of oncogenes 
(gain-of-function) (37). 
 
Mutations and specific post-translational modifications in the C-terminal 
domain affect p53 transcriptional activity by means of its dimer-tetramer 
equilibrium (38). Also p53 degradation mediated by ubiquitination is 
subject to control through this conformational equilibrium. Thus, the 
tetramerization domain (p53TD) plays a pivotal role in p53’s activation 
state (39). 
 
The tetramerization domain: p53TD 
 
Since it was discovered, p53TD has been the matter of thorough structural 
and biophysical studies. Its structure, as revealed by x-ray crystallography 
(40) and in solution by NMR (41), is best described as a dimer of primary 
dimers. The monomer of the tetramerization domain is formed by a β-strand 
and an α-helix linked by a sharp turn (Gly334). Two monomers form a 
primary dimer, which is stabilized via an antiparallel intermolecular β-sheet 
and antiparallel helix packing (42). Residues Leu330, Ile332 and Phe341 
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make contact with each other at the interface between monomers in each 
primary dimer, and are the most critical residues for overall stability (Fig. 
2.11).  
 
 
 
 
 
Fig. 2.11: Primary dimers stabilized by α-helix packing 
(Leu330, Ile332, Phe341) shown in two different orientations 
(ribbon representation, residues 326-356, pdb: 2JOZ). 
 
Moreover, the side chains of Phe328, Phe338, Met340 and the aliphatic 
portion of Arg337 surround the minicore formed by the three critical 
residues and are partially buried. In addition, ionic interactions, such as 
Arg337-Asp352 -described later in more detail- contribute to the stability of 
the primary dimers (43). Two such dimers associate through their helices to 
form a four-helix bundle tetramer of C2 symmetry. The driving force is 
mainly the formation of a hydrophobic core (44). Thermodynamic studies 
on p53TD stability have shown that nine hydrophobic residues per 
monomer, highlighted in Fig. 2.12, constitute critical determinants for its 
stability and oligomerization status: Leu330, Ile332, Phe341, Leu344 and 
Leu348 and, to a lesser extent, Phe328, Arg337, Phe338 and Met340 (45). 
 
 
 
 
 
90º
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Fig. 2.12: Wild type p53TD with highlighted residues in sphere 
representation: Leu330, Ile332, Phe341, Leu344, Leu348, 
Phe328, Arg337, Phe338, Met340, Asp352 in two different 
orientations. 
 
The topology of the tetramerization domain is reflected by its folding 
pathway, which proceeds via a dimeric intermediate (46). Moreover, a 
study of in vitro p53 biogenesis found that dimer formation occurs co-
translationally on the polysome, whereas tetramers are formed post-
translationally by dimerization of dimers in solution (47). 
 
Germline mutation p53-R337H 
 
It has been shown that mutations compromising the ability to form the 
tetrameric functional structure in the tumor suppressor protein p53, may 
end in cancer development (48). For instance, p53-R337H, the most 
frequent germline mutation of p53 gene (Arg337 is replaced by a histidine) 
(49), is associated to the high rate of adrenocortical carcinoma (ACC) cases 
in an infant population of southern Brazil. The tetramerization domain of 
mutant R337H can adopt a native-like structure, but is less stable than the 
90º
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wild-type domain. The tetrameric stability is highly sensitive to pH in the 
physiological range (pH 6.5 to 8.0) (50), and this sensitivity can be 
correlated with the protonation state of His337.  
In the wild-type sequence, the guanidinium group of Arg337 side-chain 
forms a hydrogen bonded salt bridge and with the carboxylate group of the 
Asp352 side-chain (51). This ionic pair, together with the hydrophobic 
interactions established between the methylene groups of the arginine and 
other residues (i.e. Ile332, Met340, Phe341 and Phe348), markedly 
contribute to the stability of the whole tetrameric structure (Figs. 2.12 and 
2.13). 
 
a)                                                       b) 
 
 
 
 
 
 
 
Fig. 2.13: Dimer with highlighted Arg337-Asp352 residues 
naming as A and C the two monomers forming one primary 
dimer (a) and pKa’s of histidine vs arginine (b). 
 
When His337 is protonated, the mutant protein can form a stable tetramer, 
and roughly functions like the wild-type p53 (wt p53). However, the 
neutralization of the His337-Asp352 salt bridge at the high end of the 
physiological pH range results in an unstable tetramerization domain that is 
hardly folded under physiological conditions. As such, intracellular pH 
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modulates the function of mutant R337H (Fig. 2.14) (52). Therefore, the 
tissue specificity observed in ACC disease may be associated with the high 
pH of adrenal cells (~7.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.14: CD melting curves of 8 µM wt p53 and 10 µM p53-
R337H (monomer) at several pH’s. Experiments reproduced by 
Dr. S. Gordo from ref. 52. 
 
In conclusion, under certain situations, p53-R337H can not efficiently 
assemble the active tetramer and consequently leads to an organism prone 
to tumor set up (53).  
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 2.3 Designed ligands to interact with p53TD 
 
In the design of ligands with the capacity to modulate protein-protein 
surface interactions most of the effort has concentrated so far on molecules 
able to disrupt specific protein interactions (15) or to inhibit unspecific 
aggregation (54). However, little precedents refer to molecules which could 
induce oligomerization (55), or allow the stabilization or recovery of 
proteins which have lost their ability to oligomerize (56). 
 
Previous work on bicyclic guanidinium ligands 
 
A decade ago, the research group of Javier de Mendoza, in collaboration 
with those of Andrew D. Hamilton (Yale, USA), who first designed 
guanidinium based molecules for α-helical anionic peptides (57), and Ernest 
Giralt (PCB, Barcelona) showed that bicyclic guanidinium compounds, 
such as ligand III, bind helical tetraanionic patches on the surface of 
peptides in alcoholic media, via charge and shape complementarity (Fig. 
2.15) (58).  
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Fig. 2.15: Ligand III and interaction of III with a tetranionic 
peptide: Molecular dynamics simulation at 300 K and 500 ps on 
a peptide with an D i(i+3) motif, in the presence (a) and in the 
absence (b) of ligand III (from ref. 58a). 
 
Two overlapping helical tetraanionic patches on the surface of p53TD 
were identified, one formed by residues Glu336, Glu339, Glu343 and 
Glu346 and the other by Glu343, Glu346, Glu349 and Asp352 (Fig. 2.16).  
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Fig. 2.16: P53TD primary sequence with highlighted acid 
residues belonging to two overlapping tetranionic patches on 
the α-helix (top). Highlighted hexanionic patch on p53TD 
(bottom, ribbon repr.: PyMol). 
 
Binding of III was studied against p53TD by NMR-techniques ([1H,15N]-
HSQCi and STDii) in 10% aqueous methanol and an approximate Kd = 50 
µM was observed (59). A preferred interaction was predicted for residues 
Glu343, Glu346, Glu 349 and Asp352. However, computational studies, 
carried out by Eva Santos and Carles Bo at the Institute of Chemical 
Research in Catalonia (ICIQ), showed that III shifts from one binding site 
to the other (non published data) so the synthesis of new hexacationic 
bicyclic guanidinium ligands was envisaged. 
 
                                                          
i
 Heteronuclear Single Quantum Correlation 
ii
 Saturation Transfer Difference Spectroscopy 
α-helixß-sheet
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Recently, Giralt et al. designed a polyguanidilated peptide to interact with 
the surface of p53TD by employing a combination of molecular mechanics 
and molecular dynamics simulations. Peptide IV (Fig. 2.17) was obtained 
after four iterations of design, based on an extended conformation in which 
four arginine residues are arranged in an i/i+2/i+4/i+6 distribution, thus 
mimicking the interguanidinium distances of tetraguanidinium III. 
 
 
Fig. 2.17: Ligand IV. 
The interaction with p53TD was evaluated by several techniques ([1H, 
15N]-HSQC and ITCiii), and a Kd of 8 µM was calculated. This value 
represents almost an order of magnitude of improvement in binding affinity 
compared to tetraguanidinium ligand III (Fig. 2.15) (60).  
 
P53TD ligands based on calix[4]arenes 
 
Compounds III and IV interact on a patch buried in the hydrophobic core 
of the globular domain p53TD. Hence, this recognition event may disrupt 
the tetramer rather than stabilize it.  
 
Thus, taking advantage of the spatial arrangement of E336 and E339 
                                                          
iii
 Isothermal Calorimetry 
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residues in strands of two different monomers, whose free carboxylate side 
chains form an almost perfect square just above the hydrophobic pocket 
located within the strands, we reasoned that a hydrophobic, conically 
shaped molecule, such as 1, endowed with four cationic residues at suitable 
distances to the above mentioned anionic residues, would efficiently 
complement the shape of the protein tetramer, thus stabilizing the whole 
ensemble (Fig. 2.18).  
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a)                                                              b) 
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c)                
 
 
 
 
 
 
 
 
Fig. 2.18: (a) Chemical formula of ligands 1a and 1b. (b) Top 
view showing one of the ligands interacting with Glu336 and 
Glu339 of two different chains/monomers. (c) Tetramerization 
domain with two molecules of ligand 1b (side view). Molecular 
mechanics optimization (Insight-II/Discover). 
 
This is the case for conical calix[4]arene compounds 1a and 1b bearing: i) 
four guanidiniomethyl residues at the upper rim to interact with Glu336 and 
Glu339 of two different monomers via ion-pairing and hydrogen bonding 
and ii) an hydrophobic surface (the calixarene and the lower rim O-
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substituents) to fit into the hydrophobic pocket located within the strands.  
 
Each guanidine motif is linked to the calixarene platform by means of a 
methylene spacer, to enable the correct alignment of the group for an 
optimal chelation with a minimal distortion of the side chains of the protein. 
Moreover, ligand 1a presents propyl chains, whereas 1b is functionalized 
with diethyleneglycol loops in its lower rim. Hence, macrocycles 1a and 1b 
are both fixed in a conical conformations but their overall flexibility differs. 
This should be mirrored in their respective binding behavior (61).  
 
The narrower edge of calixarene 1a contains four conformationally-free 
propyl chains, long enough to prevent internal rotation of the calix[4]arene 
(cone inversion), but allowing the cone to oscillate between two distorted, 
pinched structures (Fig. 2.19).  
 
 
Fig. 2.19: Oscillation between two distorted pinched 
conformations in the conical O-propyl ligand 1a. 
 
On the contrary, macrocycle 1b is endowed with an enhanced conical 
rigidity preventing its collapse into these pinched-cone conformations (64). 
A priori, we expected these latter property to reduce the entropic penalty of 
complexation of 1b with p53TD compared to 1a, and thus favoring 
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association.  
 
As the therapeutic target we selected the naturally mutated p53-R337H 
tetramer, whose overall destabilization has already been described (Section 
2.2). Hence, the system constituted by protein p53TD and its less stable 
mutant p53-R337H with defective association properties, represents an 
optimum model for the evaluation of our de novo designed calix[4]arene 
ligands, slightly differing in their overall flexibility. 
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2.4 Synthesis of p53TD ligands 
 
The initial steps of the synthesis of compounds 1a and 1b (up to 
compound 2), were described by Ungaro et al. (62): dealkylation of tert-
butylcalix[4]arene, to yield calix[4]arene 8, was followed by O-alkylation 
with either propyl groups for 21a (63), or CH2OCH2 bridges in the case of 
21b (2, 64) Next, para positions were treated with N-bromosuccinimide 
(NBS) in DMF, to generate p-bromocalix[4]arenes 22a and 22b. Bromine 
atoms were replaced by cyano groups with CuCN in N-methyl 
pyrrolidinone (NMP) to yield the O-alkylated-p-cyanocalix[4]arenes 23a 
and 23b. Use of a microwave oven at 200 ºC shortened the reaction times 
from the reported 24 h (62) to 15 min. Subsequently, the cyano groups were 
reduced to amines with borane in THF (1M BH3-THF) in a screw-capped 
tube, in order to incorporate bis-Boc-protected guanidinium groups on the 
free bases of 2a and 2b. The guanidilation reagent used was N,N’-bis-(tert-
butoxycarbonyl)guanidine N’’-triflate (25), described by Feichtinger et al. 
(65).  
 
After deprotection of the Boc groups from precursors 24a and 24b under 
standard acid conditions, pure 1a was obtained after sonication, wherease 
1b required additional semi-preparative HPLC purification (Fig. 2.20). 
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Fig. 2.20: Synthesis of ligands 1a and 1b. 
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In addition, the chloride salts of 2a and 2b were isolated and employed as 
negative controls for the need to assess the importance of guanidinium-
groups at the upper rim. Compared to ammonium, the guanidinium group is 
more basic and forms concomitantly multiple hydrogen bonds, hence 
binding strength should be significantly higher.  
 
Since p53TD is rich in positively charged amino acids (Arg333, Arg335, 
Arg337, Arg342 and Lys351), the tetracarboxylate ligand 27 was also 
employed as a control to rule out non-specific ionic binding of the designed 
ligands (Fig. 2.21).  
 
Compounds 27a/b were obtained by oxidation of the corresponding 
tetraformyl precursors 26a/b as described by Ungaro et al. (66). 
 
i) ii)
i) HMTA, TFA, 100 ºC, 18h, HCl 1h at rt (a: 87%; b: 60%). ii) H2NSO3H, NaClO2, Acetone/H2O/CHCl3,
(a: 73%; b: 70%).
OR OR'
2
OR OR'
2
20a/b
26a/b 27a/b
a R = R' = Propyl
b R R' = CH2CH2OCH2CH2
O O O OH H OH OH
Fig. 2.21: Synthesis of compound 27. 
 
Tetra-p-guanidine-tetrapropylcalix[4]arene tetrahydrochloride (V) (11a), 
an analogue to compound 1a, was kindly provided by F. Sansone and R. 
Ungaro. The guanidinium moieties of V are directly bound to the aromatic 
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rings (Fig. 2.22) hence missing the methylene bridges which in our design 
should facilitate H-bond orientation towards carboxylates of residues 
Glu336 and Glu339.  
 
 
Fig. 2.22: Chemical structure of V. 
 
Ligands 1a and 1b were evaluated as stabilizing ligands of wild type 
p53TD (wt p53TD) and mutated tetramer p53-R337H by i) molecular 
dynamics (67), and ii) a full complement of biophysical methods (68).  
 
Interaction, binding mode and relevance of lower vs upper rim 
functionalization for 1a/1b, were investigated by both approaches. In 
addition, biophysical studies highlighted the different interaction affinities 
relying on the distinct lower rim functionalization of 1a vs 1b (69).  
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  2.5 Results from computational studies performed at ICIQ (Drs. C. 
Bo, E. Santos) 
 
To validate the above described design, protein and protein-ligand 
stabilities were assessed by analyzing the trajectories obtained over 10 ns 
molecular dynamics simulations in a box of water at 300 and also at 400 K 
(aimed at simulating thermal denaturating conditions). Amber94 force field 
parameters were applied on wt p53TD (pdb: 1aie) (40b) and molecular 
dynamics simulations were performed using the Gromacs simulation 
package (70). 
 
Although a recent 15 ns trajectory study reports on the changes caused by 
the R337H mutation in the hydrogen bonding network at different pH 
values (71), we wished to have a deeper insight into the contribution of both 
the hydrogen bonds and the hydrophobic contacts along the trajectory. As a 
measure of the structural changes of the protein backbone over time, hence 
of structural stability, we studied the root mean square deviation (RMSD) 
of the backbone referred to the x-ray structure, Fig. 2.23.  
 
In the absence of ligands the structure of wt p53TD was highly stable at 
either 300 or 400 K over the whole dynamics and remained undisturbed in 
the presence of calix[4]arene ligands at both temperatures (Figs. 2.23a and 
b). On the contrary, the RMSD of mutant p53-R337H was moderate but 
grew gradually at 300 K, never recovering its initial value. Interestingly, at 
thermal denaturing conditions (400 K), the differences between wild type 
and mutated proteins were evident from the very early steps of the 
trajectory (Fig. 2.23c and d). These results nicely agreed with the circular 
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dichroism studies reported by DiGiammarino and reproduced by us (52). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.23: Comparison of RMSD backbone at 300 K and 400 K. 
(a) wt p53TD + 1a. (b) wt p53TD + 1b. (c) p53-R337H + 1a. 
(d) p53-R337H + 1b (reproduced from ref. 67). 
 
Docked ligands 1a and 1b remained stable at the same site they were 
initially positioned, interacting with the protein through hydrogen bonds 
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and hydrophobic interactions. Most remarkably, they strongly stabilized 
mutant p53-R337H, as clearly show the decrease in the RMSD value and 
the attenuation of fluctuations (Fig. 2.23c and d). This fully agrees with the 
design principles stated above. Moreover, in the presence of the bridged 
ligand 1b, p53-R337H structure resembles more the native tetramer than 
the one promoted by ligand 1a.  
 
Time-evolution analysis of the secondary structure of wt p53TD and p53-
R337H allowed to zoom into the site where the mutated protein in 
denaturing conditions experiments the largest changes. Analysis of the 
dimer-to-dimer interactions revealed that hydrogen bond distances for the 
Arg337-Glu349 ion-pair were quite constant and short in wt p53TD, 
whereas the corresponding His337-Glu349 pair was never hydrogen bonded 
along the trajectory. Other analyzed distances, such as Arg333-Asp352, or 
Arg/His337-Asp345, fully supported a weaker dimer-to-dimer hydrogen 
bonding network in the mutated protein.  
 
On the other hand, relevant hydrophobic contacts which were essential for 
tetramer integrity (44), were strongly affected by the mutation. For instance 
(naming as A and C the two monomers forming one primary dimer, and B 
and D those forming the other one), His337A-Phe341A, Ile332A-Phe341A, 
Met340A-Met340C and Ile332A-His337A, were notably weakened, whereas 
Leu330D-Phe341A turned shorter. Therefore, the replacement of Arg337 by 
His in the mutated protein caused not only missing three hydrogen bonding 
contacts (with Glu349, Asp352 and Asn345) but also deeply disturbed the 
hydrophobic surface responsible of the stability of the structure. However, 
all hydrophobic distances remained at their wild-type values in the presence 
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of ligands 1a and 1b, while no improvement in the distances between pairs 
involved in hydrogen bonding was observed. 
 
Hence, addition of both ligands 1a or 1b to the mutated protein does not 
produce significant shortening in the hydrogen bonding distances. 
However, the structure keeps fairly fixed along the whole trajectory, as in 
wild-type protein, due to hydrophobic contacts with the lower rim of the 
calixarenes, which prevent from the very beginning the cascade of events 
leading to disassembly. 
 
In conclusion, MD simulations predict the stabilizing effect of ligands 1a 
and 1b on mutated p53TD, by major stabilization of the hydrophobic core 
(69). However, these studies do not shed light on the different association 
modes of 1a and 1b, revealed by the several binding studies described 
below (68). 
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 2.6 Binding studies performed at PCB (Drs. E. Giralt, S. Gordo) 
 
   2.6.1 Binding results for 1a 
 
Stability effects 
 
The tetramerization domains of both wt p53TD and mutant R337H 
experienced a significant increase in their thermal stability in the presence 
of 1a, as observed by differential scanning calorimetry (DSC, Fig. 2.24).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.24: DSC thermograms for 1a with wt p53TD (top) and 
for 1a with p53-R337H (bottom) (reproduced from ref. 68). 
 
The shift in the transition peak for the stable wild-type tetramer was 
moderate with a slight increase in the unfolding enthalpy (72). However, 
the changes were substantially larger for the tetramerization-defective 
mutant p53-R337H: The shift observed in the maximum of the DSC 
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endotherm was of nearly 30 ºC, raising the melting temperature (TM) from 
62 ºC for the free protein, to nearly 89 ºC.  
 
Similar results were revealed by circular dichroism: CD changes induced 
by 1a on p53-R337H were more evident compared to wt p53TD, in both the 
secondary structure and in the CD unfolding curves. In accordance with 
DSC, CD unfolding curves were largely shifted towards higher 
temperatures (∆T05 ~ 25 ºC). Interestingly, the unfolding profiles for p53-
R337H and wt p53TD in the presence of 8 eq. of ligand were very similar, 
just as observed by DSC. 
 
Structural and thermodynamic characterization by NMR 
 
Once the interaction through thermal stabilization was confirmed, we 
addressed further structural issues by NMR. Titration of 15N-labelled 
protein with 1a, followed by 1H-15N-HSQC spectra (Fig. 2.25), revealed 
that the ligand binds the protein in a slow chemical exchange (in the NMR 
time scale). Hence, the interaction should occur with high binding affinity, 
and the thermodynamic dissociation constants might be in the very low 
micromolar range. Changes for p53-R337H take place more easily than for 
the wild-type protein which, in agreement with the aforementioned DSC 
results, suggest a higher affinity of 1a towards the mutant (70). 
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Fig. 2.25: Evolution for the 1H-15N-HSQC resonances of 100  
µM tetrameric protein during the titration with the calix[4]arene 
1a, in water (pH 7.0, 298 K). (a) Wild-type p53TD and (b) p53-
R337H titrated with ligand 1a (reproduced from ref. 68). 
 
The fact that almost every resonance was affected by the presence of 1a, 
together with the slow exchange regime and the lost trace of the former 
resonances, strongly suggested that the proteins underwent some structural 
rearrangements upon ligand binding.  
 
No single-bound (hence, asymmetric) intermediate was detected by 
NMR. This indicated that the interaction of the two ligand molecules was 
sequential and highly cooperative (73). However, the slow exchange 
regime, the significant structural rearrangements and the loss of track in the 
resonances did not enable to map the protein binding site. Therefore, we 
tested the lower affinity tetrapropylcalix[4]arene ligand 2a where the four 
guanidinium groups in the upper rim have been replaced by primary 
amines. Titration of the proteins with this calix[4]arene was also monitored 
by HSQC and confirmed the lower affinity of the ligand. Moreover, 
mapping the chemical shifts for the first binding event on the wild-type 
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p53TD structure (Fig. 2.26), revealed that the parts of the protein most 
sensitive to the presence of ligand were those defining the hydrophobic 
pocket and the hydrophobic core. Such a map indicates that 2a is bound to 
the protein hydrophobic pocket. Thus, the interaction seems to take place 
mainly with the highly stable hydrophobic core.  
 
 
 
 
 
 
 
 
 
 
Fig. 2.26: wt p53TD mapping with 2a. In red, residues with 
changes above 0.1 ppm, in yellow, those changing above 0.053 
ppm. The terminal tails are removed to better appreciate the 
hydrophobic cavity; side view (left), top view (right, reproduced 
from ref. 68). 
 
The final spectra for both proteins after titration with 1a and 2a, although 
similar, were not identical. The differences could account for looser 
interaction of the amino groups from the ligand with the protein 
carboxylates. In conjunction with the lower affinity displayed by the amino-
ligand, this highlights the relevance of the guanidinium-carboxylate 
chelation for ligand binding (74). The effects of V on the protein structures 
were also evaluated by 1H-15N-HSQC. Interestingly, the changes promoted 
by V were identical to those described for the tetraamino-ligand 2a. The 
90º
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newly emerged set of resonances presented only some minor differences 
with the ones corresponding to 2a, and the ligand concentrations required to 
promote the changes (i. e. shifts and peak disappearance) in the spectra 
were almost the same. 
These results reveal the importance of upper rim functionalization: 
Comparing the three cationic ligands tested (1a, 2a, V) it seems obvious 
that the length, the flexibility as well as the basicity and H-bond formation 
ability influence the interaction. The higher affinity results obtained for 1a 
may be explained by optimal distance and orientation for carboxylate 
chelation, provided by methylguanidinium groups, as suggested in Fig. 
2.27.  
 
Fig. 2.27: Comparative representation of interaction of upper 
rim cations with carboxylates on the protein.  
 
Furthermore compound 27a, the tetracarboxylic calix[4]arene with propyl 
groups at the lower rim, was employed as a negative control. Considering 
the large number of positive residues on the protein surface, the 
carboxylates from the calix[4]arene might establish interactions with them. 
However, this was not the case, as calix[4]arene 27a behaved primarily as a 
detergent, generating foam when the sample was mixed and causing 
denaturation and precipitation of the protein (68). 
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Non covalent complex formation 
 
The stoichiometry of the complex with 1a for both the wild-type and the 
mutant was confirmed by mass spectrometry using soft electrospray 
ionization (ESI-MS) (Fig. 2.28). ESI-MS experiments not only detected the 
non-covalent tetramer of wt p53TD, but also the non-covalent complexes 
with one and two calix[4]arene-bound molecules and were even better 
detected for mutant p53-R337H. However, the intensity of the observed 
species in the gas phase cannot be directly related to the affinity in solution, 
given that ESI-MS has a bias for electrostatic interactions, whereas it 
weakens the hydrophobic ones (75).  
 
 
 
 
 
 
 
 
Fig. 2.28: Samples with ligand 1a (125 µM) and (a) wt p53TD 
(12.5 µM) or (b) p53-R337H (12.5 µM). Masses labeled in 
black correspond to the free protein; in green, to the single-
bound complex; and in red, to the double-bound complex. The 
charge state of the respective tetramer is indicated above the 
peaks (10 mM NH4Cl, pH 7.0, reproduced from ref. 68). 
 
In conclusion, 1a promoted large thermal stabilization, especially on 
protein p53-R337H. The large shift in TM as well as the enthalpic increase 
in the unfolding of the ligand-bound protein, suggested a tight and energetic 
a) b)
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interaction of sequential and cooperative nature. Moreover the changes 
experienced by the protein resonances strongly pointed towards important 
structural changes not only for p53-R337H but also for wt p53TD. Finally, 
mass spectrometry confirmed the tight binding of two molecules of 1a. 
 
As predicted in the model, hydrophobic interactions (Fig. 2.18) play a 
major role in the interaction of ligands 1a, 2a and V. However, a better 
carboxylate chelation and thus higher affinity was achieved by ligand 1a 
through methylguanidinium moieties.  
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   2.6.2 Binding results for 1b 
 
Stability effects 
 
Experimentally, the thermal effects caused by ligand 1b on the stability of 
both, wild-type and mutated proteins, were also evaluated by DSC (Fig. 
2.29) and CD, showing very similar behaviors compared to 1a. Calixarene 
ligand 1b displayed rather low affinity for the stable wild type protein, 
while it induced an outstanding thermal stabilization in mutant p53-R337H 
(Fig. 4B), shifting TM 20 ºC, a little less than 1a (27 ºC). Hence, as for 1a, 
thermal changes pointed not only to a tight protein-ligand interaction but 
also suggested that the tetramer was the actual stabilized structure, because 
TM for ligand-bound p53-R337H (~82 ºC) rose close to that for wt p53TD 
(85.5 ºC).  
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Fig. 2.29: DSC thermograms of 1b with (a) wild-type p53TD 
and (b) p53-R337H (reproduced from ref. 69a). 
 
 
Structural and thermodynamic characterization by NMR 
 
Structural aspects were examined by NMR on both the ligand and the 
protein. These experiments not only determined that wt p53TD and ligand 
1b interacted specifically, but also mapped the interacting molecules. 
 
1H-Saturation Transfer Difference (1H-STD) experiments were employed 
to resolve the ligand binding mode (76). Normalized values for the different 
protons are directly labeled on formula 1b (Fig. 2.30), 100% meaning the 
highest saturation, i.e. the proton closest to the protein.  
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Fig. 2.30: STD epitope mapping: Saturation normalized 
percentages for the protons of ligand 1b. 100% corresponds to 
the 1H with the highest saturation degree, thus, the one closer to 
the protein. 
 
STD results completely agreed with the design rationale for ligand 1b 
(Fig. 2.18), with the hydrophobic lower rim of the calixarene “inserted” like 
a cork into the protein cleft (hence experiencing higher saturation), while 
the upper rim remained outside (lower saturation).  
 
Regarding the protein, a thorough titration of 15N-p53TD with ligand 1b, 
followed by 1H-15N-HSQC proved which parts of the protein structure were 
directly involved in the interaction. Representation of the most strongly 
shifted residues at the end of the titration led to the mapping of the protein 
binding site (Fig. 2.31), which was in perfect agreement with the designed 
model, since all the solvent exposed residues constituting the protein cleft 
were sensitive to the presence of ligand 1b. 
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Fig. 2.31: wt p53TD mapping with 1b: In red, residues shifted 
> 0.075 ppm; in orange, those shifted > 0.04 ppm (the mean 
shift, reproduced from ref. 69a). 
 
When a similar titration was carried out for mutant p53-R337H, a totally 
different evolution for the HSQC spectra occurred, indicating that 
interaction of ligand 1b with p53-R337H took place through a different and 
more complex mechanism. Likely, the histidine mutated residue, as a part 
of the hydrophobic pocket, causes significant distortions and 
conformational changes with respect to the wild type protein. 
 
Further understanding about the binding mechanism and its 
thermodynamics was achieved by analyzing changes in NMR line shape, 
shift and intensity upon titration of the protein with the ligand (77). The 
interaction between the wild-type p53TD and the calixarene underwent a 
fast chemical exchange (in the NMR time scale), and unidirectional shift in 
the 2D spectrum movement was only feasible assuming both sites on the 
protein equivalent and independent. Adjustment of the clear chemical shifts 
for Met340 signal (Fig. 2.32a) to a 1:2 protein-ligand binding model (Fig. 
90º
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2.32b), resulted in an apparent dissociation constant of ~280 ± 40 µM.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.32: (a) 1H-15N-HSQC overlaid spectra for the titration of 
p53TD with 1b. Only central region shown. Color code: black: 
free protein (125 µM tetramer); grey scale: up to 500 µM of 
ligand (i.e. < 4 eq); green scale: from 500 µM to 2.5 µM of 1b 
(b) Perturbation of Met340 resonance adjusted to a simplified 
1:1 binding model (reproduced from ref. 69a). 
 
The contribution of the guanidinium groups to the binding was assessed 
by comparison with the ammonium derivative 2b: Though 2b also bound to 
the protein, it displayed considerably lower affinity, in analogy to 2a.  
 
For mutant p53-R337H, the interaction with calixarene 1b took place by a 
more complex mechanism, that could be interpreted considering two 
sequential events, as suggested for 1a, each of them probably corresponding 
to the binding of a molecule of calixarene ligand to the tetramer. No clear 
intermediate was detected suggesting again, as for 1a, that the second 
binding event is of larger affinity than the first one. Indeed, the dissociation 
b)
a)
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constants for both binding events were estimated to be Kd1 = 70 ± 6 µM and 
Kd2 = 8 ± 5 µM, clearly lower than that for the wt p53TD. 
 
Additional evidence for robustness of the final assembly came from 
electrospray mass spectrometry (ESI-MS) measurements, in which the 
tetrameric protein, non covalently bound to two synthetic ligands, was 
detected. 
 
In conclusion, the experimental results here presented, fully validate the 
rational design for 1b binding to p53TD: Thermal stability induced by on 
p53-R337H mutant was observed. Moreover, characterization by NMR 
enabled to assess first the structural binding model on either p53TD 
proteins and ligand 1b, as well as their thermodynamic behaviour: On the 
stable and well-packed wt p53TD, the two binding sites for 1b were likely 
equivalent and independent, while for the mutated protein the binding of the 
two ligand molecules was cooperative and implied some major structural 
rearrangements. Finally, the predicted stoichiometry was confirmed by ESI-
MS. 
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   2.7 Conclusions and outlook 
 
Associations between either calixarenes 1a and 1b and tetramers wt 
p53TD and mutant p53-R337H were correctly predicted by molecular 
dynamics (MD) and characterized by a variety of biophysical methods. 
Both approaches, the theoretical and the empirical one, show that 
hydrophobic forces play the major role, while optimized ionic and 
hydrogen bond interactions further contribute to strengthen the complexes.  
 
Stabilization and tighter binding to mutant p53-R337H vs wt p53TD were 
observed with both ligands 1a and 1b. This outstanding observation may be 
explained by a greater plasticity of the mutant tetramer, which enables 
better adaptation to the protein-ligand complex.  
 
Furthermore, 1a interacts stronger with both tetramers, as assessed by the 
approximated Kd’s of both ligands. Again this may have its origin in the 
greater flexibility of 1a over 1b. Remarkably, our results show that 1a binds 
more tightly to both proteins, thereby supporting the hypothesis that higher 
flexibility helps the ligand (and the protein) to adopt the optimal 
conformations for the best fit. Moreover, through this tight binding, 1a also 
promotes some structural perturbation on the proteins, which could not be 
predicted in advance, but results in more stable species. These findings 
underscore the crucial role of flexibility in recognition processes, not only 
for the ligand, but also for the biomolecular surface. 
 
In this respect, it would be interesting to evaluate novel ligands with 
different O-substituents, such as methylene, ethylene or even using OH-free 
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p-methylguanidinium calix[4]arenes, in order to better assess or even 
quantify the importance of conical prearrangement and hydrophobic surface 
in binding.  
 
Finally, we wanted to verify if ligands 1a and 1b could still efficiently 
bind to p53TD, as part of the whole p53 protein, since the in vitro affinity 
of these ligands for p53TD (µM range) might be not enough to interact with 
p53 or their multivalency might lead to nonspecific interactions with other 
biomolecules (e.g. DNA, RNA and lipids). However, though experiments 
using entire p53 were originally envisioned, we were unable to carry them 
out, as both ligands precipitated in buffered solutions.  
 
Nevertheless, our study paves the way for new strategies in drug 
discovery and provides a proof of principle for the feasibility of approaches 
using designed complex chemical ligands to recover the supramolecular 
integrity of damaged protein assemblies, through surface recognition. 
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 2.8 Experimental part 
 
General procedures. 
 
Synthesis. All reactions were carried out under argon with dry solvents 
unless otherwise noted. All commercially available reagents were used 
without further purification. The solvents were dried and distilled as 
described in the literature (78).  
Chromatography. Reactions were monitored by thin layer 
chromatography (TLC) performed on DC-Fertigplatten SIL G-25 UV254 
(MACHEREY-NAGEL GmbH) or by analytical high performance liquid 
chromatography (HPLC) with a RP-C18 column Symmetry300TM C18 5 µm 
4.6 x 150 mm, UV210-220, 5 µl inj., 1 ml/min flux, on a high performance 
liquid chromatograph (HPLC: Agilent Technologies Series 1200 with UV-
detection). Semipreparative-HPLC purification was performed on Waters 
HPLC 600 equipment with a quaternary pump (0.01-20 mL/min). Standard 
column chromatography was done on silica gel by SDS (chromagel 60 
ACC, 40-60 mm) following the procedure described by W. C. Still (79).  
Analysis. Yields refer to chromatographically pure compounds. 1H NMR 
and 13C NMR spectra were recorded on Bruker Avance 400 UltraShield 
spectrometer (1H: 400 MHz, 13C: 100 MHz) and are reported in parts per 
million (ppm) relative to the residual solvent peak. Data for 1H are reported 
as follows: chemical shift (δ ppm), multiplicity (s = singlet, bs = broad 
singlet, d = doublet, tr = triplet, q = quartet, sex = sextet, m = multiplet), 
coupling constant in Hz, and integration. Exact masses were measured on a 
Waters LCT Premier liquid chromatograph coupled time-of-flight mass 
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spectrometer (HPLC/MS-TOF) with electrospray ionization (ESI). Melting 
points (Mp) were measured with a Büchi B-540 apparatus.  
 
25,26,27,28-Tetrahydroxycalix[4]arene (8). 
 
To a suspension of p-tert-butylcalix[4]arene (3 g, 4.6 mmol) in toluene (45 
mL), phenol (0.46 g, 4.9 mmol) and AlCl3 (3 g, 23 mmol) were added 
sequentially. The mixture was stirred at rt for 18 h. Thereafter, the reaction 
was quenched with 1M HCl (25 mL) and stirred at rt for an additional hour. 
Next, CH2Cl2 (100 mL) was added to the mixture and the aqueous layer 
was extracted several times with CH2Cl2 (3 x 30 mL). The combined 
extracts were washed with H2O (30 mL) and brine (30 mL). After drying 
the organic layer over MgSO4 and filtering, the solvents were eliminated in 
vacuo. The final residue was triturated in cold Et2O and a colorless 
precipitate was obtained which was filtered and dried under reduced 
pressure. Compound 8 was obtained in a 84% yield. Product 8 may be 
further recrystallized in CHCl3/CH3OH (80). Mp: 315-318 ºC. 1H NMR 
(CDCl3): δ 10.19 (s, 4H, OH), 7.22-6.64 (m, 12H, ArH), 3.63-3.48 (bs, 8H, 
CH2). 13C NMR (CDCl3): δ 148.4, 129.0 (CAr), 128.2, 122.2 (CHAr), 31.7 
(CH2). ESI(-): m/z: [M - H]-:  423.2 uma. 
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25,26,27,28-Tetrapropoxy-calix[4]arene (21a). 
 
 
A mixture of calix[4]arene 8 (2.00 g. 4.7 mmol), NaH (2.26 g, 47.1 mmol 
of a 50% dispersion in oil), propyl iodide (4.6 mL, 47.1 mmol), and DMF 
(30 mL) was stirred overnight at rt, and then slowly poured into aqueous 
1M HCI (100 mL) to precipitate crude compound 21a. The solid was 
recovered by filtration, dried and triturated with CH3OH to give pure 21a as 
a colorless solid in a 74% yield: Mp: 197-199 ºC.1H NMR: δ 6.61-6.55 (m, 
12H, ArH), 4.44 (d. J = 13.3 Hz, 8H, ArCHHaxAr), 3.84 (tr, 8H, J = 7.4 
Hz, OCH2CH2CH3), 3.14 (d, J = 13.3 Hz, 8H, ArCHHeqAr), 1.91 (sex, J = 
7.4 Hz, CH2CH2CH3), 0.98 (tr, J = 7.4 Hz, 12H, CH3). 13C NMR: δ 156.6, 
135.1 (CAr), 128.1, 121.9 (CHAr), 76.7 (OCH2CH2CH3), 31.0 (ArCH2Ar), 
23.2 (CH2CH2CH3), 10.3 (CH3). ESI(+) m/z: [M + Na]+: 615.3 uma. 
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25,26-27,28-Biscrown-3-calix[4]arene (21b). 
 
4
OH
8
O
21b
NaH, (CH2CH2OTs)2O,
DMF
41%
O
O
2
H H H
 
NaH (1.7 g, 38.0 mmol of a 50% dispersion in oil) was added to a 
solution containing calix[4]arene 8 (2.00 g, 4.7 mmol) dissolved in DMF 
(500 mL) and the mixture was heated to 80 ºC. Thereafter, diethylene 
glycol ditosylate (4.9 g, 11.8 mmol) dissolved in 5 mL of DMF was added. 
The reaction was stirred for 4 h at rt and evaporated to dryness.The residue 
was taken up with 10% HCl (100 mL, caution!) and extracted with EtOAc. 
The organic layer was dried over anhydrous Na2S04 and purified by column 
chromatography on silica gel (eluent: Hex/EtOAc, 5:1→3:1. Finally 
compound 20b was obtained as a colorless solid in a 41% yield. Mp 265-
268 ºC. 1H NMR (CDCl3): δ 7.01-6.98 (m, 8H, ArH), 6.73 (tr, J = 7.5 Hz, 
4H, ArH), 5.05 (d, J = 12.1 Hz, 2H, ArCHHaxAr) 4.49 (d, J = 12.1 Hz, 2H, 
ArCHHaxAr), 4.31-3.84 (m, 16H, CH2O), 3.26 (d, J = 12.1 Hz, 2H, 
ArCHHeqAr), 3.21 (d, J = 12.1 Hz, 2H, ArCHHeqAr). 13C NMR (CDCl3): 
δ 135.6, 135.5 (CAr), 129.0, 128.1, 123.7 (CHAr), 76.3, 74.8 (CH2O), 30.7, 
29.8 (ArCH2Ar). ESI(+) m/z: [M + H]+: 565.25 uma. 
 
General procedure for the synthesis of p-bromo-calix[4]arenes 22a and 
22b 
To a stirring solution of 1.7 mmol of precursors 21a or 21b in 30 mL of 
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DMF, NBS (8.4 mmol for 21a and 14 mmol for 21b) was added. After 24 h 
at rt, the reaction mixture was quenched by addition of 50 mL of a 1M HCl 
solution. The resulting solid was filtered on a Buchner funnel and 
recrystallized from CH3OH. 
 
5,11,17,23-Tetrabromo-25,26,27,28-tetra-n-propoxycalix[4]arene (22a). 
 
Compound 22a was obtained as a colorless solid in a 90% yield. Mp: 
277-280 °C. 1H NMR (CDCl3): δ 6.78 (s, 8H, ArH), 4.33 (d, J = 13.5 Hz, 
4H, ArCHHaxAr), 3.78 (tr, J = 7.5 Hz, 8H, OCH2CH2CH3), 3.07 (d, J = 
13.5 Hz, 4H, ArCHHeqAr), 1.85 (m, J = 7.5 Hz, 8H, OCH2CH2CH3), 0.94 
(tr, J = 7.5 Hz, 12H, CH3). 13C NMR (CDCl3): δ 155.6, 136.6 (CAr), 131.3 
(CHAr), 115.4 (CAr), 77.3 (OCH2CH2CH3), 31.0 (ArCH2Ar), 23.3 
(OCH2CH2CH3), 10.4 (CH3). ESI(+) m/z: [M + Na]+: 927.0 uma. 
 
5,11,17,23-Tetrabromo-25,26-27,28-biscrown-3-calix[4]arene (22b). 
O
22b
95%
O
O
2
O O
O
2
21b
Br Br
NBS, DMF
 
Compound 22b was obtained as a colorless solid in a 95% yield. Mp: > 
350 °C. 1H NMR (CDCl3): δ 7.15 (d, J = 2.4 Hz, 4H, ArH), 7.13 (d, J = 2.4 
Hz, 4H, ArH), 4.96 (d, J = 12.1 Hz, 2H, ArCHHaxAr), 4.37 (d, J = 12 Hz, 
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2H, ArCHHaxAr), 4.33 (tr, J = 11.6 Hz, 4H, CH2O), 4.21, 4.08 (m, 8H, 
CH2O), 3.82 (tr, J = 11.6 Hz, 4H, CH2O), 3.33 (d, J = 12.2 Hz, 2H, 
ArCHHeqAr), 3.28 (d, J = 12.1 Hz, 2H, ArCHHeqAr).13C NMR (CDCl3): δ 
154.7, 137.2, 137.0 (CAr), 132.3, 131.3 (CHAr), 116.6 (CAr), 75.9, 74.7 
(CH2O), 30.5, 29.7 (ArCH2Ar). ESI(+) m/z: [M + Na]+: 898.9 uma. 
 
General procedure for the synthesis of p-cyanocalixarenes 23a and 23b. 
To a microwave tube with tetrabromo-calix[4]arenes 22a or 22b (0.3 
mmol), CuCN (224 mg, 2.15 mmol) and NMP  (1,5 mL) were added. The 
reaction was stirred and heated in a microwave reactor at 200 °C for 15 min 
(200 Watt and 100 PSI). After cooling the reaction mixture to 50 ºC, a 
solution of FeCl3 (0.54 g, 3.4 mmol) in 10 mL HCl 1N was added and the 
mixture was stirred additionally for 30 min. The resulting solid was filtered 
on a Buchner funnel and compounds 18a and 18b were purified by silica 
gel flash chromatography.  
 
5,11,17,23-Tetracyano 25,26,27,28-tetra-n-propoxycalix[4]arene (23a). 
 
 
Eluent: CH2Cl2/EtOAc, 80:20. Subsequently, 23a was triturated in hexane 
and obtained as a grey solid in a 62% yield. Mp: > 350 °C. 1H NMR 
(CDCl3): δ 6.99 (s, 8H, ArH), 4.44 (d, J = 11.5 Hz, 4H, ArCHHaxAr), 3.90 
(tr, J = 6.2 Hz, 8H, OCH2CH2CH3), 3.25 (d, J = 11.5 Hz, 4H, 
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ArCHHeqAr), 1.88 (sex, J = 6.2 Hz, OCH2CH2CH3, 8H), 0.99 (tr, J = 6.2 
Hz, 12H, CH3). 13C NMR (CDCl3): δ 154.8, 135.8 (CAr), 132.7 (CHAr), 
116.2 (CN), 107.3 (CAr), 77.6 (OCH2CH2CH3), 30.6 (ArCH2Ar), 23.4 
(OCH2CH2CH3), 10.3 (CH3). IR (KBr): 2224 cm-1 (ν, C≡N). ESI(+) m/z: 
[M + Na]+: 715.4 uma. 
 
5,11,17,23-Tetracyano-25,26-27,28-biscrown-3-calix[4]arene (23b). 
 
 
Eluent: CH2Cl2/EtOAc, 95:5→80:20. Compound 23b was obtained as a 
cream coloured solid in a 48% yield. Mp: > 350 °C. 1H NMR (CDCl3): δ 
7.82 (d, J = 1.8 Hz, 4H, ArH), 7.77 (d, J = 1.8 Hz, 4H, ArH), 5.02 (d, J = 
12.1 Hz, 2H, ArCHHaxAr), 4.38 (d, J = 12.2 Hz, 2H, ArCHHaxAr), 4.33 
(tr, J = 9.8 Hz, 4H, OCH2), 4.21-4.08 (m, 8H, OCH2), 3.82 (tr, J = 9.8 Hz, 
4H, OCH2), 3.33 (d, J = 12.2 Hz, 2H, ArCHHeqAr), 3.28 (d, J = 12.1 Hz, 
2H, ArCHHeqAr). 13C NMR (CDCl3): δ 158.3, 136.0, 135.8 (CAr), 134.4, 
133.2 (CHAr), 119.0 (CN), 108.0 (CAr), 76.8, 74.7 (CH2O), 29.3, 28.6 
(ArCH2Ar). ESI(+) m/z: [M + Na]+: 687.2 uma. 
 
General procedure for the synthesis of p-amino-calixarenes 2a and 2b. 
Tetracyano-calixarenes 23a or 23b (0.15 mmol) were introduced into a 
screw-capped tube and a solution of 1M BH3-THF (4.5 mL, 4.5 mmol) was 
added at 0 ºC. The solution was heated at 80 ºC for 24 h. Then CH3OH (1 
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mL) and 1N HCl (3 mL) were added dropwise to the solution and the 
reaction mixture was heated at 50 °C for additional 30 min. THF and 
CH3OH were removed under reduced pressure and the tetramino 
derivatives were isolated as follows. 
 
5,11,17,23-Tetraminomethyl-25,26,27,28-tetra-n-propoxycalix[4]arene 
tetrahydrochloride (2a). 
 
To the resulting residue CH2Cl2 was added and the colorless solid was 
filtered and washed repeatedly. The chloride salt of compound 2a was 
obtained in a 79% yield. Mp: 290-293 °C (dec.). 1H NMR (CD3OD): δ 6.87 
(s, 8H, ArH), 4.49 (d, J = 13.2 Hz, 4H, ArCHHaxAr), 3.88 (tr, J = 5.3 Hz, 
8H, OCH2), 3.82 (bs, 8H, NH2), 3.30 (bs, 8H, CH2N); 3.26 (d, J = 13.2 Hz, 
4H, ArCHHeqAr), 1.94 (m, J = 7.4 Hz, 8H, OCH2CH2CH3), 1.02 (t, J = 7.4 
Hz, 12H, CH3). 13C NMR (CD3OD): δ 158.4, 136.7 (CAr), 130.5 (CHAr), 
128.3 (CAr), 78.1 (OCH2CH2CH3), 44.0 (CH2N), 31.7 (ArCH2Ar), 24.4 
(OCH2CH2CH3), 10.7 (CH3). ESI(+) m/z: [M - 4HCl + H]+: 709.5 uma. 
Compound 2a, in its non-protonated form, can be obtained by extraction 
in CH2Cl2 from 1N NaOH aqueous solution. 
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5,11,17,23-Tetraminomethyl-25,26-27,28-biscrown-3-calix[4]arene 
tetrahydrochloride (2b). 
O
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CN CN
Cl Cl
NH3H3N
 
After removal of the aqueous solvent under reduced pressure, the 
remaining residue was triturated in EtOAc and filtered. 2b was obtained as 
a pure colorless compound in a 80% yield. Mp: > 350 °C. 1H NMR 
(CD3OD): δ 6.93 (s, 8H, ArH), 4.92 (d, J = 12.8 Hz, 2H, ArCHHaxAr), 
4.40 (d, J = 12.7 Hz, 2H, ArCHHaxAr), 4.23-4.14 (m, 8H, OCH2), 3.80-
3.73 (m, 8H, OCH2), 3.56 (s, 8H, CH2N), 3.21 (d, J = 12.7 Hz, 2H, 
ArCHHeqAr), 3.15 (d, J = 12.8 Hz 2H, ArCHHeqAr), 2.85 (bs, 8H, NH2). 
13C NMR (CD3OD): δ 155.4, 136.7, 135.4 (CAr), 129.7, 128.8 (CHAr), 
77.4 (CH2O), 75.7 (CH2O), 55.4 (CH2N), 30.5 (ArCH2Ar). ESI(+) m/z: [M 
- 3HCl + H]+: 717.3 uma.  
Compound 2b, in its non-protonated form, can be obtained by extraction 
in CH2Cl2 from 1N NaOH aqueous solution. 
 
General procedure for the synthesis of p-bis-tert-
butoxycarbonyl)guanidinemethyl-calix[4]arenes 24a and 24b. 
To a solution of the basic forms of p-aminomethylcalix[4]arenes 2a or 2b 
(0.16 mmol) in CH2Cl2 (1.5 mL), were added Et3N (0.088 mL, 0.63 mmol) 
and N,N’-bis-(tert-butoxycarbonyl)guanidine N’’-triflate (25) (0.249 g, 0.63 
mmol), previously dissolved in CH2Cl2 (1.5 mL). The reaction was stirred 
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at rt, 4 h for 2a and 36 h for 2b. Quenching was performed by washing with 
HCl 1N (2 x 2 mL), water (1 x 2 mL) and brine (1 x 2 mL). After drying the 
organic solvent over anhydrous Na2CO3 and filtering it, it was removed 
under reduced pressure and pure compounds were purified by silica gel 
flash chromatography as follows. 
 
5,11,17,23-Tetradibocguanidinemethyl-25,26-27,28-
tetrapropoxycalix[4]arene (24a). 
 
Eluent: 100% CH2Cl2→Hex/Et2O, 4:1. Compound 24a was obtained pure 
as a colorless compound in a 40% yield. Mp: > 350 ºC.1H NMR (CDCl3): δ 
8.27 (s, 4H, NH), 6.60 (s, 8H, ArH), 4.40 (d, J = 13.2 Hz, 4H, 
ArCHHaxAr), 4.28 (d, J = 5.7 Hz, 8H, CH2N), 3.83 (t, J = 7.4 Hz, 8H, 
OCH2CH2CH3), 3.12 (d, J = 13.2, 4H, ArCHHeqAr), 1.93 (m, 8H, 
OCH2CH2CH3), 1.48 (d, J = 5.7 Hz, 72H, C(CH3)3), 0.98 (t, J = 7.4 Hz, 
12H, CH3). 13C NMR (CDCl3): δ 163.6 (CO), 156.0, 155.6 (CGuan), 153.1, 
134.9, 130.5 (CAr), 127.8 (CHAr), 82.8 (C(CH3)3), 78.9 (OCH2CH2CH3), 
44.9 (CH2N), 31.0 (ArCH2Ar), 28.4, 28.1 (C(CH3)3), 23.2 (OCH2CH2CH3), 
10.3 (CH3). Exact Mass (ESI): m/z [M + H]+: calc. 1678.9793 uma, found: 
1678.9995 uma.  
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5,11,17,23-Tetrakis(N,N’-bis-tert-butoxycarbonyl)guanidinemethyl-
25,26-27,28-biscrown-3-calix[4]arene (24b). 
 
Eluent: Hex/Et2O, 4:1. Compound 24b was obtained as a colorless solid 
in a 48% yield. Mp: > 350 °C. 1H NMR (CDCl3): δ 8.38 (s, 4H, NH), 6.88 
(d, J = 5.0 Hz, 8H, ArH), 4.90 (d, J = 12.3 Hz, 2H, ArCHHaxAr), 4.39-4.27 
(m, 10H, ArCHHaxAr, CH2O), 4.19-4.13 (m, 12H, CH2O, CH2N, 
ArCHHaxAr), 3.79-3.73 (m, 4H, CH2O), 3.16 (d, J = 11.7 Hz, 2H, 
ArCHHeqAr), 3.11 (d, J = 12.3 Hz, 2H, ArCHHeqAr), 1.41 (d, J = 10.5 Hz, 
72H, C(CH3)3). 13C NMR (CDCl3): δ 163.6 (CO), 155.7, 154.79 (CGuan), 
153.1, 135.7, 135.5, 132.1 (CAr), 128.6, 127.6 (CHAr), 83.0 (C(CH3)3), 
79.1 (CH2O), 74.8 (CH2O), 45.0 (CH2N), 30.8, 30.0 (ArCH2Ar), 28.3, 28.1 
(C(CH3)3). Exact Mass (ESI): m/z [M + H]+: calc.: 1649.8713, found: 
1649.8678. 
 
General procedure for the synthesis of p-guanidinemethyl-
calix[4]arenes 1a and 1b. 
To a solution of bis-Boc guanidine derivatives 24a or 24b (0.03 mmol) in 
1,4 dioxane (3 mL), concentrated HCl (1 mmol per Boc group) was added 
dropwise. The solution was stirred for 24 h at rt. Solvents were removed 
under reduced pressure and the products were obtained as follows. 
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5,11,17,23-Tetraguanidinemethyl-25,26-27,28-tetra-n-
propoxycalix[4]arene tetrahydrochloride (1a). 
 
After elimination of the solvent, the product was recrystallized by 
dissolving it in CH3OH (0.5 mL) and adding dropwise cold EtOAc. The 
suspension was left standing for 24 h at rt, giving rise to a colorless solid in 
a 87% yield. Mp: > 350 ºC. 1H-NMR (MeOD): δ 6.27 (s, 8H, ArH), 4.51 (d, 
J = 13.2 Hz, 4H, ArCHHaxAr), 4.12 (s, 8H, CH2Guan), 3.83 (t, J = 7.4 Hz, 
8H, OCH2 CH2CH3), 3.22 (d, J = 13.2 Hz, 8H, ArCHHeqAr), 1.93 (m, 8H, 
OCH2CH2CH3), 1.04 (t, J = 7.4 Hz, 9H, CH3). 13C NMR (CD3OD): δ 
158.41 (CGuan), 157.67, 136.63, 130.82 (CAr), 129.04 (CHAr), 78.15 
(OCH2CH2CH3), 46.06 (CH2Guan), 31.94 (ArCH2Ar), 24.45 
(OCH2CH2CH3), 10.82 (CH3). Exact Mass (ESI+): m/z of [M - HCl + H]+: 
calc.: 987.4836 uma, found: 987.4896 uma. Elemental Analysis: 
C48H72Cl4N12O4+3H2O, calc.:C (53.53%), H (7.3%), N (15.61%), found: C 
(53.80%), H (6.96%), N (15.47%). 
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5,11,17,23-Tetraguanidinemethyl-25,26-27,28-biscrown-3-calix[4]arene 
tetrahydrochloride (1b). 
 
After evaporation of the solvent, the residue was triturated in EtOAc. The 
resulting solid was purified by semi-preparative HPLC (conc.: 37.5 mg/mL, 
elution: 5→35% CH3CN in H2O + 0.05% TFA along 20 min, inj.: 100 µL, 
flux: 4.7 mL/min, UV220). The final compound was obtained in a 50% 
yield. Anion exchange to chloride yielded the tetrahydrochloride salt 1b. 
Mp: > 350 °C. 1H NMR (CD3CN): δ 7.08 (s, 8H, ArH), 5.03 (d, J = 12.1 
Hz, 2H, ArCHHaxAr), 4.48 (d, J = 12.1 Hz, 2H, ArCHHaxAr), 4.28-4.23 
(m, 12H, CH2O), 4.13 (d, J = 6.2 Hz, 8H, CH2Guan), 3.74-3.69 (m, 4H, 
CH2O), 3.28 (d, J = 12.3 Hz, 2H, ArCHHeqAr), 3.21 (d, J = 12.3 Hz, 2H, 
ArCHHeqAr). 13C NMR (CD3CN): δ 157.3 (CAr), 154.8 (CGuan), 135.9, 
132.0 (CAr), 129.9, 128.1 (CHAr), 76.7, 74.4 (CH2O), 43.3 (CH2Guan), 
29.7 (ArCH2Ar), 29.0 (ArCH2Ar). Exact Mass (ESI+): m/z of [M - HCl + 
H]+ : calc.: 957.3867 uma, found: 987.3824 uma. 
 
N,N’-Di-Boc-N’’-trifluoromethanesulfonylguanidine (25). 
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1,4-Dioxane (7 mL) was added to a solution of guanidine hydrochloride 
(0.32 g, 3.38 mmol) and NaOH (0.5 g, 13.5 mmol) in H2O (3 mL). Di-tert-
butyl dicarbonate (1.6 g, 7.4 mmol) was added in one portion, and the 
reaction mixture was allowed to warm to rt within 2 h. After stirring for 20 
h, the mixture was concentrated in vacuo to 1/3 of its original volume. The 
resulting suspension was diluted with H2O (7 mL) and extracted with 
EtOAc (3 x 7 mL). The combined extracts were washed with 10% citric 
acid (7 mL) , H2O (7 mL), and brine (7 mL) and dried over MgSO4. After 
filtration and removal of the solvent under reduced pressure, the crude 
product was purified by flash chromatography on silica gel (eluent: 100% 
CH2Cl2→CH2Cl2/CH3OH, 97:3). Then, the resulting colorless powder (0.52 
g, 2.0 mmol) was dissolved in anhydrous CH2Cl2 (10 mL). Et3N (0.29 mL, 
2.1 mmol) was added and the solution was cooled to -78 ºC. Triflic 
anhydride (0.35 mL, 2.1 mmol) was added dropwise at a rate such as that 
the reaction temperature did not exceed -65 ºC. After the addition, the 
mixture was allowed to warm to rt within 4h. The solution was washed with 
2M NaHSO4 (7 mL) and H2O (7 mL), and dried over anhydrous Na2SO4. 
After filtration and removal of the solvent in vacuo, the crude was purified 
by flash column chromatography on silica gel (eluent: 100% CH2Cl2).  
Compound 25 was obtained as a colorless powder in a 52% yield. Mp: 114-
116 ºC. 1H NMR (DMSO-d6): δ 11.45 (bs, 2H), 1.45 (s, 18H). ESI(+) m/z: 
[M + H]+: 392.1 uma. 
 
General procedure for the synthesis of p-formylcalixarenes 26a and 
26b. 
A mixture of calixarenes 21a or 21b (0.96 mmol), 
hexamethylenetetramine (HMTA, 4.04 g. 28.8 mmol), and trifluoroacetic 
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acid (20 mL) was stirred at 125 ºC tube for 5 h in a screw-capped tube for 
precursor 21a, or at reflux for 24 h in the case of 21b. Thereafter the 
reactions were cooled to rt and treated with aqueous solutions as follows.  
 
5,11,27,23-Tetraformyl-25,26,27,28-tetrapropoxycalix[4]arene (26a). 
 
The mixture was diluted with 1M HCl (50 mL) and CH2Cl2 (50 mL), and 
vigorously stirred at rt for additional 3 h. The organic layer was separated, 
and the aqueous layer was extracted with CH2Cl2 (50 mL). The combined 
organic layers were washed with sat. Na2CO3 (50 mL), dried over 
anhydrous Na2SO4 and evaporated to dryness. Trituration of the residue 
with CH3OH afforded 26a as a colorless solid in a 87% yield. Mp: 289-290 
ºC. 1H NMR (CDCl3): δ 9.58 (s, 4H, CHO), 7.15 (s, 8H, ArH), 4.51 (d, J = 
13.8 Hz; 4H, ArCHHaxAr), 3.94 (tr, J = 7.4 Hz, 8H, OCH2CH2CH3), 3.35 
(d, J =13.8 Hz, 4H, ArCHHeqAr), 1.90 (sex, J = 7.4 Hz, 8H, CH2CH2CH3), 
1.01 (tr, J = 7.5 Hz, 12H, CH3). 13C NMR (CDCl3): δ 191.1 (CHO), 161.7, 
135.4, 131.3 (CAr), 130.1 (CHAr), 76.4 (OCH2CH2CH3), 30.8 (ArCH2Ar), 
23.2 (OCH2CH2CH3), 10.1 (CH3). ESI(+) m/z: [M + Na]+: 727.3 uma. 
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5,11,17,23-Tetraformylcalix[4]arene-25,26:27,28-biscrown (26b). 
 
 
The mixture was poured into ice/water (50 mL), neutralized with Na2CO3 
and extracted with EtOAc. The organic phase was washed with H2O (2 x 30 
mL), dried over anhydrous Na2CO3 and evaporated to dryness. Purification 
by column chromatography in silica gel (eluent: Hex/EtOAc, 4:1) led to 
pure 26b in a 60% yield. Mp: 303 °C (dec.).1H NMR (CDCl3): δ 9.76 (s, 
4H, CHO), 7.61 (d, J = 2.4 Hz, 8H, ArH), 7.57 (d, J = 2.4 Hz, 8H, ArH), 
4.57 (d, J = 12.4 Hz, 4H, ArCHHaxAr), 5.21 (d, J = 12.4 Hz, 4H, 
ArCHHaxAr), 3.9-4.4 (m, 16H, H20), 3.41 (d, J = 12.4 Hz, 4H, 
ArCHHeqAr), 3.46 (d, J = 12.4 Hz, 4H, ArCHHeqAr). 13C NMR (CDCl3): 
δ 161.11 (CHO), 136.50, 133.10, 131.66 (CAr), 130.62 (CHAr), 76.67, 
74.37 (CH2O), 30.00, 30.05 (ArCH2Ar). ESI(+) m/z: [M + Na]+: 699.2 uma. 
 
General procedure for the synthesis of p-carboxycalix[4]arenes 27a and 
27b. 
p-Tetraformylcalix[4]arenes 26a and 26b (0.5 mmol) were dissolved in 
CHCl3/acetone (1:1, v/v, 15 mL) and the solution cooled to 0 ºC. An 
aqueous solution (1.5 mL) of sulfamic acid (0.58 g, 6 mmol) and sodium 
chlorite (0.45 g, 5 mmol) was rapidly added and the mixture was vigorously 
stirred at rt for 18 h. The reaction was quenched by removal of the organic 
solvents and addition of 2N HCl (2 mL). The resulting precipitate was 
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filtered and purified by trituration in CH3OH. 
 
25,26,27,28-Tetra-n-propoxycalix[4]arene-5,11,17,23-tetracarboxylic 
acid (27a). 
 
Compound 27a was obtained as a colorless solid in a 73% yield. Mp > 
350 °C. 1H NMR (CD3OD): δ 7.37 (s, 8H, ArH), 4.51 (d, J = 13.5 Hz, 4H, 
ArCHHaxAr), 3.95 (tr, J = 7.3 Hz, 8H, OCH2CH2CH3), 3.31 (d, J = 13.5 
Hz, 4H, ArCHHeqAr), 1.97-1.87 (m, 8H, OCH2CH2CH3), 1.03 (tr, J = 7.4 
Hz, 12H, CH3).13C NMR (CDCl3/CD3OD 9/1): δ 169.5 (CO), 161.7, 135.7, 
131.3 (CAr), 125.2 (CHAr), 77.9 (OCH2CH2CH3), 31.8 (ArCH2Ar), 24.2 
(OCH2CH2CH3), 10.9 (CH3). ESI(-) m/z:  [M - H]-: 767.3 uma. 
 
5,11,17,23-Tetracarboxycalix[4]arene-25,26:27,28-biscrown (27b). 
 
 
Compound 27b was obtained as a colorless solid in a 70% yield. Mp: > 
350 ºC. 1H NMR (DMSO-d6): δ 7.72 (s, 8H; ArH), 5.00 (d, J = 12.0 Hz, 
2H; ArCHHaxAr), 4.45 (d, J = 12.3 Hz, 2H, ArCHHaxAr), 4.41-4.20 (m, 
8H, CH2O), 3.75-3.65 (m, 8H, CH2O), 3.51 (d, J = 12.3 Hz, 2H; 
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ArCHHeqAr), 3.43 (d, 2H, J = 12.0 Hz, 2H, ArCHHeqAr). 13C NMR 
(DMSO-d6): δ 166.7 (CO), 159.2, 135.5 (CAr), 130.5, 129.7 (CHAr), 126.2 
(CAr), 76.6, 73.8 (CH2O), 29.5, 28.9 (ArCH2Ar). ESI(-) m/z [M - H]- 739.2 
uma. 
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Chapter 3  
 
Conical calix[4]arenes as reversible blockers of voltage-
dependent potassium channels 
   
 3.1 Potassium channels: Function, structure and Kv-family 
 
K+ conduction: at the basis of cell functionality 
 
Potassium channels are the most common type of ion channels occuring 
in virtually every eukaryotic and prokaryotic cell (1). They conduct K+ ions 
across the cell membrane through potassium-selective pores that span 
membranes and are key elements for cell function, as they underpin 
excitability, proliferation, secretion and volume regulation. 
 
There are over 80 mammalian genes that encode potassium channel 
subunits (2). The diversity among members of the K+ channel family is 
related to the various stimuli they respond to: cations like Ca2+ (e.g.: BK, 
SK, MthK), voltage (e.g.: Shaker, Kv family) or ligands such as ATP (Kir), 
cAMP (KcsA) and phosphoinositol derivatives (3). 
  
From a structural point of view they are formed by four subunits which 
have a distinctive pore-loop structure that lines the top of the pore and is 
responsible for K+ selectivity. Depending on the number of membrane-
spanning helices and the number of pores they contain, the following 
classes are distinguished: the two-transmembrane class (2TM) which 
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includes the inward rectifier channels (Kir) and the bacterial channels KcsA 
and MthK, and the six-transmembrane class (6TM) which contains the 
family of voltage gated potassium channels (Shaker, KvAP, Kv channels 
and others), as well as the KCNQ and the eag-like channels. However, 
channels of the 6TM family are an extended version of the 2TM family, as 
will be described later (1). 
 
The most important subunit (α-subunit) of K+ channels of the 2TM and 
6TM category, assembles as either homomeric or heteromeric tetramers to 
form the K+-selective pore (4). Furthermore bacterial, archael and 
eukaryotic K+ channels belong to a single protein family because they 
contain a highly conserved segment called the K+ channel signature 
sequence (5).  
 
Structure-function correlation in K+ channels 
 
Since 1998, several x-ray structures of bacterial and mammalian 
potassium channels have been solved by MacKinnon et al.: KcsA 
(bacterial, cAMP-gated channel) (6), MthK (bacterial, Ca2+-gated) (7), 
KvAP (archaebacterial, voltage-gated channel) (8), Kv1.2·β2 (mammalian 
Shaker like channel, voltage-gated) (9), and the Kv1.2-Kv2.1 (paddle 
chimaera, voltage gated) (10). In all crystal structures, four identical 
subunits assemble as a tetramer with a central C4 axis of symmetry.  
 
A single K+-subunit, from KcsA crystal structure, represented in Fig. 3.1, 
shows the characteristic sections: 1st the S5 and S6 helices (grey), 2nd the 
turret loop (grey), 3rd the pore helix (red), and 4th the selectivity filter 
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(yellow).  
 
 
 
 
 
 
 
Fig. 3.1: (a) Two of the four subunits from the KcsA pore are 
shown with the extracellular part on the top. (b) Detail of pore 
domain: blue mesh shows electron density for K+ and water 
along the pore.  
 
The S5 helix spans the membrane. Once the polypeptide chain reaches the 
extracellular surface, it unwinds to form an approximately s-shaped turret 
loop, connecting S5 to the so-called pore helix (P-helix). The turret is a 
region of hypervariability specific to every K+ channel. The main chain 
then turns back into the membrane, crossing it halfway as the P-helix. At 
this point the backbone bends back again, towards the extracellular side and 
forms the selectivity filter (Fig. 3.1a).  
 
The pore itself is formed by the highly conserved sequence (XGYG), 
whose backbone carbonyl groups provide the selectivity filter and underpin 
the ability of the channel to prevent the passage of Na+ (11). The selectivity 
filter contains multiple binding sites that mimic specifically a hydrated K+ 
ion’s hydration shell. Four evenly spaced layers of carbonyl oxygen atoms 
and a single layer of threonines hydroxyl oxygen atoms create four K+ ion 
Selectivity filter
Pore helix
Cation “trap”
cavity
Turret loop
S6
S5
a) b)
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binding sites, as shown in Fig. 3.1b. The ability of these proteins to conduct 
K+ ions at levels near the limit of diffusion is traditionally described in 
terms of concerted mechanisms in which ion-channel attraction and ion-ion 
repulsion have compensating effects, as several ions are moving 
simultaneously in single file through the narrow pore.  
 
Across the four positions of the selectivity filter there are, on average, two 
K+ ions present at a given time and they reside predominantly in two 
configurations: 1,3 and 2,4 (Fig. 3.2a).  
 
 
 
 
 
 
 
Fig. 3.2: (a) Electron density in the filter corresponds to two 
configurations of K+ ions (green) alternating with water 
molecules (red). (b) Throughput cycle for K+ conduction 
(reproduced from ref. 5b).  
 
These two configurations represent the end point of a simple conduction 
cycle: an ion enters the queue from one side while another one exits from 
the other side (Fig. 3.2b). 
 
Moreover, by directing the C-terminal negative end-charge of α-helices 
(helix macrodipole) toward the ion pathway, while releasing a high free 
energy through ion rehydration of K+, the ion is stabilized in the center of 
a) b)
1,3 2,4
1,3 2,4
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the membrane prior to release into the intracellular space (12).  
 
 
Targeting Kv1-subfamily 
 
So far, approximately 90 genes for K+-channels subunits have been 
identified in the human genome. However, this enormous diversity at 
genomic level, especially when combinatorial assembly of different 
subunits is considered, is contrasted with the relatively small number of 
human channels that are functionally characterized. However, since they 
are involved in many disease settings, considerable efforts have been made 
to study their properties and identify potential drug candidates. In 
particular, the family of voltage gated K+ channels (Kv) has been identified 
as pharmacologically relevant (13). 
 
In addition to the two α-helices of the pore domain (S5-S6), Kv channels 
have four S1-S4 helices, which compose the voltage sensing domain that 
“reads” the membrane voltage and regulates the pore (Fig. 3.3) (8). 
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Fig. 3.3: A KvAP subunit viewed from the top (left) and the 
highlighted domain from the side, with the intracellular solution 
below (right). Pore domain (P, S5, S6) and voltage sensitive 
domain (S1-S4) are highlighted, reproduced from ref. 8b. 
 
The minimum voltage sensing region actually corresponds to S4-S3b, 
termed the voltage sensing paddle, rich in arginine residues (14). As a 
response to membrane voltage, the paddle switches between two 
conformations which are transmitted via S5-S6 helices to the pore, 
determining its open or closed conformation (15).  
 
Triethylammonium (TEA) interacts non specifically with Kv1 channels 
with weak to moderate affinity. For this reason and because of its 
accessibility it has been employed to reveal structural and biophysical 
properties of voltage dependent channels (16). Moreover, to facilitate these 
studies, mutants of Shaker channel -a prototypical Kv1 channel from D. 
megalonaster- with enhanced susceptibility to TEA (Shaker T449Y/F) are 
commonly employed (17). The reason for this is that amino acids with 
aromatic side chains in position 449 enhance TEA binding through cation- 
90º
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π interaction (18).  
 
Also a large number of natural inhibitors from poisonous animals have 
been exploited to study Kv1 channel properties and several structures of 
toxins complexed to Kv1 channels have been reported (19). As an example, 
the footprint of Agitoxin (AgTx) on the extracellular surface of Shaker 
channel was modelled by Ericsson et al. (2002) based on experimental 
distance restraints extracted from thermodynamic mutant cycles (Fig. 3.4) 
(20). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4: Two views of the AgTx2-Shaker complex rotated 90° 
around the pore axis relative to each other. The rear and front 
monomers have been removed for easier visualization and the 
letters refer to Shaker monomers. Important side chains are 
highlighted in colors (reproduced from ref. 20). 
 
From a biomedical perspective, Kv1.3 and Kv1.5 channel subtypes have 
revealed as very interesting targets: Kv1.3 is related to prevention of 
proliferation and clonal expansion of human T-cells. Hence, various small 
molecular blockers, with inhibitory activity in the nanomolar range, have 
90º
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been identified as potential anti-inflammatory drugs and therapeutics for 
autoimmune diseases (21). Moreover, Kv1.5 has been implicated in a 
number of cardiac diseases. However, to date no selective blocker has been 
reported (22).  
 
Further voltage gated K+ channel blockers targeting the pore domain but 
lacking specific subtype selectivity have been described (23). However, 
despite the high affinity of some of these inhibitors, none of them makes 
full use of the four-fold symmetry of the homotetrameric channels.
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3.2 Designed OH-free calix[4]arene ligands to interact with Kv1 
channels 
 
Fourfold symmetrical ligands greatly benefit from the polyvalency effect 
and some examples of high affinity binding to protein surfaces by have 
been introduced in Chapter 1 and further described in Chapter 2 (see 
references herein). 
 
Trauner et al. (2003) studied synthetic ligands with a four-fold symmetry 
based on water-soluble tetraphenylporphyrins (24). These compounds were 
functionalized at their edges with amines, amino acids and dipeptides with 
positive charges at neutral pH. Competitive binding assays against 125I-
hongotoxin-A19Y/Y37F, as well as electrophysiological studies on 
Xenopus laevis oocytes, showed that positively charged ligands with 
appropriate geometry strongly interact with Kv1.3 channel. 
 
However, though porphyrins fulfill the symmetry requirement, they are 
flat and rigid scaffolds that do not ideally complement the conical pore-
entrance of the channels. In fact, the binding model based on a porphyrin 
lying on top of the channel and perpendicular to the pore, was recently 
revised by Trauner, Baldus et al., who showed by solid state NMR and 
molecular dynamics that the core is twisted almost parallel to the channel 
axis, with only one positively charged side arm actually interacting with the 
channel pore domain (Fig. 3.5) (25).  
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Fig. 3.5: (a) Top view of KcsA-Kv1.3 bound to the porphyrin 
and (b) side view with overlay of the ten lowest-energy 
structures according to HADDOCK docking (26), reproduced 
from ref. 25. 
 
Unlike porphyrins, calix[4]arenes display conical shapes which would 
likely complement the shape of the extracellular face of a Kv channel. Thus, 
in collaboration with D. Trauner and E. Isacoff (Departments of Chemistry 
and Molecular & Cell Biology, UC-Berkeley), we designed C4 symmetric 
ligands based on calix[4]arenes with a well-defined cavitand conformation.  
 
We expected the affinity to arise from i) interactions of four positively 
charged “arms” at the upper rim of the ligands with the extracellular surface 
of the channel, the “turret loop” and ii) geometric complementarity of the 
conical calix[4]arene scaffold with the extracellular vestibule of the 
channel.  
Preliminary docking studies, based on the crystal structures of KcsA (6) 
and p-thiourea calix[4]arene (27), confirmed that OH-free calix[4]arenes 
were small enough to deeply penetrate the extracellular surface of the 
channel, keeping the lower rim oriented towards the pore (Fig. 3.6). 
a) b)
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Fig. 3.6: Docking of an OH-free calix[4]arene (stick model) on 
KcsA (ribbon model): top view (left) and side view (right). 
 
Hence we focused on the synthesis of a series of OH-free calix[4]arenes 
with positively charged groups on the upper rim as potential blockers of Kv 
channels. We further generated neutral and negatively charged ligands, as 
well as O-alkyl analogues, as negative controls for the binding event. 
Electrophysiological methods and molecular dynamics were employed to 
investigate the blocking properties as well as the interaction mode of the 
ligands. 
90º
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 3.3 Synthesis of Kv1 channel blockers  
 
Our initial goal was to generate the p-(aminomethyl)calix[4]arene 
precursor 28, which would give rise to a series of guanidinium-, amino 
acid- and peptide-endowed OH-free calix[4]arenes (Fig. 3.7). 
 
 
Fig. 3.7: Compound 28 as precursor for various OH-free calix[4]arenes. 
 
To generate the tetramino precursor we first attempted a strategy via a 
tetraazide intermediate 30 (Fig. 3.8). A similar synthesis has been reported 
by Regnouf-de-Vains et al. (28), on OH-free calix[4]arenes with longer 
alkyl chains between the aromatic ring and the ammonium groups, based on 
a previous work from Gutsche et al. (29). Calix[4]arene 8 reacts smoothly 
with formaldehyde and secondary amines to yield a Mannich base, 
following the traditional procedure described in the literature (30). Mannich 
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bases are currently converted to the corresponding quaternary ammonium 
salts and subsequently reacted with a nucleophile to replace the amino 
group (31). Hence, treatment of the salt with sodium azide yielded 
precursor 30.  
 
Fig. 3.8: Failed synthetic pathway via tetraazide intermediate 30. 
 
However, reduction to the expected compound 28 failed under different 
methods: hydrogen over palladium (32), triphenylphosphine (33), and 
lithium aluminium hydride (34). Likely, the acidic phenol groups interfere 
with the reduction reagents. Actually, although access to 28 via azide 
reduction was suggested by Gutsche et al. (29), neither the synthesis, nor 
the product were described. In fact, the product was detected by MS-ESI(+) 
analysis in crudes from LAH reduction, but it likely degraded during work-
up, no matter the base or the salt were targeted.  
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Thus, we switched to a strategy in which lower rim phenols were initially 
protected with semi-permanent groups and deprotected only after the upper 
rim had been properly functionalized. O-protecting benzyl and p-
methoxybenzyl groups were employed (Fig. 3.9).  
 
 
Fig. 3.9: Failed synthesis of compounds 28 and 29 via O-benzyl 
protected precursors. 
 
Starting from calix[4]arene 8, p-bromocalix[4]arene 32 was obtained 
quantitatively (35). Lower rim alkylation proceeded smoothly either with 
benzyl bromide or with its p-methoxybenzyl analogue (32,36). Thereafter, 
cyanation was attempted on a microwave oven, as described for compounds 
23a/b, but conditions were too harsh for precursors 33a/b and only 
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degradation products were harvested. However, using conventional heating 
and no pressure (37), enabled to generate cyano derivative 34 in satisfactory 
yields. This was not feasible for precursor 33b, which degraded prior to 
complete nitrile incorporation. 
 
Reduction of the cyano groups following previous described conditions 
yielded p-amino precursor 35 almost quantitatively. In this context, we tried 
to obtain compound 28 via O-benzyl removal on precursor 35 through 
hydrogenolysis (38), but again failed to isolate final product (Fig. 3.9). 
 
Incorporation of N,N'-bis-(tert-butoxycarbonyl)guanidine N''-triflate on 
35 led to compound 36, in analogy to 24a/b, although in surprisingly low 
yields (16%). Furthermore, upper and lower rim protecting groups removal 
under acidic conditions (TFA) did not proceed as expected: Whereas Boc 
groups were cleaved easily, as assessed by analytical HPLC, O-benzyl 
group removal proceeded more slowly. Prior to complete conversion, the 
final compound started to disappear, probably due to concomitant N-
debenzylation, as shown in Fig. 3.10.  
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Fig. 3.10: HPLC chromatograms of Boc and O-Bn cleavage 
crude reactions of compound 36 under acid conditions after 10 
min, 2 h, and 4 h. Before full conversion takes place, 
degradation occurs (see peak at ~ 2.5 min and others, conds.: 5-
95% CH3CN in H2O + 0.05% TFA in 20 min, 3 µl, 1 ml/min, 
220 nm). 
 
Meanwhile the p-tetracarboxylic compound 37 was generated through 
classical nitrile oxidation (39). Thereafter incorporation of N-tert-
butoxycarbonyl-guanidine, following a procedure described by Schmuck et 
al. (40), was attempted. Obtention of final OH-free compound 3 was 
straightforward, as shown in Fig. 3.11, by simultaneous upper and lower 
rim removal of protecting groups in a trifluoroacetic solution.  
 
N
3OH
NH2H3N
N
OBn
NH3H2N
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Fig. 3.11: Synthesis of ligand 3. 
 
The functional acylguanidine group has an increased acidity, as compared 
to simple guanidinium cations, besides additional hydrogen bonds to bind 
to carboxylates in polar solvents (40). Thus, compound 3 was as good as 
molecule 28 to bind the pore entrance of Kv1 channels. 
 
Encouraged by this result, we decided to build the series of OH-free 
calix[4]arenes by generating amide bonds on carboxylic precursor 37, thus 
obtaining C-linked instead of N-linked functionalized ligands, a procedure 
previously reported by Ungaro et al. (41). 
 
Carboxylic acid activation was attempted by three methods, prior to 
reaction with N-(tert-butoxycarbonyl)-ethylenediamine (Fig. 3.12).  
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Fig. 3.12: Carboxylic acid activation. 
 
Very low yields (6%) were obtained employing classical coupling 
reagents such as N,N’-dicyclohexylcarbodiimide (DCC) and 
hydroxybenzotriazole (HOBt) (A), but yields slightly improved (to 18%) 
with O-(benzotriazol-1-yl)-N,N,N',N'-
bis(pentamethylene)uroniumtetrafluoroborate as coupling reagent in the 
presence of Et3N (B). In both cases, reaction went almost to completion but 
crudes were cumbersome to purify by precipitation and silica gel 
chromatography. Hence, though method (C) involved two steps instead of 
one, the intermediate O-succinimidoyl ester 39 was easily isolated by 
precipitation from the reaction crude and both reactions occurred with 
satisfactory yields. Moreover, the succinimidoyl derivative 39 provided us 
with a stable and storable compound on which to perform additional amide 
couplings in a straightforward manner.  
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Thus, protected compounds 40-43 were obtained from 39 by 
incorporation of N-(tert-butoxycarbonyl)-ethylenediamine, L-Lys(Boc)-
OMe, L-Arg(Pbf)-OMe and L-Ala-OMe, respectively. Further deprotection 
of these intermediates at the upper and lower rims resulted in cationic 
ligands 4-6 and in neutral compound 7 (Fig. 3.13).  
 
Methoxy esthers did resist the acidic conditions employed for final benzyl 
removal as long as no water traces were present and temperature conditions 
were controlled. Surprisingly, amide-protected amino acids, such as L-Lys-
NH2, gave rise to secondary reactions during the acid O-benzyl removal 
step, thus amide-protected amino acids were discarded therein.  
 
Amino acid L-Arg-OMe had to be incorporated with its guanidinium 
group masked, as otherwise no incorporation would occur. Fortunately, Pbf 
(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sufonyl) was also cleaved 
under TFA treatment and could easily be removed during work-up. 
 
 
Fig. 3.13 : Synthetic scheme of compounds 4-7.  
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Obtention of tetraanionic negative control 9 via oxidation of OH-free p-
formyl-calix[4]arene 44 with a mixture of sulfamic acid and sodium 
chlorite was attempted next, as described for O-alkyl p-
formylcalix[4]arenes (42), but the reaction was unsuccessful. Thus 9 
resulted from debenzylation of 37 (Fig. 3.14).  
 
 
Fig. 3.14: Synthesis of compound 9. 
 
Several O-alkyl calix[4]arenes controls (10-12) were synthesized by 
analogous procedures as for compound 3, from the corresponding 
carboxylic acids (Fig. 3.15) (refs. 61 and 63, Chapter 2). Compound 10 
contains two short loops that cannot enter the channel simultaneously but 
that could allow the molecule to adjust in a slightly distorted way, which 
cannot be possible with longer or less structured side chains, such as in 11 
and 12. 
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Fig. 3.15: Synthetic scheme of compounds 10-12. 
 
Finally, phenol derivative 13, a non macrocycle negative control, was 
readily prepared in two steps from commercially available 4-
benzyloxybenzoic acid (Fig. 3.16). 
 
Fig. 3.16: Synthesis of control compound 13. 
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Finally, in collaboration with E. Dalcanale and E. Biavardi (Department 
of Chemistry, University of Parma, Italy), we synthesized ligand 14, 
analogous to compound 3, but based on a resorcinarene platform (Fig. 
3.17). 
 
Fig. 3.17: Synthesis of resorcinarene 14. 
 
To this aim, the readily available calix[4]resorcinarene 48, (43) was 
brominated in phenol’s orto-position with NBS to give 49 as described 
(44). After bridging the phenol positions with dibromomethane, metal-
halogen exchange was performed on compound 49 followed by 
methoxycarbonyl incorporation. The esthers were subsequently hydrolysed 
to their free acids and these were transformed into carboxyguanidinium 
groups, following the same procedure described for compounds 3 and 10-
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13. Reaction of the tetralithium intermediate with CO2(g), to directly obtain 
the tetracarboxyl derivative was unsuccessful in our hands (45). 
 
At this point we had succeeded to generate a series of conical 
calix[4]arenes, shown in Fig. 3.18, comprising seven OH-free 
calix[4]arenes 3-9 with different upper rim functionalization in addition to 
several O-alkyl calix[4]arenes 10-12, one control for the C4 symmetric 
design, phenol 13, and a control for the calixarene platform, resorcinarene 
14, endowed with carboxyguanidinium groups on their wider edges. 
 
 
Fig. 3.18: Calix[4]arenes 3-12, phenol 13 and resorcinarene 14 
studied as channel blockers. 
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3.4 Molecular dynamics performed at ICIQ (Dr. E. Santos) 
 
Docking studies were performed with structures 3, 6 and 11, employing 
the coordinates of the crystal structure of the Kv1.2 potassium channel, 
(pdb: 2a79) (9), excluding chain A and part of chain B (residues 32 to 131). 
Thus, the integral membrane component of Kv1.2 was considered.  
 
They indicated that the conical platform of OH-free calix[4]arenes was 
indeed well suited to deeply penetrate the extracellular outer vestibule of 
the channel (Fig. 3.19) (46).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19: Top and side wireframe views of calix[4]arenes 3 (a), 
6 (b), and 11 (c) docked into the x-ray structure of the human 
voltage dependent Kv1.2 potassium channel. Only the backbone 
helices of the alpha subunits are shown. The Asp379 side chains 
are represented, showing the four ion-pair, hydrogen bonded 
contacts with the guanidinium residues of the calix[4]arene. 
Structures were optimized in vacuo at 300 K applying 
positional restraints to Kv1.2 (reproduced from ref. 46). 
 
 a b c 
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Protein-ligand stabilities were assessed by analyzing the trajectories 
obtained in 1500 ps molecular dynamics simulations in vacuo at 300 K with 
positional restraints. To evaluate protein-ligand binding affinity, we 
computed both the Xscore empirical scoring function and the variation in 
the guanidinium-carboxylate (Asp379) distances versus time. Xscore was 
used to evaluate, for each trajectory, 128 structures collected every 12 ps. 
The values obtained for the three calixarenes were very similar and only 
slightly fluctuated during the molecular dynamics simulations. The average 
Xscore value of all the complexes formed with 3 was 6.65. The complexes 
in which 6 and 11 intervened had values of 6.30 and 6.32 respectively. This 
demonstrated high and similar protein-ligand affinity in the three cases.  
 
To estimate the variation of the hydrogen bond guanidinium-carboxylate 
distances we monitored all the NH-OC distances at every step. The two 
values corresponding to a same guanidinium-carboxylate interaction were 
averaged. Thus, the result depended on the fine orientation of both 
interactions. Comparison of the plots versus time pointed out a slightly 
larger fluctuation of the hydrogen bond distances in 3. In this ligand the 
four interactions oscillated between 1.6 and 2.4 Å during the whole 
trajectory. In compound 6 the four of them were highly fixed at a distance 
of 1.6-1.7 Å. Three of the interactions in compound 11 were maintained at 
this distance but the remaining one highly fluctuated between 1.6 and > 3 
Å. This was due to the tilted orientation of the calixarene on the Kv1.2 
surface, which caused one of the guanidinium groups of the calixarene to 
keep away from the corresponding aspartate. Thus, 6 was the ligand with 
most favorable hydrogen bonding distances followed by 11. In any case, the 
Conical calix[4]arenes as reversible blockers of voltage-dependent potassium channels 
 126 
three compounds showed to maintain all the guanidinium-carboxylate 
groups at standard hydrogen bonding distances. 
 
In conclusion, molecular dynamics indicated that all three ligands bound 
the protein with high affinity by establishing strong hydrogen bonds and by 
maintaining the lower rim embedded in the channel pore. The two crown 
ether bridges apparently did not prevent the interaction of 11 with Kv1.2, 
but instead caused the ligand to be slightly twisted with respect to 3 and 6. 
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 3.5 Results from eletrophysiology studies performed at UC 
Berkeley (S. C. Bell and Dr. E. Y. Isacoff) 
 
3.5.1 Introduction to voltage clamp 
 
The two-electrode voltage clamp (TEVC) is a method that allows ion 
flow across the cell membrane to be measured as an electric current (I), 
since the transmembrane potential is held under constant experimental 
control with a feedback amplifier. Voltage dependent potassium channels 
expressed in Xenopus oocytes can be studied using TEVC (Fig. 3.20): The 
membrane of the oocyte is penetrated by two microelectrodes, one for 
voltage sensing, relative to the ground, and one for current injection. The 
user sets a "holding voltage", or "command potential", and the voltage 
clamp uses negative feedback to maintain the cell at this voltage. The 
electrodes are connected to an amplifier, which measures membrane 
potential and feeds the signal into a feddback amplifier. This amplifier also 
gets an input from the signal generator that determines the command 
potential, and it subtracts the membrane potential from the command 
potential (Vcommand-Vm), magnifies any difference, and sends an output to 
the current electrode. Whenever the cell deviates from the holding voltage, 
the operational amplifier generates an "error signal", that is the difference 
between the command potential and the actual voltage of the cell. The 
feedback circuit passes current into the cell to reduce the error signal to 
zero. Thus, the clamp circuit produces a current equal and opposite to the 
ionic current. This can be measured, giving an accurate reproduction of the 
currents flowing across the membrane (47).  
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Fig. 3.20: Two-electrode voltage clamp. 
 
X. laevis oocytes provide a convenient system to study potassium 
channels because they are single cells of macroscopic size (~1 mm in 
diameter) that possess an endogenous expression system and an efficient 
trafficking of proteins to the membrane. 
 
They are obtained from ovarian lobes in the abdomen of the frogs through 
surgery (Fig. 3.21). The follicle wall is removed and the sorted oocytes are 
incubated until microinjection of messenger RNA (mRNA). Injection of the 
mRNA of the channel under study leads to its overexpression on the 
membrane of the oocyte, and minimizes the presence of endogenous 
channels that otherwise would interfere with electrophysiological 
experiments. After injection into the cytosol, the oocytes are incubated for 
12 h to 3 days at 12-18 ºC, depending on the mRNA construct, the oocyte 
batches, the channel expression requirements etc. Thereafter oocytes are 
ready for TEVC studies.  
3.5.1 Introduction to voltage clamp 
 
 129 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.21: From Xenopus frog to TEVC experiments.
 
3.5.2 TEVC results  
 
Inhibition of Kv1 channels by calix[4]arene compounds. 
 
TEVC experiments for this project were initiated by us during a short 
research stage (Aug. 07-Oct. 07) at the laboratories of Profs. D. Trauner and 
E. Isacoff, in the Departments of Chemistry and Molecular Biology at UC-
Berkeley, and later taken up and completed by PhD student Sarah Bell (E. 
Isacoff’s group).  
 
Either Shaker potassium channel and Kv1.3, both members of the Kv1 
subfamily, were expressed in oocytes. Moreover, two different Shaker 
3. Incubation 2. Microinjection 
4. TEVC
1. Surgery
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channel constructs were initially employed: Shaker H4 IR(∆6-46) T449F 
(Shaker T449F) and Shaker H4 IR(∆6-46) wt (Shaker wt). Both Shaker 
constructs lack an N-terminus domain which inactivates the channel from 
the intracellular side, in a voltage independent manner (N-type 
inactivation). However, they differ in that mutation T449F renders the 
channel more sensitive to external block by TEA.i 
 
                                                          
i
 The Shaker clone Sh H4 IR (∆6-46) in the pBluescript2 KS+ vector was previously 
prepared by Sarah Bell (E. Isacoff’s group) performing site-directed mutagenesis from the 
Shaker H4 IR T449F (QuikChange protocol, Strategene). The rKv1.3 construct was cloned 
into in the pGEM-HE vector as well. Finally, all DNA was confirmed by DNA-sequencing 
previous to performing transcription (mMessage mMachine T7 transcription kit, Ambion).  
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Ionic currents were measured by TEVC in cells expressing the Shaker or 
Kv1.3 channel in the presence of each calix[4]arene compound. A typical 
experiment included three sequential protocols: First, current elicited by test 
voltages that range from -80 mV to +60 mV, are applied in 10 mV 
increments, from a holding potential of -80 mV, and recorded in order to 
evaluate the channel expression and leak of the oocyte cell under study. 
Once, the expected behavior is observed, the second protocol, which 
consists in pulses from resting (-80 mV) to open states (+20 mV), is 
launched to test Imax. After reaching the steady state, inhibitor solution is 
perfused and current decrease is expected. Once maximum inhibition is 
achieved, a washout solution is perfused to remove any reversible blocker 
from the oocyte surface. Finally the first protocol is repeated to evaluate if 
the oocyte membrane has been fully recovered. The sequence of protocols, 
gives rise to three different graphs represented in Fig. 3.22. 
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Fig. 3.22: Sequence of graphs [I(µA) vs time] 
obtained with CLAMPEX software for the three 
protocols described, while perfusing compound 6 
(50 µM) on oocytes expressing Shaker wt. 
 
Normalizing the current obtained during the second protocol gives rise to 
a graph, as the one depicted in Fig. 3.23, showing the typical response of an 
oocyte expressing Shaker channel, when exposed to 50 µM compound 6. 
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Fig. 3.23: Reversible reduction of Shaker ionic current in 
response to application of 50 µM ligand 6 (% inhibition vs 
time). Ligand 6 was applied at A and washed out at B. Note that 
inhibition and recovery occur in two distinct phases (reproduced 
from ref. 46).  
 
The percent inhibition elicited by application of compounds 3-14 was 
compared to that induced by the pore blocker TEA (Fig. 3.24). At this 
concentration, calixarenes 3-14 caused different levels of reduction in 
Shaker wt ionic current, which in most cases was reversible. TEA was used 
as a positive control of a reversible open voltage-dependent K+ channel pore 
blocker (16-18). 
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Fig. 3.24: % inhibition elicited by application of 50 µM of 
compounds 3-14 and TEA to Xenopus laevis oocytes expressing 
the Shaker channel. (n > 4 for each condition; error bars 
indicate SEM). 
 
At 50 µM, compounds 3-14 caused different levels of reduction in Shaker 
ionic current, which in most cases was reversible: Compounds 
functionalized either with carboxylates, ammonium or neutral functional 
groups at the upper rim, did not exert significant reduction in Shaker ionic 
current. On the contrary, ligands 3 and 6 containing guanidinium groups at 
the upper rim of a OH-free calix[4]arene scaffold, aimed at interacting with 
negatively charged residues and hydrogen bonding in the turret loop, 
proved promising ligands. When applying O-alkyl derivatives 10 and 12 to 
oocytes expressing the Shaker channel, decreases in ionic current were also 
seen, but these effects were not reversible and cell health was visually 
compromised. Lower rim alkylation with hydrophobic residues might cause 
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non-specific interactions with the membrane lipids or other hydrophobic 
portions of the Shaker channel which could not be restored by application 
of the aqueous recording solution used for the washout. Quite remarkably, 
but in agreement with computer modeling studies, ligand 11, carrying two 
crown ether loops at the lower rim, caused reduction in Shaker ionic 
currents in a reversible manner and even to a larger extent than the OH-free 
analogues 3 and 6. It is known that crown ether bridges at vicinal lower rim 
positions in a calix[4]arene strongly contribute to keep the conical shape of 
the macrocycle, preventing it from collapsing into the so-called pinched 
conformations (43a). The conical shape is also maintained in the OH-free 
derivatives, due to the cyclic array of hydrogen bonds. At the same time, 
the crown ether bridges on 11 do not create a severe steric effect, since the 
ligand can comfortably fit at the top of the channel in a slightly tilted 
orientation, as was clearly seen by molecular dynamics simulations, 
described later.  
 
Furthermore, the effect of the multivalency present in the calix[4]arene 
macrocycle was evidenced by the fact that a simple phenol such as 13 
showed very little inhibition at 50 µM. Even at four times the concentration 
employed for ligand 3, thus at the same effective concentration, phenol 13 
did not reduce the positive current and even caused some minor negative 
current to arise (Fig. 3.25). 
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Fig. 3.25: Comparison of monomer vs fully assembled 
calixarene compound: X. laevis oocytes expressing Shaker wt 
were incubated with either 25 µM ligand 1 (n = 4), 100 µM 
ligand 11 (n = 5), or DMSO (2% v/v), n = 4). Data in bar 
graphs, error bars indicate SEM (reproduced from ref. 46). 
 
Changes in the counter-anions (either chloride or trifluoroacetic acid) had 
no measurable effect on the channel binding properties of the 
calix[4]arenes. Furthermore, the presence of < 2% DMSO in the bath 
solution was not harmful to the cells (Fig. 3.25).  
 
Finally resorcinarene analogue 14 had a minor effect on current reduction 
(Fig. 3.24), probably due to the insolubility of this material at 50 µM in 
ND96 -the buffer employed throughout the electrophysioloy studies- with 
1% DMSO. Thus no conclusion could be drawn concerning the adaptability 
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of resorcinarene 14 architecture to Shaker surface compared to 
calix[4]arene 3. 
Among the most active ligands (3, 6 and 11), ligand 3 had a limited 
solubility and ligand 11 with bulkier substituents on the lower rim did dock 
into the pore in a tilted orientation. Therefore, in the rest of our studies, we 
focused on ligand 6. 
 
Inhibition includes gating modification.  
 
Ligand 4 showed a concentration dependent inhibition of both Shaker and 
Kv1.3, the two related members of the Kv1.x ion channels subfamily 
employed in this study (Fig. 3.26). While the inhibition was greater in 
Kv1.3, the apparent affinity was similar for the two channels. The Hill 
coefficients for the two channels (1.0±0.3 and 1.1±0.7, respectively) were 
close to 1, fitting with the proposed molecular model in which a single 
calix[4]arene docks in the outer mouth of the pore and interacts with 
residue Asp379 (Kv1.2 sequence numbering), which is shared by all Kv1.x 
subfamily members. 
 
Even at saturating concentrations of calix[4]arene 4, Shaker ionic current 
was not completely inhibited (Fig. 3.26), suggesting, an incomplete 
occlusion of the pore. 
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Fig. 3.26: Concentration dependence of compound 6 on 
macroscopic ionic currents in X. laevis oocytes expressing 
Shaker channels (a) or Kv1.3 channels (b). (n > 3 for each data 
point; error bars indicate SEM). Data fit to a single Boltzmann. 
Shaker: max = 63±10, Kd = 25±11 µM, m = 1.0±0.3. Kv1.3: max 
= 85±16, Kd = 14±9 µM, m = 1.1±0.7.  
 
The effect of ligand 6 could not be entirely attributed to pore block. The 
rate of channel opening was slowed (Fig. 3.27a) and the voltage 
dependence of channel opening was shifted in the positive direction by 
ligand 6 (Fig. 3.27b), indicating that binding relatively stabilizes the resting 
state or an intermediate state preceding opening in the activation pathway.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.27: (a) Voltage-step protocol from -80 to +60 mV: Opening 
kinetics are slower in the presence of 50 µM ligand 6 (right traces) 
compared to control (left traces). (b) Ligand 6 (50 µM) shifts the 
voltage dependence of channel opening to the right. Conductance 
measured from inward tails in 98 mM external K+. (n = 4, error bars 
indicate SEM). Control solution before exposure: max = 0.97±0.04, 
V0.5 = -42±1 mV, m = 3.6±0.9. During ligand 6 application: max = 
0.68±0.02, V0.5 = -12±1 mV, m = 11±1.2 (ref. 46). 
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The onset of current inhibition and of the gating effect occurred in 
parallel, with reduction in current amplitude tracked by the slowing of 
channel opening (Fig. 3.28 a,b). 
 
a)                                                                b) 
 
 
 
 
 
 
 
 
 
Fig. 3.28: (a) Progressive slowing of opening kinetics 
accompanies progressive inhibition of current amplitude upon 
application of 50 µM ligand 6 (steps from holding potential of -
80 mV to +20mV). (b) Time course of reduction of current 
amplitude parallels slowing of channel opening following 
application of 50 µM ligand 6 (reproduced from ref. 46). 
 
We wondered whether the gating effect reflected an influence of ligand 6 
on the protein motions underlying voltage sensing. To address this we 
employed a technique that would distinguish between effects on the voltage 
sensing domain and pore blocking properties. 
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3.5.3 Voltage clamp fluorometry results  
 
A structural link between reversible block and inactivation of a voltage 
dependent channel chimaera (KcsA-Kv1.3) has been previously reported 
with reversible pore blocking tetraphenylporphyrin derivatives whose 
positively charged arms deeply insert into the selectivity filter (24,25). 
Likely, the interaction of 6 with the selectivity filter of Shaker channels 
exerts the same inactivation effect observed for the porphyrin ligands on 
KcsA-Kv1.3.  
 
For a structural proof of this allosteric effect, we employed voltage clamp 
fluorometry which measures structural rearrangements in the S4 voltage 
sensor (48). Recordings were carried out in the W434F mutation, which 
locks the channel in the non-conducting P-type inactivated state, but 
permits free motion of S4 (49). A single cysteine mutation was also 
introduced in the extracellular portion of the Shaker S4 segment (A359C) to 
allow for site-specific conjugation with tetramethylrhodamine-6-maleimide, 
an environmentally sensitive fluorophore, and to monitor the movement of 
the voltage sensing domain (50). Ligand 6 (200 µM) was found to slow the 
rate of S4 motion at the top of the voltage dependence curve where 
channels open (Fig. 3.29).  
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Fig.3.29: Fluorescence analysis of kinetic effects of ligand 6. 
Representative normalized fluorescence traces showing Shaker 
voltage sensor movement in the absence (top) and presence 
(bottom) of ligand 6. A slowing in kinetics upon 
hyperpolarization and depolarization steps is seen upon 
application of ligand 6 (200 µM, reproduced from ref. 46). 
 
This result is consistent with the observation that channel opening is 
slowed by the ligand (Figs 3.27a,b and 3.28a,b). 
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3.6 Conclusions and outlook 
 
In conclusion, we show that guanidilated OH-free and bis-crowned 
calix[4]arenes, constitute a versatile class of non toxic reversible voltage 
dependent K+ channel ligands.  
 
Molecular modeling predicts an interaction with the turret loop and 
docking in the outer mouth of the pore of Kv channels for compounds 3, 6, 
and 11. A Hill coefficient of 1 for inhibition of the current is consistent with 
this model. The inhibition is incomplete at saturating concentrations. In 
addition, the ligand shifts the voltage dependence of gating and slows down 
both the opening of the gate and the voltage sensing motion of S4.  
 
Similar allosteric behaviour have been recently described by Baldus and 
co-workers based on solid state NMR: conformational changes induced by 
different natural and abiotic pore blocking ligands of Kv channels cause 
subsequent changes in their gating and activation properties (25,51). Hence, 
similar solid state NMR studies with calixarene ligand 6 would provide us 
with structural data to fully understand the movements caused by calixarene 
6 binding on Kv1.x conformation and confirm the C4 symmetric binding 
predicted by molecular modeling.  
 
Furthermore, based on the results obtained so far, a new generation of 
ligands is under study, taking advantage of the divergent synthetic strategy 
for upper rim functionalization of OH-free and the rigidity of bridged 
calix[4]arenes. Therefore, a study of the footprints of toxins like AgTx 
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(20,52), and δ-dendrotoxin (53) on the surface of Shaker channel will be 
performed. Increasing the affinity of the channel-calix[4]arene interaction 
through further functionalization of 6 with suitable peptide chains attached 
to the upper rim is currently underway. Ultimately, the development of this 
new class of compounds might lead to novel therapeutic agents against 
various ailments such as autoimmune disorders, diabetes, epilepsy, or 
cardiac diseases (54).  
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3.7 Experimenal part 
 
General procedures: See section 2.8. 
 
Compounds 51 and 52 were obtained and kindly provided by PhD student 
Elisa Biavardi at Enrico Dalcanale’s group (University of Parma, Italy). 
 
5,11,17,23-Tetraazidomethyl-25,26,27,28-tetrahydroxycalix[4]arene 
(30). 
OH
30
ICH3, N3Na, DMSO
4
OH
31
460%
N3N
 
To a solution of compound 31 (0.15 g, 0.23 mmol) in DMSO was added 
ICH3 (0.085 mL,1.38 mmol) with a syringue and the solution was stirred at 
rt for 40 min. Thereafter NaN3 (0.15 g, 2.3 mmol) was added and the 
reaction was heated to 80 ºC and stirred for additional 4 h. Next, the 
reaction was cooled on an ice bath and ice/water (10 mL) was added. The 
aqueous solution was additionally acidified with 2M HCl until the 
appearence of a precipitate which was filtered and air dried. Product 30 was 
obtained as a yellow solid in a 60% yield. Mp: 150-152 ºC (dec). 1H NMR 
(DMSO-d6): δ 7.04 (s, 8H, ArH), 4.29 (bs, 4H, CH2Ar), 4.17 (s, 8H, 
ArCH2N3), 4.14 (s, 8H, ArCH2N); 3.58 (bs, 4H, CH2Ar). 13C NMR (CDCl3) 
δ 148.7, 129.3 (CAr), 128.9 (CHAr), 128.3 (CAr), 54.1 (ArCH2N3), 31.9 
(ArCH2Ar). ESI(-) m/z [M - H]-: 643.3 uma. 
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5,11,17,23-Tetradimethylamine-25,26,27,28-tetrahydroxycalix[4]arene 
(31). 
OH
31
AcOH, HCHO, N(CH3)2
THF
4
OH
8
485%
H
N
 
To a solution of 8 (0.5 g, 1.18 mmol) dissolved in THF (11 mL) were 
added acetic acid (1.3 mL), 40% aqueous dimethylamine (0.74 mL) and 
37% aqueous formaldehyde (0.48 mL). The reaction was stirred for 24 h at 
rt, thereafter the solvents were removed in vacuo, and the residue was taken 
up in water (15 mL) and washed with Et2O (3 x 15 mL). Next, the aqueous 
solution was neutralized with 10% K2CO3 solution. The suspension formed 
was stirred overnight at 4 ºC and finally a precipitate was obtained and 
filtered, yielding 85% of pure 31. Mp: 150 ºC (dec).1H NMR (DMSO-d6): δ 
6.85 (s, 8H, ArH), 4.25 (s, 4H, CH2Ar), 3.27 (s, 8H, CH2N), 3.16 (d, J = 
12.0 Hz, 4H, CH2Ar), 2.18 (s, 24H, CH3N). 13C NMR (DMSO-d6) δ 154.1, 
129.9 (CAr), 128.4 (ArH), 125.2 (CAr), 62.5 (ArCH2N), 44.0 (CH3N), 32.5 
(ArCH2Ar). ESI(+) m/z: [M + H]+: 653.4 uma. 
 
5,11,17,23-Tetrabromo-25,26,27,28-tetrahydroxycalix[4]-arene (32). 
 
OH
32
CHCl3, Br2
4
OH
8
H
4quant.
Br
 
To a solution of compound 8 (1.5, 3.53 mmol) in CHCl3 cooled down to 0 
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ºC, bromine (1.5 mL, 29 mmol) was added dropwise and the mixture was 
stirred at rt for 4 h. Thereafter, the reaction was quenched by adding 10% 
NaHSO3 (20 mL) and the mixture was stirred vigorously for 1 h. Thereafter 
a precipitate was filtered and washed with CHCl3 and water (quant. yield). 
Mp: > 350 ºC. 1H NMR (CDCl3) δ 9.72 (s, 4H, OH), 7.25 (s, 8H, ArH), 4.0 
(bs, 8H, ArCH2Ar). ESI(+) m/z: [M + H]+: 736.8 uma. 
 
General procedure for the synthesis of p-bromo-calix[4]arenes 33a and 
33b. 
To a solution of calix[4]arene 27 (0.2 g, 0.27 mmol) in DMF (12 mL) was 
added NaH (0.114 g, 2.85 mmol) and the reaction was heated at 55 ºC for 
30 min. Thereafter the corresponding alkylating reagent was added and the 
reaction allowed to cool down to rt within 4 h. Quenching was performed 
by evaporating the solvent until dryness. Subsequently the residue was 
taken up in CH2Cl2 (8 mL) and washed with 1M HCl (2 x 8 mL), as well as 
once with water (8 mL) and brine (8 mL). Finally, the organic phase was 
dried over anhydrous Na2SO4, filtered and evaporated in vacuo. The 
compounds were obtained after trituration in EtOH. 
 
5,11,17,23-Tetrabromo-25,26,7,28-tetrabenzyloxycalix[4]arene (33a). 
 
 
Product 33a was obtained as a fine cream-colored powder in a 81% yield. 
Mp: 213-216 ºC. 1H NMR (CDC13): δ 7.38-7.20 (m, 20H, ArH), 6.68 (s, 
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8H, ArH), 4.83 (s, 8H, OCH2Ar), 4.04 (d, J = 13.4 Hz, 4H, ArCH2Ar), 2.81 
(d, J = 13.4 Hz, 4H, ArCH2Ar). 13C NMR (CDC13): δ 154.2, 136.8 (CAr), 
131.0, 129.8 (CHAr), 115.5 (CAr), 76.7, 31.0 (ArCH2Ar). ESI(+) m/z: [M + 
H]+ 1097.0 uma. 
 
5,11,17,23-Tetrabromo-25,26,7,28-tetrakis[(p-methoxy)-
benzyloxy]calix[4]arene (33b). 
 
 
Product 33b was obtained as a fine colorless powder in a 64% yield. Mp: 
235-238 ºC. 1H NMR (CDC13): δ 7.14 (d, J = 8.6 Hz, 8H, ArH), 6.79 (d, J 
= 8.6 Hz, ArH), 6.73 (s, 8H, ArH), 4.85 (s, 8H, OCH2Ar), 4.00 (d, J = 13.6 
Hz, 4H, ArCHHaxAr), 3.81 (s, 12H, CH3O), 2.75 (d, J = 13.6 Hz, 4H, 
ArCHHeqAr). ESI(+) m/z: [M + H]+ 1217.0 uma. 
 
5,11,17,23-Tetracyano-25,26,27,28-tetrabenzylcalix[4]arene (34). 
 
 
To a stirred solution of p-bromo-calix[4]arene 33a (1 g, 0.912 mmol) in 
NMP (28 mL) in a 100 mL two-necked flask, CuCN (0.824 g, 9.196 mmol) 
was added under argon. The reaction was heated for 5 h at 200 ºC. After 
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cooling the solution to 50 °C, a solution of FeCl3 (1.80g, 11.2 mmol) in 1M 
HCl (30 mL, caution!) was added and the mixture stirred for an additional 
0.5 h. Thereafter, the solution was cooled down to 7 ºC and the resulting 
cream-colored solid was filtered and recrystallized in toluene. Compound 
29 was obtained as a a fine colorless solid in a 52% yield. Mp: > 350 ºC. 1H 
NMR (CD3CN): δ 7.40-7.27 (m, 20H, ArH), 7.04 (s, 8H, ArH), 5.06 (s, 8H, 
CH2Ar), 4.16 (d, J = 13.8 Hz, 4H, ArCHHaxAr), 3.00 (d, J = 13.8 Hz, 4H, 
ArCHHeqAr). 13C NMR (CD3CN): δ 158.5, 136.1, 135.4, 132.3, 129.7, 
128.9, 128.5 (CAr, CHAr), 118.0 (CN), 107.0 (CAr), 77.26 (OCH2Ar), 
30.71 (CH2). 
 
5,11,17,23-Tetraminomethyl-25,26-27,28-tetrabenzyloxycalix[4]arene 
(35). 
OBn
35
92%
1M BH3-THF
H2N
4
OBn
34
CN
4
 
The same general procedure described to obtain compounds 2a and 2b 
was followed. After removal of the organic solvents, the aqueous layer was 
basified and extracted with CH2Cl2 (2 x 3 mL). The organic layer was dried 
over anhydrous Na2CO3, filtered and evaporated to dryness. Thereafter, the 
residue was triturated in Et2O and final compound 35 was obtained as a 
colorless solid in a 92% yield. Mp: 172-175 ºC (dec). 1H NMR (CD3OH): δ 
7.40-7.22 (m, 20H, ArH), 6.65 (s, 8H, ArH), 5.01 (s, 8H, OCH2Ar), 4.30 (d, 
J = 13.8 Hz, 4H, ArCHHaxAr), 3.49 (s, 8H, CH2N), 2.97 (d, J = 13.8 Hz, 
4H, ArCHHeqAr). 13C NMR (CD3OD): δ 154.1, 136.6, 135.0, 129.3, 127.7, 
126.8 (CAr, CHAr), 71.4 (OCH2Ar), 46.7 (ArCH2N), 31.0 (ArCH2Br). 
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ESI(+) m/z: [M + H]+: 901.5 uma. 
 
5,11,17,23-Tetrakis(N,N’-bis-tert-butoxycarbonyl)guanidinemethyl-
25,26-27,28-tetrabenzyloxycalix[4]arene (36). 
 
The same general procedure described to obtain compounds 19a and 19b 
was followed. Eluent: 100% CH2Cl2→CH2Cl2/Et2O, 98:2. and compound 
31 was obtained as a colorless foam in a 16% yield. Mp: > 350 ºC. 1H NMR 
(CDCl3): δ 8.27 (tr, 4H, NH), 7.34-7.20 (m, 20H, ArH), 6.56 (s, 8H, ArH), 
4.99 (s, 8H, OCH2Ar), 4.29 (d, J = 6.3 Hz, 8H, CH2N), 4.13 (d, J = 12.5 
Hz, 4H, ArCHHaxAr), 2.87 (d, J = 12.5 Hz, ArCHHeqAr), 1.51 (d, J = 6.3 
Hz, 72H, C(CH3)3). 13C NMR (CDCl3): δ 163.8 (CO), 155.8 (CAr), 153.03 
(CGuan), 137.7, 135.4, 130.8 (CAr), 129.9, 128.1 (CHAr), 82.8 (C(CH3)3), 
78.9 (OCH2Ar), 44.8 (CH2N), 31.6 (ArCH2Ar), 29.3, 28.4 (C(CH3)3). Exact 
Mass (ESI+): m/z [M + H]+: calc.: 935.9949 uma, found: 935.9935 uma. 
 
25,26,27,28-Tetrabenzyloxy[4]arene-5,11,17,23-tetracarboxylic acid 
(37).  
 
p-Cyano-calix[4]arene precursor (34) (95 mg, 0.107 mmol) was dissolved 
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in EtOH (11 mL) in a round 100 ml two-necked flask. KOH (6 g, 107 
mmol) was dissolved in deionized water (4 mL) and added to the flask, 
which was heated under reflux overnight. The reaction was then acidified 
with concentrated HCl and the product was precipitated out, washed with 
H2O (5 mL) and with Et2O (5 mL). Final compound was obtained as a 
colorless solid in a 96% yield. Mp: > 350 ºC.1H NMR (MeOD): δ 12.3 (s, 
4H, CO2H), 7.27-7.29 (m, 20H, ArH), 7.24 (s, 8H, ArH), 5.00 (s, 8H, 
CH2Ar), 4.19 (d, J = 13.8 Hz, 4H, ArCHHaxAr), 3.14 (d, J = 13.8 Hz, 
ArCHHeqAr). 13C NMR (DMSO-d6): δ 167.2 (CO2H), 159.26, 137.08, 
135.11 (CAr), 130.17, 128.60 (CHAr), 125.19 (CAr), 76.62 (CH2CO), 
32.04 (ArCH2Ar). Exact Mass (ESI+): m/z of [M + Na]+: calc.: 983.3043, 
found: 983.3040. 
 
General procedure for the synthesis of compounds 38, 45-47 and 53. 
A solution of (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP, 0.33 g, 0.62 mmol) and N-methylmorpholine 
(NMM, 0.08 mL, 0.67 mmol) in dry DMF (4 mL) was added to a solution 
of the calix[4]arene tetraacid precursor (32, 22, 39 or 4-benzyloxybenzoic 
acid, 0.16 mmol), N-(tert-butoxycarbonyl)guanidine (0.1 g, 0.62 mmol), 
and NMM (0.08 mL, 0.67 mmol) in dry DMF (4 mL). The reaction mixture 
was stirred at rt for 24 h to several days, and then poured into water. The 
resulting colorless precipitate was filtered and dried. The crude compound 
was purified by flash chromatography in silica gel. 
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25,26,27,28-Tetrabenzyloxycalix[4]arene-5,11,17,23-tetrakis[tert-
butylamino(benzamido) methylcarbamate] (38). 
 
The reaction mixture was stirred for 24 h and pure CHCl3 was employed 
as eluent for the chromatographic purification. The product was obtained in 
a 72% yield. Mp: > 350 ºC. 1H NMR (CDCl3): δ 7.30-7.23 (m, 28H, ArH), 
4.99 (s, 8H, CH2Ar), 4.15 (d, J = 14.5 Hz, 4H, ArCHHaxAr), 3.22 (d, J = 
14.5 Hz, 4H, ArCHHeqAr), 1.53 (s, 36H, C(CH3)3). 13C NMR (DMSO-d6): 
δ 159.2 (CGuan), 137.3, 130.3, 128.6 (CAr), 31.7 (ArCH2Ar), 28.4 
(C(CH3)3). Exact Mass (ESI+): m/z of [M + H]+: calc: 1525.6720 uma, 
found: 1525.6753 uma. 
 
25,26,27,28-Tetra-n-propoxycalix[4]arene-5,11,17,23-tetrakis[tert-
butylamino(benzamido) methylcarbamate] (45). 
O
45
PyBOP, NMM, GuanBoc
DMF
4
O
27a
442%
OHO O N
H
NH2N
Boc
 
The reaction mixture was stirred for 4 days and was purified by flash 
chromatography eluting with Hex/Et2O, 9:1. The yield of pure product 45 
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was 42%. Mp: > 350 ºC (dec.). Product 45 was sparingly soluble in all 
common deuterated solvents, therefore its purity was checked by HPLC 
(50→95% CH3CN in H2O + 0.1% TFA for 15 min followed by a 95 to 
100% gradient over 5 min). Exact Mass (ESI+): m/z [M + H]+: calc.: 
1333.6833 uma, found: 1333.6896 uma.  
 
25,26-27,28-Biscrown-3-calix[4]arene-5,11,17,23-tetrakis[tert-
butylamino(benzamido) methylcarbamate] (46). 
O
46
O
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2
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The reaction mixture was stirred for 3 days and the purification was 
achieved by flash chromatography in silica gel (eluent: Hex/Et2O, 4:1). 
Yield was 38%. Mp: > 350 ºC. 1H NMR (CDCl3): δ 7.80 (s, 8H, ArH), 5.09 
(d, J = 12.2 Hz, 2H, ArCHHaxAr), 4.51 (d, J = 12.2 Hz, 2H, ArCHHaxAr), 
4.32-4.22 (m, 12H, CH2O), 3.89 (tr, J = 10.4 Hz, 4H, CH2O), 3.39 (tr, J = 
13.6 Hz, 4H, ArCHHeqAr), 1.51 (s, 36H, C(CH3)3). 13C NMR (CD3OD): δ 
158.9 (COGuan), 152.4 (CGuan), 138.3 (CAr), 129.0, 127.3 (CHAr), 75.1, 
74.3 (CH2), 28.1 (C(CH3)3). Exact Mass (ESI+): m/z [M + H]+: calc.: 
1419.5720 uma, found: 1419.5770 uma.  
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4-(Benzyloxy)-N-(N-(tert-butoxycarbonyl)carbamimidoyl)benzamide 
(47). 
 
The reaction mixture was stirred for 24 h and pure CHCl3 was employed 
as eluent for the chromatographic purification. The product was obtained in 
a 60% yield. Mp: > 350 ºC. 1H NMR (CDCl3): δ 8.06 (d, J = 8.5 Hz, 2H, 
ArH), 7.47-7.32 (m, 5H, ArH), 7.01 (d, J = 8.5 Hz, 2H, ArH), 5.14 (s, 2H, 
OCH2Ar), 1.45 (s, 9H, C(CH3)3). 13C NMR (CDCl3): δ 153.6 (CO), 141.4 
(CGuan), 131.1 (CAr), 125.4, 123.4, 123 (CHAr), 122.9 (CO), 122.2, 109.2 
(CHAr), 64.8 (CH2), 22.7 (C(CH3)3). Exact Mass (ESI+): m/z [M + H]+: 
calc.: 370.1767 uma, found: 370.1779 uma.  
 
tert-Butylamino(benzamido) methylcarbamate resorcinarene (53). 
 
The reaction mixture was stirred at rt for 24 h. The crude was purified by 
flash column chromatography in silica gel (eluent: CH2Cl2/CH3OH, 
99:1→98:2) and obtained in a 52% yield. 1H NMR (CD3OD): δ 7.5 (s, 4H, 
ArH), 5.65 (d, J = 7.4 Hz, 4H, OCHaxHO), 4.95 (q, J = 7.0 Hz, 4H, CH), 
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4.51 (d, 4H, OCHHeqO), 1.82 (d, J = 7.0 Hz, 12H, CH3), 1.45 (s, 36H, 
C(CH3)3). 13C NMR (MeOD): δ 150, 139 (CAr), 100 (CH2), 31 (CH), 27 
(C(CH3)3), 15 (CH3). Exact Mass ESI(+): m/z [M + Na]+: calc.: 1355.5197 
uma, found: 1355.5221 uma. 
 
5,11,17,23-Tetrakis(succinimidoxycarbonyl)-25,26,27,28-
tetrabenzyloxycalix[4]arene (39). 
 
To a suspension of the acid precursor 37 (0.310 g, 0.32 mmol) in dry 
CH2Cl2 and DMF (1:2, 18 mL) were added N-hydroxysuccinimide (0.204 
g, 1.77 mmol) and 1,3-dicyclohexylcarbodiimide (0.372 g, 1.80 mmol). The 
reaction was stirred at rt for 24 h. Then, the solvent was evaporated to 
dryness and the residue was sonicated in a mixture of CH3OH and CH2Cl2 
(1:1, 30 mL). The solid product was filtered and obtained as a grey solid 
(62% yield). Mp: 300 ºC (dec.). 1H NMR (CDCl3): δ 7.48 (s, 8H, ArH), 
7.40-7.21 (m, 20H, ArH), 5.04 (s, 8H, CH2Ar), 4.12 (d, J = 14.4 Hz, 4H, 
ArCHHaxAr), 3.00 (d, J = 14.4 Hz, 4H, ArCHHeqAr), 2.83 (s, 16H, CH2). 
13C NMR (CDCl3): δ 170.3 (CONR), 161.3 (CO2), 161.0, 136.3 (CAr), 
130.7, 130.4, 128.7, 128.5 (CHAr), 119.7 (CAr), 77.2 (ArCH2O), 30.9 
(ArCH2Ar), 25.5 (CH2). Exact Mass (ESI+) m/z [M + Na]+ calc.: 1371.3699 
uma, found: 1371.3693 uma.  
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General procedure for the synthesis of compounds 40-43. 
Compound 34 (0.2 g, 0.15 mmol) was dissolved in a solution of dry 
CH2Cl2 and DMF (1:2, 10 mL). Et3N (0.25 mL, 1.78 mmol) and the 
protected amine (1.78 mmol) were added to the solution. The reaction was 
stirred at rt for 48 h. The solvent was evaporated and the residue dissolved 
in CH2Cl2. The organic phase was washed once with 1N HCl (5 mL) and 
with H2O (2 x 5 mL). After drying with anhydrous Na2CO3 and filtering, 
the solvent was eliminated in vacuo and the products were purified by flash 
chromatography in silica gel as follows.  
 
25,26,27,28-Tetrabenzyloxycalix[4]arene-5,11,17,23-tetrakis(N-tert-
butyl-2-benzamidoethylcarbamate) (40). 
 
The reaction was performed with N-(tert-butoxycarbonyl)-
ethylenediamine and for the purification the eluent was a gradient of 
CH2Cl2/acetone, 3:1→1:1. Product 15 was obtained as a colorless solid 
(51% yield). Mp: 145-150 ºC. 1H NMR (CDCl3): δ 7.37-7.21 (m, 20H, 
ArH), 7.04 (s, 8H, ArH), 6.84 (bs, 4H, NH), 4.98 (s, 8H, CH2Bn), 4.1 (d, J 
= 13.6 Hz, 4H, ArCHHaxAr), 3.44-4.12 (m, 16H, CH2); 2.86 (d, J = 13.6 
Hz, 4H, ArCHHeqAr), 1.44 (s, 36H, C(CH3)3). 13C NMR (CDCl3): δ 168.7 
(CONH), 158.1, 136.8, 135.3 (CAr), 130.1, 128.4, 127.6 (CHAr), 79.6 
(C(CH3)3), 69.7(ArCH2O), 41.1, 40.4 (CH2), 31.9 (ArCH2Ar), 28.5 
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(C(CH3)3). Exact Mass (ESI+): m/z [M + Na]+: calc.: 1551.7539 uma, 
found: 1551.7468 uma.  
 
25,26,27,28-Tetrabenzyloxycalix[4]arene-5,11,17,23-tetrakis[carbonyl-
L-(N-tert-butoxycarbonyl)lysine methyl ester] (41). 
 
H-L-Lys(Boc)-OMe·HCl was employed as the amine reagent and 
chromatographic purification was performed with CH2Cl2/acetone 4:1 as 
the eluent. The product was obtained as a colorless solid (45% yield). Mp: 
150-153 ºC. 1H NMR (CDCl3): δ 7.45-7.1 (m, 28H, ArH), 4.98 (s, 8H, 
CH2Ar), 4.55 (m, 4H, CHα), 4.12 (d, 4H, J = 13.3 Hz, ArCHaxHAr), 3.76 
(s, 12H, CO2CH3), 3.15-3.07 (m, 8H, CH2ε), 2.95 (d, 4H, J = 13.3 Hz, 
ArCHHeqAr), 1.90-1.75 (m, 8H, CH2δ), 1.73-1.50 (m, 8H, CH2ß), 1.52-
1.30 (m, 44H, CH2γ, C(CH3)3). 13C NMR (CDCl3): δ 173.2 (CO2CH3), 
167.0 (CONH), 157.7 (CAr), 156.1 (C), 136.6, 136.3, 135.2 (CAr), 130.1, 
129.8, 129.5, 128.5, 128.3 (CHAr), 53.9 (CHα), 52.8 (CH3O), 40.5 (CH2ε), 
31.5 (ArCH2Ar), 30.3 (CH2ß), 29.3 C(CH3)3, 26.7 (CH2δ ), 22.9 (CH2γ). 
Exact Mass (ESI+) m/z [M + 2Na]2+ calc.: 987.9748 uma, found: 987.9746 
uma. 
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25,26,27,28-Tetrabenzyloxycalix[4]arene-5,11,17,23-tetrakis[carbonyl-
L-N-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)arginine 
methyl ester] (42). 
 
The diprotected amino acid employed was H-L-Arg(Pbf)-OMe·HCl and 
chromatographic purification was performed eluting with CH2Cl2/acetone, 
9:1. The product was obtained as a colorless solid (70% yield). Mp: 170-
172 ºC. 1H NMR (CD2Cl2): δ 7.40-7.22 (m, 28H, ArH), 5.07-4.88 (m, 
CH2Ar), 4.12 (d, 4H, J = 13.7 Hz, ArCHaxHAr), 3.76 (s, 12H, CO2CH3), 
3.2 (m, 8H, CH2δ), 2.98 (d, 4H, J = 13.7 Hz, ArCHHeqAr), 2.97 (s, 8H, 
CH2-Pbf), 2.58 (s, 12H, CH3-Pbf), 2.5 (s, 12H, CH3-Pbf ), 2.08 (s, 8H, CH3-
Pbf), 1.92-1.82 (m, 8H, CH2ß), 1.58-1.48 (m, 8H, CH2γ), 1.46 (s, 24H, 
CH3-Pbf). 13C NMR (DEPTQ135, CD2Cl2): δ 172.7 (CO2CH3), 167.5 
(CONH), 158.7 (CAr), 156.4 (CGuan), 138.4, 136.4, 132.3, 132.3 (CAr), 
129.9, 128.4, 128.3 (CHAr), 124.5, 123.9, 117.6 (CAr), 86.5 (C), 53.8 
(CHα), 52.5 (CO2CH3), 43.3 (CH2δ), 40.4 (CH2ß), 40.0 (ArCH2Ar), 29.3 
(CH2γ), 28.7, 19.3, 18.1, 12.5 (CH3-Pbf). Exact Mass (ESI+) m/z [M + 
2Na]2+ calc.: 1347.5541 uma, found: 1347.5502 uma. 
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25,26,27,28-Tetrabenzyloxycalix[4]arene-5,11,17,23-tetrakis(carbonyl-
L-alanine methyl ester) (43). 
 
The protected amino acid employed was H-L-Ala-OMe·HCl and 
chromatographic purification was performed with CH2Cl2/acetone, 2.5:2 as 
eluent. The pure product was obtained as a colorless oil (46% yield). Mp: 
268-671 ºC. 1H NMR (CDCl3): δ 7.35-7.18 (m, 20H, ArH), 7.09 (s, 4H, 
ArH), 6.99 (s, 4H, ArH), 6.64 (d, J = 7.0 Hz, 4H, NH), 6.63 (s, 4H, NH), 
4.99 (d, J = 15.3 Hz, 8H, CH2Ar), 4.55 (q, J = 7.0 Hz, 4H, CHα), 4.10 (d, J 
= 13.6 Hz, 4H, ArCHHaxAr), 3.77 (s, 12H, CO2CH3), 2.91 (d, J = 13.6 Hz, 
4H, ArCHHeqAr), 1.46 (d, J = 7.0 Hz, 12H, CH3). 13C NMR (DEPTQ135, 
CDCl3): δ 173.73 (CO2CH3), 166.9 (CONH), 157.9, 136.6, 135.2, 125.1 
(CAr), 129.8, 128.4, 128.3, 128.0, 127.05 (CHAr), 76.8 (CH2), 52.3 
(CO2CH3), 48.7 (CHα), 31.4 (ArCH2Ar), 18.1 (CH3). Exact Mass (ESI+): 
m/z [M + Na]+: calc.: 1323.5154 uma, found: 1323.5146 uma. 
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5,11,17,23-Tetraformyl-25,26,27,28-tetrahydroxycalix[4]arene (44). 
 
The same general procedure described to synthesize compounds 21a and 
21b was followed. The mixture was diluted with 1M HCl (50 mL) and 
CH2Cl2 (50 mL) and stirred vigorously for additional 3 h. Therafter, the 
organic layer was separated and washed with water (2 x 30 mL). The 
organic layer over anhydrous Na2CO3 and the solvent was removed in 
vacuo. The remaining residue was taken up in water (10 mL) and the 
resulting precipitate was filtered and washed until neutral pH. Pure 
compound 44 was obtained as a colorless solid in a 85% yield. Mp: > 350 
ºC. 1H NMR (DMSO-d6): δ 9.63 (s, 4H, CHO), 8.75 (bs, 4H, OH), 7.65, (s, 
8H, ArH), 3.95 (bs, 8H, ArCH2Ar). 13C NMR (DMSO-d6): δ 190.4 (d, 
CHO), 160.1 (CAr), 130.5 (CHAr), 129.8, 128.1 (CAr), 31.2 (ArCH2Ar). 
ESI(+) m/z: [M + H]+: 537.2 uma. 
 
General procedure to obtain compounds 3-7 and 10-14. 
Trifluoroacetic acid (103 eq.) was added to a solution of the 
corresponding protected compounds 38, 40-43, 45-47 (1 eq.) dissolved in 
the same volume of CH2Cl2. The reaction was stirred at rt or carried out 
under reflux, depending on the substrates. Analytical HPLC was employed 
to monitor the reaction: 5-95% CH3CN in water + 0.1% TFA in 20 min. 
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25,26,27,28-Tetrahydroxycalix[4]arene-5,11,17,23-tetrakis[N-
(diaminomethyl)benzamide] hydrochloride (3). 
 
Compound 38 (50 mg, 0.033 mmol) was refluxed for 24 h. The solvent 
was evaporated and the residue was dissolved in a solution of 1M HCl (1.5 
mL). The aqueous phase was then washed twice with CH2Cl2 (1.5 mL), the 
solvent was evaporated and the residue was lyophilized to afford 3 as a 
colorless compound (90% yield). Mp: > 350 ºC. 1H NMR (DMSO-d6): δ 
11.02 (s, 4H, OH), 8.49 (br s, 4H, NHGuan), 8.40 (br s, 4H, NHGuan), 7.71 
(s, 8H, ArH), 4.36 (br s, 4H, ArCHHaxAr), 3.48 (br s, 4H, ArCHHeqAr). 
13C NMR (DMSO-d6): δ 167.44 (COGuan), 161.7 (CGuan), 157.7, 130.1 
(CAr), 129.5 (CHAr), 120.9 (CAr), 32.4 (ArCH2Ar). Exact Mass (ESI+): 
m/z [M + H - 4HCl]+: calc.: 765.2857 uma, found: 765.2887 uma.  
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5,26,27,28-Tetrahydroxycalix[4]arene-5,11,17,23-tetrakis[N-(2-
aminoethyl)benzamide] hydrochloride (4). 
90%
OH
4
O
4
NH
NH3 Cl
OBoc
O
4
NH
HN
TFA/CH2Cl2
40
Boc
 
Reaction with 40 (115 mg, 0.075 mmol) was performed at rt for 70 min. 
Work-up as described above for 3, afforded 4 as a colorless compound 
(73% yield). Mp: 160-170 ºC. 1H NMR (D2O): δ 7.55 (s, 8H, ArH), 3.90 
(bs, 4H, ArCH2Ar), 3.51 (tr, J = 5.8 Hz, 8H, CH2CH2), 3.11 (tr, 8H, J = 5.8 
Hz, 8H, CH2CH2). 13C NMR (DMSO-d6): δ 170.23 (CONH), 153.32 (CAr), 
128.53 (CH), 128.37, 125.9 (CAr), 39.39, 37.2 (CH2). Exact Mass (ESI+) 
m/z [M + H - 4HCl] +: calc.: 769.3673 uma, found: 769.3709 uma.  
 
25,26,27,28-Tetrahydroxycalix[4]arene-5,11,17,23-tetrakis(carbonyl-L-
lysine-methyl ester) trifluoroacetate (5). 
 
Reaction with 41 (40 mg, 0.02 mmol) was performed at rt for 18 h. The 
solvent was evaporated to complete dryness (until all traces of acid were 
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removed) and the residue was dissolved in water. Work-up as for 3 gave 
pure 5 as a colorless solid (80% yield). Mp: > 250 ºC (dec.). 1H NMR 
(CD3OD): δ 7.68 (s, 8H, ArH), 4.54-4.50 (m, 4H, CHα), 4.05 (bs, 8H, 
ArCH2Ar), 3.70 (s, 12H, CO2CH3), 2.91 (t, J = 7.6 Hz, 8H, CH2ε), 2.01-
1.81 (m, 8H, CH2δ), 1.73-1.63 (m, 8H, CH2ß), 1.58-1.48 (m, 8H, CH2γ). 
13C NMR (DMSO-d6): δ 172.9 (CO2CH3), 168.8 (CONH), 153.4 (CAr), 
128.53 (CHAr), 127.7, 126.27 (CAr), 52.8 (CHα), 51.4 (CO2CH3), 39.1 
(CH2ε), 30.3 (CH2ß), 26.7 (CH2γ), 22.9 (CH2δ). Exact Mass (ESI+): m/z [M 
+ 2H - 4CH3COOH]2+: calc.: 585.2919 uma, found: 585.2932 uma.  
 
25,26,27,28-Tetrahydroxy-calix[4]arene-5,11,17,23-tetrakis(carbonyl-L-
arginine methyl ester) trifluoroacetate (6). 
 
 
Reaction was performed with precursor 42 (50 mg, 0.019 mmol) at rt for 
13 h. The solvent was evaporated to complete dryness (until all traces of 
acid were removed) and the pure product was obtained by crystallization in 
CH3CN (60% yield). Mp: 245-247 ºC. 1H NMR (CD3OD): δ 7.7 (s, 8H, 
ArH), 4.55-4.50 (m, 4H, CHα), 3.65 (s, 12H, CO2CH3), 3.24-3.18 (m, 8H, 
CH2δ), 1.99-1.78 (m, 8H, CH2ß), 1.70-1.60 (m, 8H, CH2γ). 13C NMR 
(CD3OD): δ 172.7 (CO2CH3), 168.9 (CONHR), 157.4 (CGuan), 156.4 
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(CAr), 128.6 (CHAr), 127.7, 126.3 (CAr), 52.6 (CHα), 51.6 (CO2CH3), 
40.5 (CH2δ), 30.6 (ArCH2Ar), 28.0 (CH2β), 25.2 (CH2γ). Exact Mass 
(ESI+): m/z [M + 2H - 2CF3COOH]2+: calc.: 755.2971 uma, found: 
755.2971 uma.  
 
25,26,27,28-Tetrahydroxycalix[4]arene-5,11,17,23-tetrakis(carbonyl-L-
alanine methyl ester) (7). 
 
Reaction with compound 43 was performed in a TFA:CH3Cl (1:1) 
mixture, at reflux in a closed tube for 1 h. The solvent was evaporated and 
the residue was sonicated in CH3OH, filtered and lyophilized. The product 
was obtained as a colorless solid (quant. yield). Mp: > 350 ºC (dec.).  
1H NMR (CD3OD): δ 7.67 (s, 8H, ArH), 4.52 (m, 4H, CHα), 4.04 (bs, 8H, 
CH2Ar), 3.71 (s, 12H, OCH3), 1.45 (s, 12H, CH3). 13C NMR (CD3OD): δ 
173.8 (CO2CH3), 168.4 (CONHR), 153.1 (CAr), 128.7 (CHAr), 127.7, 
126.7 (CAr), 51.3 (CHα), 48.6 (CO2CH3), 15.6 (CH3). Exact Mass ESI(-): 
m/z [M - H]-: calc.: 939.3300 uma, found: 939.3343 uma.  
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25,26-27,28-Biscrown-3-calix[4]arene-5,11,17,23-tetrakis[N-
(diaminomethyl)benzamide] trifluoroacetate (10). 
 
 
The reaction with precursor 46 was stirred at rt for 13 h. The solvent was 
evaporated and the crude was triturated in EtOAc. The product was 
obtained as a colorless solid (90% yield). Mp: > 350 ºC. 1H NMR 
(CD3OD): δ 7.81 (d, J = 13.3 Hz, 8H, ArH), 5.37 (d, J = 12.4 Hz, 2H, 
ArCHHaxAr), 4.70 (d, J = 12.4 Hz, 2H, ArCHHaxAr), 4.5 (d, J = 12.4 Hz, 
CH2O), 4.37-4.23 (m, 8H, CH2O), 3.89 (m, 4H, CH2O), 3.5 (d, J = 12.7 Hz, 
2H, ArCHHeqAr), 3.43 (d, J = 12.7 Hz, 2H, ArCHHeqAr). 13C NMR 
(CD3OD): δ 168.2 (CONH), 159.7 (CGuan), 157.3, 136.1 (CAr), 126.3 
(CHAr), 76.6, 74.4 (CH2), 30.1, 29.1(ArCH2Ar). Exact Mass (ESI+): m/z 
[M + H - CF3COOH]+: calc.: 1247.3593 uma, found: 1247.3546 uma.  
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25,26-27,28-Tetra-n-propoxycalix[4]arene-5,11,17,23-tetrakis[N-
(diaminomethyl)benzamide] trifluoroacetate (11). 
 
The reaction was stirred overnight at rt. The solvent was evaporated and 
the residue sonicated in CH3CN. The resulting precipitate was filtered and 
the product obtained as a colorless solid (90% yield). Mp: > 350 ºC (dec.). 
1H NMR (CD3CN): δ 8.21 (br s, 6H, NH), 7.80 (br s, 6H, NH),  7.30 (s, 8H, 
ArH), 4.52 (d, J = 13.9 Hz, 4H, ArCHHaxAr), 3.97 (t, J = 7.3 Hz, 8H, 
OCH2CH2CH3), 3.36 (d, 8H, J = 13.9 Hz, ArCHHeqAr), 1.99-1.89 (q, J = 
7.3 Hz, 8H, OCH2CH2CH3), 1.0 (t, J = 7.3 Hz, 12H, OCH2CH2CH3). 13C 
NMR (CD3CN): δ 167.9 (CONH), 161.7 (CGuan), 156.2, 135.7 (CAr), 
128.8 (CHAr), 124.9 (CAr), 77.4 (OCH2CH2CH3), 30.5 (ArCH2Ar), 23.2 
(OCH2CH2CH3), 9.6 (CH3). Exact Mass (ESI+): m/z of [M + H - 
CF3COOH]+: calc.: 1275.4521, found: 1275.4561 uma.  
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25,26-27,28-Tetrabenxyloxycalix[4]arene-5,11,17,23-tetrakis[N-
(diaminomethyl)benzamide] trifluoroacetate (12). 
 
The reaction with compound 38 was stirred at 0-5 ºC (to avoid O-
debenzylation) for 26 h. The reaction was quenched with distilled water, 
and the solvent was evaporated at rt. The residue was dissolved in CH3OH 
and the solvent was eliminated in vacuo again. The pure compound was 
obtained as a colorless solid (90% yield). Mp: > 350 ºC. 1H NMR 
(CD3CN): δ 8.10 (bs, 6H, NH), 7.83 (bs, 6H, NH), 7.38-7.28 (m, 20H, 
ArH), 7.23 (s, 8H, ArH), 6.08 (bs, 1H, 8H), 5.08 (s, CH2Ar), 4.28 (d, J = 
14.3 Hz, 4H, ArCHHaxAr ), 3.07 (d, J = 14.3 Hz, 4H, ArCHHeqAr). 13C 
NMR (CD3OD): δ 167.5 (CONH), 160.4 (CGuan), 156.2, 136.2 (CAr), 
130.2, 128.7, 128.6, 128.3 (CHAr), 125.1 (CAr), 76.9 (CH2Ar), 30.8 
(ArCH2Ar). Exact Mass (ESI+): m/z [M + H - 4CF3COOH]+: calc.: 
1125.4848 uma, found: 1125.4806 uma.  
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N-(diaminomethyl)-4-hydroxybenzamide trifluoroacetate (13). 
 
 
This compound was prepared following the same procedure as for 
compound 3, except for purification on semi-preparative HPLC: the crude 
was dissolved in CH3CN (32 mg/mL), and a gradient of CH3CN in water + 
0.1% CF3COOH (5-60% for 15 min and 60 to 95% for 3 min). The 
compound was obtained as a colorless solid (43% yield). Mp: 282-285 ºC. 
1H NMR (CD3OD): δ 8.57 (s, 1H, OH), 7.97 (d, J = 8.8 Hz, 2H, ArH), 6.98 
(d, J = 8.8 Hz, 2H, ArH). 13C NMR (CD3OD): δ 167.7 (CGuan), 163.3 
(CONH), 130.5 (CHAr), 121.8 (CAr), 115.49 (CHAr). Exact Mass (ESI+): 
m/z. [M + H - CF3COOH]+: calc.: 202.0592 uma, found: 202.0584 uma. 
 
N-(diaminomethyl)benzamide trifluoroacetate resorcinarene (14). 
 
 
The reaction with precursor 53 was stirred for 1 h at 0 ºC. Semi-
preparative purification was performed on an Alltech semiprep column 
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(Alltech C18. Length: 250 mm, ID: 22 mm), with gradient: 5-70% CH3CN 
in H2O + 0.1%. FA. Pure compound 14 was obtained as a colorless solid 
with trifluoroacetate as counteranion (51%). 1H NMR (DMSO-d6): δ 8.31 
(s, 1H, NHGuan), 7.6 (s, 1H, ArH), 5.45 (d, J = 7.7 Hz, 1H, OCHHaxO), 
4.68 (q, J = 7.5 Hz, 1H, CH), 4.3 (d, J = 7.7 Hz, 1H, OCHHeqO), 1.77 (d, J 
= 7.5 Hz, 3H, CH3). Exact Mass ESI(+): m/z of [M + 3FA + Na]+: calc.: 
1093.3264 uma, found: 1093.3241uma 100%. 
 
25,26,27,28-Tetrahydroxycalix[4]arene-5,11,17,23-tetracarboxylic acid 
(9). 
This known compound (55),  was synthesized by a novel procedure. 
 
4
OBn
OH
4
OH
OHO
937
AcOH/HCl
60%
 
The benzyl derivative 37 (52 mg, 0.054 mmol) was suspended in a 
mixture of conc. HCl and acetic acid (1:2, 8 mL). The reaction was stirred 
and heated at reflux for 48 h in a sealed tube. The solvents were evaporated 
and the residue was dissolved in THF-water (3:1) and purified by semi-
preparative HPLC (2.5 mg/mL, 30-36% CH3CN in water + 0.1% TFA 
gradient in 15 min). The pure product was obtained (60% yield) as a grey 
powder. Mp: > 350 ºC. 1H NMR (DMSO-d6): δ 7.66 (s, 8H, ArH), 3.9 (bs, 
4H, ArCH2Ar). 13C NMR (DMSO-d6): δ 167.4 (COOH), 156.7 (CArOH), 
130.9 (CHAr), 128.9, 122.7 (CAr), 31.24 (CH2). Exact Mass ESI(-): m/z 
[M]-: calc: 599.1190 uma, found: 599.1182 uma. 
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2,8,14,16-Tetrabromo-5,11,17,23-tetramethylpentacyclo-
[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28), 9, 11, 
13(27),15,17,19(26),21,23-dodecaene-4,6,10,12,16,18,22,24-octol (49). 
 
 
To a solution of precursor 48 (1.8 g, 3.3 mmol) in 2-butanone (80 mL), 
was added NBS (3.9 g, 22 mmol) in small portions. After stirring for 10 
minutes at rt a precipitate appeared. After 4 h the solid was filtered and 
washed with Et2O to obtain the final compound 49 (70% yield). Mp: > 350 
ºC (dec). 1H NMR (DMSO-d6): δ 8.38 (s, 8H, ArOH), 6.81 (s, 4H, ArH), 
4.62 (q, J = 6.2 Hz, 4H, CH), 1.58 (d, 12H, J = 6.2 Hz, CH3). ESI(+) m/z: 
[M + H]+: 860.9 uma. 
 
Tetrabromo resorcinarene (50). 
 
To a solution of 49 (0.81 g, 0.91 mmol)in dry DMF (67 mL), were added 
CH2ClBr (0.94 g, 7.3 mmol) and dry K2CO3 (2 g, 14.5 mmol). The 
resulting solution was heated at 80 º C for 3 days and thereafter was diluted 
with water (200 mL) and acidified with 2M HCl. The dark precipitate 
formed was separated and dried under vacuum to give rise to a crude 
compound which was purified by flash chromatography in silica gel 
(eluent: 100% CH2Cl2). Product 50 was obtained in 56% yield as a 
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colorless solid. Mp: > 350 ºC (dec). 1H NMR (CDCl3): δ 7.16 (s, 4H, ArH), 
5.95 (d, J = 7.2 Hz, 4H, OCHHoO), 5.06 (q, 4H, CH), 4.39 (d, J = 7.2 Hz, 
4H, OCHHiO), 1.75 (d, J = 7.0 Hz, 12H, CH3). ESI(+) m/z: [M + H]+: 908.9 
uma. 
 
Electrophysiology 
 
Surgically extracted Xenopus laevis oocytes were injected with 0.5-4 ng 
channel RNA (50 nl). The cells were incubated in ND-96 (96 mM NaCl, 2 
mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 50 mg mL-1 gentamicin, 2.5 mM 
Na pyruvate, and 5 mM HEPES, pH 7.6) at 12-18 °C for 12-48 h prior to 
experiments. All electrophysiology experiments were conducted at rt. 
 
Two electrode voltage clamp (TEVC) experiments were performed using 
a Dagan CA-1B amplifier (Dagan Corporation), Digidata-1440A board, and 
pClamp10 software. The oocytes were placed in a perfusion dish to allow 
for pre-wash, wash, and post-wash recordings. All recordings were 
performed in ND-96 recording solution (96 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.2). For each experiment, the 
oocyte membrane voltage was held at -80 mV followed by a continuous 
train of 100 or 300 ms pulses to 20 mV every 15 seconds.  
 
All compounds were dissolved in ND-96 recording solution to make a 
500 µM stock solution. When needed, a maximum of 5% (v/v) DMSO was 
added to the stock solution to facilitate solubilization. For inhibition 
experiments, small quantities of the calixarene stock solutions were 
manually applied and mixed in a stagnant bath containing the oocyte. For 
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all recordings, DMSO was present at levels less than 1% (v/v). Oocytes 
were bathed in the calixarene solution until the current measurements taken 
at +20 mV reached steady-state. The compounds were washed away with 
ND-96 administered using a gravity perfusion system at approximately 80 
mL/h. 
All ionic current measurements taken at +20 mV were leak-subtracted 
using the following formula: 
 
ILS = I+20mV – 0.25*(I-80mV) 
 
The percent reduction in ionic current (B) was determined using the 
following formula, using leak subtracted current measured at +20 mV for 
steady state levels before and after addition of the calix[4]arene: 
 
B = 100*[(Iinitial –Iligand )/ Iinitial] 
 
Each experiment was repeated with at least 4 different oocytes, and data 
are shown as averages of individual experiments. Error bars indicate 
standard error of the mean. 
 
For dose-response experiments, varying concentrations of ligand 6 were 
applied to oocytes expressing either the Shaker or rKv1.3 channel. Each 
experiment was repeated with at least 3 different occytes, and the data were 
then averaged. Then, the average reduction in ionic current elicited by 
application of ligand 6 (B) was plotted as a function of the log of ligand 6 
concentration. Error bars indicate standard error of the mean (SEM). The 
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plotted data were then fit using Igor Pro software with the modified Hill 
Equation: 
 
B = Bmax * [L]h/(Kdh +[L]h) 
 
where L represents the concentration of calix[4]arene used in the 
experiment, Kd the equilibrium dissociation constant and h the Hill 
Coefficient. The following values were obtained: 
 
Channel Bmax Kd h 
Shaker 63 ±10 25±11 1.0 ± 0.3 
rKv1.3 85±16 14 ± 9 1.1 ± 0.7 
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Chapter 4 
 
Solid phase synthesis of chiral bicyclic guanidinium 
oligomers for cellular uptake 
 
 4.1 Cell permeability of bicyclic guanidinium oligomers 
 
Chiral bicyclic guanidinium oligomers are lipophilic polycationic 
molecules based on guanidinium subunits whose moieties are incorporated 
into a decaline bicyclic framework. The resulting guanidine has several 
remarkable properties: it bears orientation-restricted NH protons which 
avoid anti conformations non suitable for hydrogen-bonding, it has an 
amphipatic character provided by a “lipophilic backbone”, and it is 
endowed with two stereogenic centers (Fig. 4.1). 
 
 
Fig. 4.1: (a) Anti and syn conformations of guanidinium group and (b) 
bicyclic guanidinium moiety. 
 
These characteristics account for the design of several chiral oxoanion 
receptors based on monomeric units of the bicyclic guanidine (1). Both, 
chirality and stable ionic complex as well as hydrogen bond formation in 
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non aqueous media, promote the folding of chiral bicyclic guanidinium 
tetramers (thereafter referred as tetraguanidinium) around suitable anionic 
templates. Reported examples of this behavior are the self-assembly of 
double stranded sulfate helicates (2), the stabilization of α-helical peptides 
endowed with carboxylic amino acids in i, i + 3 position (3), as well as the 
interaction with alpha helices of the p53 tetramerization domain (p53TD) 
(4). 
 
 
In addition, the amphipatic nature of bicyclic guanidinium oligomers 
conveys to them membrane permeability properties.  
 
Chemical characteristics of guanidinium rich transporters (GRTs) 
 
The ability of a drug or probe to cross a biological barrier has historically 
been viewed as a function of its intrinsic physical properties. This view has 
hampered the evaluation and development of many agents which did not 
meet the cell-uptake requirements. Production of molecular transporters to 
overcome these biological barriers would be highly desirable in drug 
development. In this context, a number of cell-penetrating peptides (CPPs) 
derived from HIV-1 Tat protein (5), Antennapedia protein (Antp) of 
Drosophila (6), and related peptides have been extensively studied to 
improve the absorption, distribution, metabolism, and elimination (ADME) 
properties of poorly bioavailable drugs including small molecules (7), 
proteins (8), nucleic acids and genes (9). 
 
Several groups have undertaken systematic structure-function studies with 
a series of artificial arginine peptides inspired in Tat49-57, (Fig. 4.2). They 
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concluded that the optimal number of arginines for cell-penetration in 
polyarginines lies between 7 and 15, depending on the techniques and cell 
lines employed (10). Expectedly, all-D peptides are even more efficient due 
to their greater stability towards proteolysis.  
 
Fig. 4.2: Structure-function studies with fluorescent peptides (I-
III) inspired in Tat49-57 (counterions not indicated). 
 
Moreover, cellular uptake by peptides containing lysines or ornithines 
instead of arginines was comparatively less efficient, reflecting the 
importance of arginine for cellular uptake in natural and non-natural CPPs 
(11). Promising internalization studies and optimized synthesis for D-
Arg(8) (12), have fostered its entry into clinical studies (13). 
 
In the mean time, cellular uptake by a number of artificial peptoids (14), 
oligocarbamates (15), and β-peptides (16), rich in guanidinium groups have 
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been reported by different researchers (Fig. 4.3).  
 
Fig. 4.3: Structure-function studies with fluorescent peptoids 
(IV), oligocarbamates (V) and β-peptides (VI, counterions
 
not 
specified). 
 
These guanidinium-rich molecular transporters (GRTs) differ structurally 
in many respects to CPPs, except for the key conserved oligoguanidinium 
functional group. Internalization studies with these molecules showed that 
neither the nature of the backbone, its stereochemistry nor the side chain 
position or spacing to the guanidinium head groups are critical for cell 
internalization. However, they clearly influence the efficiency of uptake 
(17). Flexibility and amphipaticity are both factors that contribute to the 
increase in uptake as reported by different studies on synthetic GRTs (18). 
Most interesting, the nature of the scaffold may determine tissue specificity 
as well as cell localization of the entering conjugate, offering strategies for 
specific tissue or cell organel targeting (19). Therefore the diversity and 
number of scaffolds reported to target fused molecules into cells or into 
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animal tissues (20) range from highly branched oligosaccharides (21) to 
polyproline helices (22), dendrimers (23), peptide nucleic acids (24), 
calix[4]arenes (25), cationic lipids (26), and even polymers (27) (Fig. 4.4).  
 
Fig. 4.4: Examples of guanidinium rich scaffolds: Dendrimers 
(VII), Proline helices (VIII), Guanidinoglycosides (IX), 
Calix[4]arenes (X), Cationic lipids (XI). 
 
In most cases the cargo is linked covalently to a vector, but there are also 
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interesting examples of non covalent conjugation and transport which 
benefit from the ability of guanidines to bind tightly to negatively charged 
cargos (DNA, RNA or anionic supramolecules) (28).  
 
Mechanisms of cellular uptake 
 
Given the structural variety of GRTs carrying a wide range of cargos, 
from small molecule probes to metals, drugs, peptides, oligosaccharides, 
proteins and plasmid DNA, a universal GRT uptake mechanism is unlikely. 
Moreover, other crucial variables involved in cellular uptake such as cell 
types, nature of the counterions, or experimental conditions, hamper the 
identification of a single entry mechanism (29). However, there are 
common aspects to several mechanistic possibilities and these derive from 
the special properties of the guanidinium group. 
 
It is of general agreement that association of the GRTs to the cell 
membrane takes place prior to translocation. Compared to ammonium, the 
guanidinium group is able to form well-oriented hydrogen bonds and is 
protonated over a wider range of pHs, which provides a rationale for the 
differing abilities of oligolysines and oligoarginines to associate and to 
cross cellular membranes (14). As the guanidinium function combines the 
positive charge with a bidentate hydrogen bond donor, it is ideally poised to 
interact with negatively charged cell surface constituents, such as 
phospholipids head groups, fatty acids, proteins and heparan sulfate 
proteoglycans (HPPGs) (Fig. 4.5).  
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Fig. 4.5: Schematic representation of some common 
associations of a polycationic guanidinium transporter with 
anionic cell membrane constituents (reproduced from ref. 30).  
 
The driving force for the initial association is supposed to be the dramatic 
increase in stability of the guanidinium-oxoanion pair as the medium 
changes from water to the non-polar membrane environment (for instance, 
~ 2.6-6.0 kcal/mol for phosphate) (30).  
 
Considerable effort has been devoted to elucidate the uptake mechanism 
of different GRTs, because of its relevance on intracellular trafficking 
processes, which in turn determine the rate at which a cargo is degraded or 
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delivered to a given organel. 
 
With some exceptions, receptor mediated transport is ruled out for GRTs, 
which makes sense considering account the broad range of structural 
variations compatible with their internalization. Instead, endocytosis and 
diffusion processes which are less structure-specific, have been detected as 
major processes. The chemical nature and size of the transported conjugate 
as well as the cell type seem to be determinant for the mechanism of entry. 
Different endocytic processes have been identified and generally visualized 
by confocal microscopy, but no predictions can be made so far. Therefore, 
clathrin-mediated, caveolin-mediated or macropinocytic transport are 
distinguished, depending on the proteins associated to the membrane 
involved in the endocytic transport (Fig. 4.6). 
 
 
 
Fig. 4.6: Proposed endocytotic uptake mechanism. From left to 
right: clathrin-mediated endocytosis, caveolin-mediated 
endocytosis, macropinocytosis (reproduced from ref. 30). 
 
Most often a clathrin mediated endocytosis is reported, but even 
concentration changes in the CPPs may permutate the endocytic mechanism 
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from a clathrin to a caveolae mediated one. For bigger conjugates, caveolae 
or macropinocytosis are generally observed (18,31).  
 
Moreover, all endocytic mechanisms are energy-dependent, thus easily 
distinguished from direct diffusion by the kinetics of internalization and 
their dependence on temperature. When cellular uptake is not inhibited at 
low temperatures it is attributed to direct diffusion. A direct diffusion of 
charged species through the cell membrane seems to contradict the intrinsic 
rules of biological barriers. However, association between the guanidinium 
charged species and the amphipatic counterions on the cellular surface 
would lead to non polar complexes, able to cross the lipid bilayer and 
dissociate once in the cytosol (32). This hypothesis has been shown 
experimentally by the groups of Matile (33) and Wender (34): Simple 
water-octanol partitioning experiments reveal that the presence of 
amphipatic anions, such as sodium laureate, a surrogate of a membrane 
constituent- is simply enough to transfer a water-soluble arginine strand 
from water to a non polar octanol phase that mimics the membrane (Fig. 
4.7). 
 
The importance of the bidentate hydrogen bond formation in this process 
was investigated by Wender et al. examining the influence of mono- and 
dimethylation of the guanidinium group on cellular internalization. 
Decrease of cellular uptake was 80% and 95% respectively, confirming the 
observation that cationic charge is not enough for efficient diffusion.  
 
The same research group studied the impact of the membrane potential on 
the passage of the ion pair complex and demonstrated a direct relation 
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between membrane potential, which naturally favors the movement of 
positive charged species into the cell, with GRT internalization (Fig. 4.7).32 
 
 
 
 
 
 
 
Fig. 4.7: a) Diffusion translocation uptake mechanism proposed 
by Wender et al. b) Octanol/water (upper and lower phases, 
respectively) partitioning of Fl-aca-Orn8-CONH2 and Fl-aca-D-
Arg8-CONH2 alone (A, B) and after addition of sodium laurate 
(C, D) (reproduced from refs. 30 and 30).  
 
Finally, some authors suggest that compounds able to fold into 
amphipatic secondary structures are best suited for cellular uptake, although 
this has not been confirmed as a general requisite for GRT internalization 
(35).  
 
Cell-permeable bicyclic tetraguanidinium oligomers 
 
Tetraguanidinium compounds XII and XIII, labeled covalently with 
carboxyfluoresceine (CF), were recently synthesized in our group and 
tested for cellular uptake in collaboration with the group of Ernest Giralt 
(PCB) (Fig. 4.8).  
 
a) b)
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Fig. 3.8: Structure of tetraguanidinium oligomers XII and XIII. 
 
Rapid and dose-dependent internalization of fluorescent compounds XII 
and XIII in HeLa cells was observed on a fluorescent microplate reader 
after 1 hour incubation at 37 ºC. The uptake was compared with Tat49-57 9-
mer and Antp, both labelled with carboxyfluorescein (CF) at their NH2-
termini, as positive controls, and with CF as a negative control. 
Interestingly, silylated conjugate XII (R = SiPh2tBu) outperforms its 
hydroxyl-free analogue XIII (R = OH) as well as peptide controls even at 
low micromolar concentration (5 µM) (Fig. 4.9a). Cell viability assays with 
1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) at up to 10 µM 
concentrations showed that the best internalized compound XII, incubated 
for 24 h with HeLa cells, reduced cell viability to 28% at 10 µM (Fig. 4.9b). 
In view of reducing toxicity, further internalization experiments were 
performed at a concentration range of 1-0.1 µM. In good agreement with 
the preliminary data obtained using a microplate fluorimeter, flow 
cytometry revealed that XII was better internalized than CF-Antp, while 
XIII and CF-Tat were both internalized to a similar extent (Fig. 4.9c). 
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Fig. 4.9: a) Fluorescence measured in a microplate fluorescence 
reader after incubation of HeLa cells with tetraguanidinium 
oligomers XII and XIII, CF-Tat, CF-Antp, and CF at 5-50 µM 
concentrations. b) Cytotoxicity of XII, XIII, CF-Tat, and CF-
Antp. Viability was quantified by MTT staining after 24 h of 
incubation. c) Fluorescence obtained FACS after incubating 
cells with XII, XIII, CF-Tat, CF-Antp, or CF at 1 µM for 1 h at 
37 °C (reproduced from ref. 37). 
 
To gain insight into the mechanism of internalization of compound XII, 
flow cytometry experiments were also performed at 4 ºC. Cellular uptake 
proved to be energy dependent as uptake of XII was substantially reduced. 
However, kinetics of the internalization indicated that some passive 
diffusion of the complex was taking place as well. Thus, we suggested that 
both pathways were indeed taking place simultaneously, as it has been 
observed for other GRTs. Furthermore, confocal laser scanning microscopy 
studies revealed that compound XII co-localized with MitoTracker Orange, 
a dye that accumulates in active mitochondria (Fig. 4.10).  
 
CF XIII XII Tat 49-57 Antp
a)
Tat 49-57 AntpXIII XIIControl
c)
b)
XII
XIII
a) b)
c)
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Fig. 4.10: a) Fluorescence measured by flow cytometry after 
incubating HeLa cells with XII, XIII, CF-Tat and CF-Antp (1 
µM) at 37 °C or 4 °C; b) Distribution of XII and colocalization 
with the mitochondrial marker MitoTracker Orange (reproduced 
from ref. 37). 
 
This particular behavior could find interesting therapeutic applications 
(36). Therefore, a new family of GRTs based on bicyclic guanidinium 
subunit, with improved mitochondrial selectivity, was necessary (37).  
 
More recently, the O-silyl tetraguanidinium oligomer was conjugated 
with a different linker to form an emissive terbium complex for optical 
imaging (collaboration with David Parker, the University of Durham, UK) 
(Fig. 4.11).  
 
XIII XII
a) b)
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Fig. 4.11: Covalent conjugate of emissive terbium complex and 
O-silyl, bicyclic tetraguaninium (XIV). 
 
Although the chemical nature of the cargo and the linker were different as 
compared to conjugate XII, similar uptake behaviors were observed for 
complex XIV through two-photon fluorescence microscopy: Thus, 
compound XIV showed efficient permeabilization and mitochondrial 
localization but optical imaging experiments with this probe were 
compromised by toxicity at low micromolar concentrations (IC50 = 12 µM). 
Moreover, XIV was observed in all cell lines assayed: HeLa, NIH-3T3 and 
CHO, pointing to a general use of bicyclic guanidinium tetramers as cell 
permeabilizing agents. However, as already mentioned, toxicity at low 
micromolar concentrations for either complexes XII and XIV hampered 
further progress of these vectors (38). In order to identify optimal 
compounds, with efficient permeability, reduced cell toxicity, and specific 
cellular localization, a systematic structure-function study was necessary, as 
has been reported for other families of GRTs. Variation of the terminal 
moieties, the linkers or the length of the strands should give rise to a series 
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of compounds for evaluation in cell uptake assays (Fig. 4.12). 
 
 
 
Fig. 4.12: Modification sites (highlighted in green) for 
systematic structure-function studies.
 
Solid Phase Synthesis of bicyclic Guanidinium Oligomers 
 196 
4.2 Development of solid phase (SP) synthetic strategies 
 
Until now, solution phase synthesis of symmetric and non symmetric 
guanidinium oligomers has been successfully employed in our group to 
obtain strands of up to six bicyclic guanidinum subunits (37,39). However, 
to synthesize series with site specific modifications, a solid phase synthesis 
(SPS), inspired in the classical peptide synthesis developed by Merrifield in 
1963, was envisaged (40).  
 
Solid phase peptide synthesis (SPPS) is based on the sequential addition 
of α-amino acids (protected at their amino end and eventually at the side 
chains) to an insoluble support or resin (Fig. 4.13). The scheme is based on 
the incorporation of the desired number of monomers through a series of 
coupling, capping and deprotection steps, followed by cleavage of the 
peptide from the solid support. The crude is analyzed by HPLC, as 
exemplified in Fig. 4.13 (41), and finally the desired peptide is purified by 
precipitation or chromatography.  
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Fig. 4.13: a) Simplified representation of SPPS b) Example of 
an analytical HPLC profile (reproduced from ref. 41). 
 
In addition to peptides, synthesis of organic compounds on solid support 
presents many advantages. First, reactions may be carried out in the 
presence of an excess of reagents to drive the reaction to completion. The 
reagents are simply washed away at each step and no synthetic 
intermediates are isolated. Second, the capping step takes place with 
quantitative yield and reduces secondary products that may originate from 
non complete coupling. Third, the final purification is the only one 
performed over the whole synthesis. Thus, solid phase synthesis (SPS) is 
convenient in terms of efficiency, ease of experimental work-up and 
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purification procedures. 
 
However, there are as well some disadvantages linked to solid support 
synthesis. For instance, the difficulty in the structural analysis of the 
supported species. Also, linkers and protecting groups have to remain stable 
under the various conditions taking place along the process, including harsh 
cleavage protocols. Therefore, their robustness has to be guaranteed. 
Finally, and most challenging, reactions have to take place in high to 
quantitative yields, otherwise after repeated coupling almost no final 
product is harvested.  
 
Over the last three decades, considerable technological and synthetic 
effort has been invested to optimize SPS for combinatorial and high-
throughput chemistry (42). As a result, this original concept has expanded 
from natural peptides to cyclic peptides, DNA, PNAs, oligosaccharides, 
peptoids and small drug compounds. In addition, during the last decade the 
in situ analysis of anchored compounds has been made possible through 
spectroscopic techniques, such as IR, RAMAN and also High Resolution 
Magic-Angle Spinning (HRMAS). As a result, the role of SPS in 
fundamental organic chemistry research is gaining importance (43).  
 
To the best of our knowledge, the synthesis of bicyclic guanidinium 
strands has not been tested on solid phase conditions, nor has this scaffold 
been applied on solid support before. Therefore, taking into consideration 
the inherent advantages and drawbacks of SPS, as well as the particular 
nature of the oligomers we aimed to obtain, the following premises were 
established:  
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1. To choose a convenient bicyclic guanidinium building block (BB) 
for reiterative coupling on solid phase. 
2. To provide sites for diverse end-functionalization, linker and 
cargo anchorage. 
3. To propose a qualitative follow-up test as well as a quantitative 
capping reaction. 
 
In the following sections several attempts to build a solid-phase synthetic 
strategies for bicyclic guanidinium oligomers fulfilling these requirements, 
will be described.  
 
In addition, in the last section of this chapter, preliminary results with an 
amino acid analogue of a bicyclic guanidinium subunit, will be presented.
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   4.2.1 Initial trials on solid phase 
 
    4.2.1.1 Objectives 
 
Almost half of the work described in this chapter was performed by us in 
the laboratory of Miriam Royo and Fernando Albericio, at the 
Combinatorial Chemistry Department, Barcelona Science Park (PCB). The 
remainin work was developed at ICIQ’s laboratories.  
 
Our first trials on SPS were performed with two building blocks which 
were already available in the group, namely BB 15 and 16 (Fig. 4.14) (44). 
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Fig. 4.14: Building Blocks 15 and 16. 
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Synthesis of compounds 15 and 16 proceed from the orthogonally 
diprotected bicyclic guanidinium precursor 56, which was obtained, on a 
large scale, in eight steps from the amino acids R-asparagine and R-
methionine (45). Molecule 56 was deprotected
 
at its OTBDMS end, and the 
free alcohol 55 was activated as mesyl. Next, compound 54 was 
functionalized through nucleophilic substitution with mercaptoacetic acid 
or with thioacetate, respectively. BB 15, endowed with a mercaptoacetic 
acid tail, is suited for anchorage to an amine functionalized resin, whereas 
BB 16 bears a protected nucleophile as anchoring moeity. 
 
Concerning the solid support, we selected Bal-linker, [5-(4-formyl-3,5-
dimethoxyphenoxy) butyric acid], as a traceless linker for attachment of the 
bicyclic guanidinium unit 15. BAL-resin was prepared by coupling [5-(4-
formyl-3,5-dimethoxyphenoxy)] butyric acid to a 4-
methylbenzhydrylamine polystyrene (MBHA) resin through a 
HOBt/DIPCDI mediated coupling, within a Fmoc solid phase strategy (46). 
This particular linker provides a potential site for cargo anchoring through a 
primary amine, whose coupling is carried out by on-resin reductive 
amination, as described by Albericio and coworkers (47). Initially we 
employed four carbon length amines as cargo models: 3-methylbutylamine 
and butylamine (Fig. 4.15). 
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Fig. 4.15: Synthesis of NHR-BAL-MBHA resin. 
 
The following synthetic sequence for bicyclic guanidinium oligomer 
synthesis was designed: First, anchorage of BB 15 would be performed 
through amide coupling to NHR-BAL-MBHA resin. Thereafter, 
deprotection of the hydroxy group, followed by its activation as an 
electrophile on solid support would pave the way for the next bicyclic BB 
16 attachment through nucleophilic attack. Compound 16 bears a 
thioacetate that can be converted into a sulfide in a basic medium, 
providing a strong nucleophile for anchorage to the electrophilic resin. 
Iteration of previous O-silyl deprotection and alcohol activation steps 
would, in theory, enable for sequential coupling steps and afford strands of 
different lengths (Fig. 4.16). 
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Fig. 4.16: Synthetic scheme for bicyclic oligomer synthesis 
based on BBs 15 and 16 and NHR-Bal-MBHA resin. 
 
   4.2.1.2 Results and discussion 
 
Amide coupling of BB 15 was carried out under HOBt/DIPDCI 
conditions overnight at room temperature (rt) and successfully monitored 
by a ninhydrine test. Moreover we verified that the presence of the 
guanidine core does not interfere with the test. Compounds were finally 
cleaved in 100% TFA (1h at rt) and the crude mixtures were analyzed by 
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LC-MS with light scattering detection (Fig. 4.17). 
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Fig. 4.17: a) Reaction scheme and b) LC-MS analysis of crude 
compound 57: ESI(+) spectrum (top), ELSD chromatogram 
(bottom) (Conditions: 0-100 % CH3CN in H20 with 0.1% 
HCOOH for 15 min). 
 
Deprotection of OTBDPS-group employing 1M tetrabutylammonium 
fluoride (TBAF) was completed in a couple of hours at rt. We tried to 
monitor this reaction by a qualitative color test for hydroxyl groups, which 
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is carried out on-bead and shows violet staining with primary alcohols. The 
reaction is based on the formation of a tosylate, its displacement by p-
nitrobenzylpyridine and conversion of the resin-bound pyridinium salt into 
a strongly colored internal salt by treatment with base (48). However this 
test was not reliable in our case. Later trials showed that conversion of this 
hydroxyl group into a sulfonate was indeed not trivial. Thus, after 
confirming deprotection by LC-MS, we attempted to convert the hydroxyl 
group into a good leaving group such as chloride, bromide or sulfonate, 
followed by nucleophilic substitution with benzylthiol (3 eq.) under basic 
conditions (3 eq. Cs2CO3), Fig. 4.18.  
 
 
Fig. 4.18: Electrophilic activation followed by nucleophilic 
attack by benzylthiol under basic conditions. 
 
Table 4.1 shows different reagent, solvent and time conditions assayed for 
this purpose: 
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Table 4.1: Attempted electrophilic activation of anchored alcohol. 
 Reagents Solvent Time at rt 
a 7.5 eq PBr3 THF/CH2Cl2 (2:1) 4 h , 8 h, 10 h  
   b 3.5 eq CBr4, 3.5 eq TPP       CH2Cl2      4 h, 8 h, 10 h 
c 
3 eq. DIPCDI, 2% Cu(I)Cl, 4.5 eq. 
NBS THF 4 h 
d 3 eq. DIPCDI, 2%Cu(II)Tf2, 4.5 eq. NBS THF 4 h 
e 
3 eq. DIPCDI, 2% Cu(I)Cl, 4.5 eq. 
NCS THF 4 h 
f 3 eq. DIPCDI, 2% Cu(II)Tf2, 4.5 eq. NCS THF 4 h 
g 7.5 eq. DsCl, 10 eq. Et3N CH2Cl2 4 h 
h 7.5 eq. TsCl, 10 eq. Et3N CH2Cl2 4 h 
i 7.5 eq. MsCl, 10 eq. Et3N CH2Cl2 4 h 
j 7.5 eq. MsCl, 10 DiPEA, DMAP CH2Cl2 4 h 
 
Initially we unsuccessfully tried to achieve the bromide incorporation 
with carbon tetrabromide (entry a) and phosphorus tribromide (entry b). 
Thus, we searched for alternative procedures for conversion of hydroxyl 
groups into halides. 
 
A mild one-pot procedure was described recently (49). The reaction takes 
place in two steps: the alcohol is first activated as O-alkylisourea via 
DIPCDI under mild acidic conditions and then N-halosuccinimide (NXS, X 
= Br, Cl) is employed as halide source to convert the alcohol into a chloride 
or bromide derivative. Following the described protocol in solution, we 
obtained 50% conversion on compound 54. Next, we tested this procedure 
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on the solid support (entries c-f) varying the Lewis acid, but in this case, no 
brominated nor chlorinated products were detected in the cleavage crude 
[MALDI and ESI(+)]. Next, we attempted to obtain different sulfonates 
(entries g-j). For entry j, the expected mass (LC-MS), after nucleophilic 
attack and cleavage, was observed (Fig. 4.19).  
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Fig. 4.19:  LC-MS analysis of crude compound 58. ESI(+) (top) 
and UV220 (bottom) (Conditions: 0-100 % CH3CN in H20 with 
0.1% HCOOH in 15 min). 
 
Addition of DMAP (entries g-h) may have led to the same outcome as for 
entry j, but this was not further studied. We analyzed crude compound 58 in 
more detail, and besides 58 its precursor 59 was identified (Fig. 4.20).  
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Fig. 4.20: LC-MS analysis of crude compound 59. ESI(+) (top) 
and UV220 (bottom), (0-100% CH3CN in H20 with 0.1% 
HCOOH in 15 min). 
 
The presence of 57 could be due to mesyl hydrolysis during the acidic 
cleavage conditions, though uncomplete conversion of the alcohol could not 
be excluded. The products in the cleavage crudes described above were not 
obtained in quantitative yields, but they were easily identified by LC-MS. 
Therefore, we attempted the anchorage of the next bicyclic guanidinium 
unit, BB 16, through a thioether linkage. In solution, analogous reactions 
have been previously performed in our research group, whereby cesium 
carbonate (Cs2CO3) can be employed as base to deprotect the sulfide in situ, 
prior to nucleophilic attack on the mesyl group. 
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Our first trial to couple a second unit (DMF, rt) was monitored for three 
days (Fig. 4.21).  
 
 
Fig. 4.21: Synthetic scheme for BB 16 coupling. 
 
Despite an excess BB 16 was employed (three-fold), precursor 57 was 
present in the crude besides the expected product 60 (Fig 4.22), and the 
reaction did not further proceed after 20 h.  
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Fig. 4.22: Chemical structure 60 and LC-MS analysis of the 
crude mixture. MS (top) and UV220 (bottom), (0-100% CH3CN 
in H20 with 0.1% HCOOH in 15 min). 
 
Repeating protocols of hydroxyl deprotection, electrophile conversion 
and coupling of BB 16, led once more to the identificaction (LC-MS) of the 
triguanidinium derivative 61. However, many unidentified subproducts 
were also detected (Fig. 4.23).  
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Fig. 4.23: LC-MS analysis after the third bicyclic unit coupling 
and cleavage: ESI(+) (top) and ELSD chromatogram (bottom) 
(0-100% CH3CN in H20 with 0.1% HCOOH in 15 min). 
 
After these preliminary results, the coupling reaction was optimized, 
taking into consideration the following parameters: phosphine reducing 
agent, time, temperature, microwave conditions and renewal of reagents. 
 
No starting product was detected in the filtrate after the reaction, but 
disulfide subproduct 62, resulting from intermolecular disulfide formation 
between deprotected molecules of 16, was highly represented. This 
indicates that nucleophilic attack and disulfide formation were actually 
competing reactions (Fig. 4. 24). 
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Fig. 4.24: Competing reactions during coupling. 
 
To prevent disulfide formation, we added reducing phosphines to the 
reaction: n-butylphosphine [n-P(Bu)3] or triphenylphosphine [P(Ph)3] (50). 
Contrary to our expectations, addition of 5 to 8 eq. of P(Ph)3 or n-P(Bu)3 
did not improve the coupling yields. Further experiments aimed at reducing 
reaction time did not improve yields, either. On the contrary, better results 
were obtained with longer reaction times (up to 72 h) at rt. 
 
Next, the temperature of the reaction was increased to 50 ºC for 24 h and 
also some trials in the microwave reactor were attempted. However, both 
approaches failed to improve the coupling yield, as assessed by the LC-MS 
analysis of the respective cleavage crudes. Finally we renewed the reaction 
solution after 24 h, and again after 24 h and 48 h, and compared the results 
to a reference resin without renewals, in the following conditions: 3 eq. of 
16, 3 eq. of Cs2CO3, 5 eq. of n-P(Bu)3 in DMF at rt for 72 h. We expected 
to improve the yields as the number of renewals of the reaction mixture was 
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 increased. Light scattering chromatograms (ELSD) obtained after 
cleavage of the different samples are shown in Fig. 4.25. 
57 60
57
60
57
60
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Fig. 4.25: ELSD chromatograms of crude compound after 72 h 
reaction (red), with one renewal after 24 h (green) and with two 
renewals (black). 
 
The reference reaction yielded a 1:4 mixture of starting and final products 
after 72 h, as estimated from the areas of the corresponding peaks 
(identified by LC-MS). Renewal of the reaction mixture once after 24 hours 
improved this yield slightly but a second renewal did not. Thus, further 
renewals were not attempted to avoid waste of starting material. 
 
In summary, our approach based on BBs 15 and 16 demonstrated that the 
synthesis was indeed possible, but we were unable to develop consistent 
protocols for the transformations. The major drawback was the coupling 
rate, much too slow under the conditions employed. Part of the failure was 
also associated to the difficulty to control disulfide formation during 
nucleophilic coupling. Moreover, use of building blocks requiring 
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functionalization prior to further elongation, increases the probability of 
incomplete conversion.  
Dahan et al. reported on a solid phase synthesis of thioether dendrons 
based on nucleophilic attack of an aromatic sulfide -deprotected in situ- on 
a resin-bound benzyl halide. Further sulfide anchorage required previous 
hydrolysis and reduction of the ester followed by electrophilic activation of 
the resulting phenols through halide conversion (51). Though further 
anchorage required prior functionalization, high yields were reported for 
this dendron synthesis. This is mainly due to the high reactivity of the aryl 
reagents employed, which enabled quantitative nucleophilic coupling of the 
sulfide-bearing monomers. In comparison, alkyl thiolates based on bicyclic 
guanidinium scaffolds are less reactive, thus they require a better adapted 
strategy . 
 
Therefore, we focused on the synthesis of bifunctionalized building 
blocks containing a good leaving group on one side and a thiolate precursor 
on the other one. In this way, we envisaged to limit synthetic steps to 
coupling and deprotection reactions. Moreover, we reasoned that the 
oxidation state of the nucleophilic sulfur might be easier to control if it is 
bound to the resin. 
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   4.2.2 Synthesis of ideal building blocks (BB)  
 
    4.2.2.1 Objectives 
 
Initial trials on solid phase described in Section 4.2.1 paved the way for 
the design of new building blocks functionalized with an electrophile at one 
side and a thiolate precursor at the other. Elongation of bicyclic 
guanidinium oligomers would be achieved by iterative repetition of three 
main steps: incorporation of a bicyclic subunit at the electrophilic end, 
deprotection of its sulfur moiety and coupling of the next BB (Fig. 4.26).  
 
Fig 4.26: Merrifield-like synthesis of bicyclic oligoguanidiniums. 
 
For this goal, we decided to synthesize a number of ideal BBs in the 
minimum synthetic steps and with the highest possible yields. We attempted 
the difunctionalization of the bicyclic guanidinium scaffold with different 
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sulfur protecting groups (Fig. 4.27) (52). 
 
Fig 4.27: Selected thiol protecting moeities. 
 
The same synthetic strategy was followed in all cases: First the protected 
sulfur was attached through nucleophilic substitution to the bicyclic 
guanidinium 54, then the O-silyl group was deprotected and finally 
transformed into a suitable eletrophile (Fig. 4.28). 
 
 
Fig. 4.28: Synthetic scheme for difunctionalized BBs. 
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    4.2.2.2 Results and discussion 
 
Thiourea attempt 
 
First we aimed at obtaining BB 63, functionalized with thioacetate, as we 
had experience on the handling of this chemical group and its use had been 
previously reported in solid phase (Fig 4.29) (53).  
 
 
Fig 4.29: Compound 63. 
However our first attempts failed in the O-silyl deprotection. In the 
presence of fluorides (such as TBAF or CsF), simultaneous deprotection of 
the thioacetate group took place, leading to disulfide 64 (Fig. 4.30). 
 
Fig 4.30: Simultaneous O-silyl and thioacetate deprotection in the 
presence of fluorides. 
 
Milder deprotection conditions, with a solution of 3% HCl in 
acetonitrile or HF-pyridine, yielded mixtures of the starting compound 16, 
the expected product 65, and disulfide 64. Isolation of product 65 was 
investigated by reducing the mixture to two compounds and exploiting the 
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differences in solubility (16 is soluble in organic solvents, whereas 65 and 
64 are water soluble). Trials at different temperature and time conditions 
are summarized in Table 4.2. 
 
Table 4.2: Thioacetate deprotection in 3% HCl under various conditions.  
3% HCl in CH3CN Temperature hours Products in aq. phase 
a 5 ºC 7 h Mixture* 
b -5 ºC 7 h Mixture* 
1 h Pure product 
2 h Pure product 
3 h Mixture* 
c-f -5 ºC 
4 h Mixture* 
*Mixture of compounds 64 and 65. 
 
Though conditions for entry c enabled isolation of compound 65 in a pure 
form from the aqueous phase, a large amount of starting product was left 
unreacted in the organic phase. Therefore, as yields did not exceed 21%, the 
thioacetate-synthetic route was abandoned. 
 
Isothiouronium attempt 
 
Thiouronium is a well known precursor for a thiolate (54). Incorporation 
of thiourea was assayed following conditions described by our group on 
different electrophilic precursors 54, 66 and 67 (2). However, all trials 
failed (Table 4.3) and most often the starting product was recovered.  
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Table 4.3: Trials to incorporate a thiouronium moiety. 
 
Reagent Conditions Time Result 
2 h 
a 1.2 eq. thiourea  22 ºC, atm pressure 
o/n 
recover 
starting 
material 
b 1.2 eq. thiourea  110 ºC, sealed tube, 4 h 
recover 
starting 
material 
c 1.2 eq. thiourea  
µW:  
110 ºC, 200 W, 100 PSI 
10, 20, 
60 min 
recover 
starting 
material 
d 14 eq. thiourea  110 ºC, sealed tube 24 h, 4 days 
no final 
product  
f 
1.2 eq. 
imidazolidine-2-
thione  
µW: 
110 ºC, 200 W, 100 PSI 
10 min 
recover 
starting 
material 
 
As a positive control, the reactivity of the thiourea reagent was checked 
on benzylbromide and the expected product was obtained quantitatively. 
Moreover imidazolidine-2-thione was employed as an alternative reagent 
(entry f) (55), but failed, too. As we were unable to progress further, we 
proceeded towards further alternatives for sulfur protection. 
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Thiobenzoate coupling 
 
We generated the potassium thiobenzoate salt under basic conditions 
following a described procedure (56) in order to incorporate thiobenzoate as 
the sulfur-containing moeity. Deprotection of the hydroxyl group with HF-
Pyridine reagent and further methylsulphonate generation, lead to building 
block 17 in good overall yield (53%, Fig. 4.30).  
 
Fig 4.30: Synthesis of BB 17. 
 
The reported deprotection conditions in solution were confirmed under 
two different conditions: 0.5 M sodium hydroxide or 10% aqueous 
ammonia solutions in DMF (52). 
 
Benzylmercaptane and Tritylmercaptane coupling 
 
Nucleophilic substitutions on 54 by Benzylmercaptane (BnSH), 
Tritylmercaptane (TrtSH) and 4-Methoxytrityl mercaptane (MmtSH) were 
achieved in basic conditions (0.25 M sodium methoxyde in methanol) (Fig 
4.31). 
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Fig 4.31: Functionalization with aromatic mercaptane moieties. 
 
However only the synthesis of methoxytrityl functionalized building 
block 18 was driven to completion (Fig. 3.32) as the deprotection 
conditions for Bn (52) and Trt (57) protecting groups on thioethers are not 
suited for orthogonal solid phase strategies, based on Fmoc group. 
 
 
Fig 4.32: Synthesis of BB 18. 
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O-silyl deprotection took place in the same basic medium as the initial 
nucleophilic substitution; therefore BB 18 was obtained in high yields after 
only two reaction steps from precursor 54. Moreover, methoxytrityl (Mmt) 
can be removed using very dilute TFA solutions in the presence of TIS as 
scavenger (5% TFA, 5% TIS in CH2Cl2), which we confirmed in solution 
(58).  
 
In conclusion, we synthesized two different bicyclic guanidinium BBs 17 
and 18 with good yields. Deprotection of the respective sulfur-protected 
moeities was confirmed in solution and was strictly orthogonal: 
Thiobenzoate liberates the sulfide in basic media while Mmt does it under 
acid conditions. In this way we might develop analoguous strategies based 
on distinct handles and solid supports. In the next section we will discuss 
the choice of resins and linkers, the synthetic drawbacks as well as the 
achievements made with BB 17 and BB 18. 
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4.2.3 Attempts with bifunctionalized BBs 
 
4.2.3.1 Objectives 
 
Building Blocks 17 and 18 differ only in their sulfur protecting groups. 
This means that similar conditions for nucleophilic substitution on their 
electrophilic end may be employed for their initial coupling to SP. 
However, deprotection of the S-protecting groups requires different 
conditions, thus different resins or linkers.  
Ideally, the selected solid support should as well offer an anchorage point 
for cargo attachment, though the cargo might also be attached to the final 
sulfur. Finally a reaction to cap non reacted coupling sites, in both cases, 
should help to prevent the formation of deletion sequences, which could 
jeopardize the final purification.  
 
4.2.3.2 Results and discussion 
 
Amine-functionalized resins are the most common commercially 
available resins, so initial trials to anchor BBs 17 and 18 through SN 
reaction to a solid support were done on Aminomethyl and Rink amine-
MBHA polystyrene resins. Different basic conditions with organic bases 
(DiPEA, Pyridine) were assayed. However, only in the presence of 
potassium carbonate and crown ether some anchorage of the building 
blocks was detected on Rink amide-MBHA resin. Since coupling still 
occurred with low yield, we focused on nucleophilic anchorage on thiol 
functionalized resins. 
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Thiol-4-methoxytrityl resin is commercially available and its cleavage 
takes place under mild acidic conditions: 1-8% TFA, 5% TIS in CH2Cl2 
(Fig. 4.33a). Thus this resin is suited for BB 17 but not for BB 18, whose 
sulfur moiety is removed as well under the same conditions. 
 
Therefore we selected a different anchoring system for BB 18, namely 
Fmoc-Cys(Mmt)-Rink amide-MBHA resin (Cys resin, Fig. 4.33b). This 
support provides an additional attachment point for cargo molecules via the 
α-amino group of the cysteine. 
 
Fig. 4.33: Thiol 4-methoxytrityl resin (a) and Fmoc-Cys(Mmt)-
Rink amide-MBHA resin or Cys resin (b). 
  
Coupling results with BB 17 
 
Attachment of 17 to thiol-4-methoxytrityl resin was achieved either in the 
presence of 3 eq. of cesium carbonate (Cs2CO3) or with Et3N. Diluted TFA 
cleavage conditions and LC-MS analysis confirmed previous anchorage of 
compound 17 (Fig. 4.34).  
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Fig. 4.34: (a) Reaction scheme and (b) LC-MS analysis of 
crude compound 74. MS (top) and UV220 (bottom) (Conds: 0-
100 % CH3CN in H20 with 0.1% HCOOH in 15 min). 
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However, to assess disulfide bond formation during the reaction we 
employed the Ellman test, a fast and easy color test to detect resin-bound 
thiols in a qualitative and/or quantitative manner (Fig 4.35) (59).  
 
 
Fig. 4.35: Ellman test reveals the presence of free thiols by 
liberating into solution a red dye. 
 
After coupling BB 74 in the described reaction, Ellman test indicated that 
no more free thiols were present on the resin. This could be due to 
completion of nucleophilic reaction or to both nucleophilic substitution and 
disulfide bridge formation during coupling. To evaluate this, reduction of 
the resin was first attempted with the following agents: P(Ph)3, n-P(Bu)3 
and 1,4-Dithiothreitol (DTT). Only treatment with a DTT (8 eq.) solution in 
DMF revealed free thiols on the resin after Ellman test. Hence, disulfide 
bridges were indeed forming between thiols of the resin beads at the 
conditions employed. 
 
Benzyl bromide was employed beforehand as a model electrophile to 
optimize coupling conditions (Fig. 4.36). After nucleophilic reaction under 
different conditions, we checked the presence of free thiols via Ellman test, 
preceeded by additional treatment with DTT (Table 4.4).  
 
 
4.2.3 Attempts with bifunctionalized BBs  
 
 227 
 
 
Fig. 4.36: Initial trials with BnBr. 
Table 4.4: Testing disulfide bond formation after coupling. 
 
 Reductive agent 
Ellman test 
after coupling 
Ellman test after   
DTT treatment 
a 5 eq. n-P(Bu)3 negative positive 
b 12 eq. n-P(Bu)3 negative positive 
c 2 eq. of DTT negative positive 
 
However, disulfide formation was observed under all conditions 
described in Table 4.4.  
 
Next, bases other than Cs2CO3 were assayed on the same reaction. In this 
context the limiting factor is solubility in DMF: Of all the inorganic bases 
reported for nucleophilic reactions with mercaptans in solution (60,61), 
only potassium tert-butoxide (KtBuO) was actually soluble in wet DMF, 
therefore we used KtBuO besides the organic base Et3N, varying the 
number of equivalents of BnBr and n-P(Bu)3, as depicted in Table 4.5. 
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Table 4.5: Different bases and reduction conditions to avoid disulfides. 
 Base Reductive 
agent BnBr 
Ellman 
test after 
reaction 
Ellman 
test after 
DTT 
treatment 
a 4 eq. n-P(Bu)3 2 eq. negative positive 
b 4 eq. n-P(Bu)3 5 eq. negative positive 
c 
3.5 eq. 
KtBuO 
pH 9 
 0 eq. n-P(Bu)3 5 eq. negative positive 
d 4 eq. n-P(Bu)3 2 eq. negative positive 
e 4 eq. n-P(Bu)3 5 eq. negative positive 
f 
3 eq. 
Et3N 
pH 9-10 
 0 eq. n-P(Bu)3 5 eq. negative positive 
 
However, once again all cases gave a positive Ellman test after DTT 
treatment, indicating the formation of disulfides under all investigated 
coupling conditions. 
 
This could be by the combination of two factors: i) High local 
concentration of free thiols (functionalization of the resin: 1.8 mmol/g) 
which might strongly favor disulfide bond formation over nucleophilic 
attack and ii) sterical hindrance of tertiary thiolate, which reduces its 
nucleophilic strength.  
 
Hence, asssuming that substitution at the highly hindered trityl thiol might 
be difficult, long reaction times or highly activated reagents may be 
required to effect complete transformation. However, neither adding n-
P(Bu)3 as reducing reagent, nor changing basic conditions did alter the high 
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rate of disulfide formation during BB 17 coupling. Maybe the phosphonium 
moiety was actually unable to react with water, due to the highly 
hydrophobic nature of the thiol-4-methoxytrityl resin, causing the reduction 
cycle not to be closed. 
 
Interestingly, incorporation of methoxytrityl mercaptan on mesyl 
compound 54 in solution occurred in a high yield under the previously 
described conditions (Fig. 4.32). Most often, however, efficient conditions 
in solution cannot be transferred “literally” to solid phase and viceversa. 
In fact, several authors consider that a solid-phase system is actually ideal 
for intramolecular disulfide bond formation: Rigid fixation of molecules on 
the solid-phase restricts their mobility and decreases intermolecular 
contacts, which ensures predominant occurrence of intramolecular reactions 
(62). However, a reported way to avoid the intramolecular reaction is to 
apply the so-called “pseudo-dilution” which consists of reducing the initial 
functionalization of the resin at will by applying capping conditions in 
quantitative yields (63). Pseudo-dilution may indeed offer an alternative to 
progress with this synthetic strategy, but was not assayed in the context of 
this thesis. 
 
Coupling results with BB 18 
 
Meanwhile, we assayed the strategy based on BB 18 and the selected 
Cys-resin, represented in Fig. 4.33b. A priori, conditions in this case were 
better suited to our purpose, because the initial resin functionalization was 
low (< 0.7 mmol/g) and because the nucleophile was a primary thiolate. 
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Also the handle provided a straightforward anchoring point for cargo 
molecules. 
 
Initial attempts to couple an electrophile via thioether formation on Cys-
resin were performed after Fmoc deprotection and acetylation of the α 
amine, because NHFmoc does not survive the basic coupling conditions 
required, Fig. 4.37.  
 
Fig. 4.37: Initial trials on Cys resin with benzyl bromide. 
 
Furthermore, as for previous strategy, benzyl bromide was employed 
beforehand as model electrophile to optimize coupling conditions (Fig. 4.37 
and Table 4.6). 
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Table 4.6: Attempts to couple quantitatively BnBr to Fmoc-Cys(Mmt)-
Rink amide-MBHA resin. 
 
Base Reductive 
agent (eq.) BnBr 
Ellman 
test after 
reaction 
Ellman 
test after 
DTT  
a 
4 eq. n-
P(Bu)3 2      ─     + 
b 0 eq. n-P(Bu)3 2      ─ + 
c 
4 eq. n-
P(Bu)3 5 ─ + 
d 
3.5 eq. 
KtBuO 
pH 9 
 
0 eq. n-
P(Bu)3 5 ─     ─ 
e 
4 eq. n-
P(Bu)3 2 ─ + 
f 0 eq. n-P(Bu)3 2 ─ + 
g 4 eq. n-P(Bu)3 5 ─ + 
h 
3 eq. Et3N 
pH 10 
 
0 eq. n-
P(Bu)3 5 ─     ─ 
 
 
Promising results, according to the Ellman test, were obtained for entries 
d and h and the results were confirmed on anal. HPLC after cleavage (Fig. 
4.38).  
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Fig. 4.38: Crude profiles for entries f-h and compounds 
identified by ESI(+). From bottom to top: entries f, g and h. 
(Conds: 5-95% CH3CN in H2O, 0.1% TFA, in 15 min, UV220). 
 
In the presence of 5 eq. of benzyl bromide, reaction was completed in 
either of the basic conditions. Moreover, as better results were obtained in 
the absence of n-P(Bu)3, this reagent was definitely discarded for 
nucleophilic coupling on solid support.  
 
The expected product 75 was obtained almost pure in the case of entry h, 
as observed by HPLC and confirmed by ESI(+) and 1H-NMR analysis (see 
Appendix, Fig. A4.1), whereas chromatograms for entries f and g showed 
residual compound from non completed reaction. Hence, conditions for 
entry h were optimum to functionalize the resin with quantitative yield.  
 
Next, similar conditions were employed with 3 eq. of BB 18 (Fig. 4.39 
and Table 4.7).  
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Fig. 4.39: Initial trials with BB 18 on Cys resin. 
 
Table 4.7: Trials to couple BB 18 to Cys resin. 
 
Base Time 
Ellman test 
after reaction 
Ellman test after 
DTT  
a 3 h ─ (+) 
b 
3.5 eq. 
KtBuO 
pH 9 
o/n ─ (+) 
c 3 h + + 
d 
3 eq. Et3N, 
pH 10 o/n + + 
 
We observed that in the case of KtBuO (entries a and b) a slightly 
positive result was obtained after DTT treatment, regardless of the reaction 
time, while for Et3N no nucleophilic coupling seemed to occur (entries c 
and d). HPLC as well as 1H NMR analysis of the cleavage crudes indeed 
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revealed that BB 18 had been anchored with satisfactory yields for entries a 
and b, while no product was identified for entries c and d (Fig. 4.40). 
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Fig. 4.40: (a) anal. HPLC crude profiles (Conds: 5-95% CH3CN 
in H2O, 0.1% TFA, in 20 min, UV214) for entries a and c, and 
(b) detail from 1H NMR spectra of crude compound 76 in 
CH3OD, entries a (top) and c (bottom). 
  
ppm
76
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However, we had not succeeded in coupling BB 18 with quantitative 
yield, therefore the previous described coupling conditions with benzyl 
bromide as capping reaction were employed (Fig. 4.41).  
 
 
Fig. 4.41: Synthetic scheme incorporating capping reaction 
after BB 18 coupling. 
 
After all synthetic steps described in Fig. 4.38, we obtained a negative 
Ellman test, indicating that all sulfur coupling sites had been successfully 
capped. After cleavage the crude was analyzed by HPLC and 1H NMR (Fig. 
4.42). 
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Fig. 4.42: (a) HPLC profile of crude compound 76 (Conds: 5-
95% CH3CN in H2O, 0.1% TFA, in 20 min, UV214), and (b) 1H 
NMR spectrum of crude compound 76 in CH3eOD. 
 
Compound 75 could not be clearly identified on the 1H NMR spectrum as 
the proton signals for CHα where the same for products 75 and 76 while the 
remaining proton signals overlapped. However, in the UV chromatogram 
compound 75 was identified as a tiny peak at 7.2 min, product 76 as the 
major peak at 11.3 min and a third peak corresponding to methoxytrityl at 
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13.3 min. At first instance we thought the methoxytrityl peak originated 
from non complete wash out after on-resin removal of SMmt. The same 
synthetic steps were repeated several times and aliquots for cleavage after 
the first, the second and the fourth coupling were taken (Fig. 4.43). 
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Fig. 4.43: Crude profiles of crude compounds 76-78. 
 
As confirmed by LC-MS, in each case, the major peak corresponded to 
the expected compound. At this point, several aspects are difficult to 
understand: first we were unable to identify the capping subproducts on 
analytical HPLC, second aromatic signals from 4-methoxytrityl were 
integrating comparatively more than the rest of the signals in 1H-NMR 
spectra, and third many difficulties were encountered during the 
purification procedures. At this point we performed a negative control to 
discard partial deprotection of Mmt at the cleavage conditions (Fig. 4.44). 
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n
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Fig. 4.44: (a) Reaction scheme and (b) HPLC profile of crude 
compound 79, showing 4-methoxytrityl residues in the cleavage 
crude. 
 
The appearance of a peak at 13.1 min, revealed that partial Mmt 
deprotection was taking place in the absence of scavenger TIS, which 
makes sense since TIS leads cleavage to completion but TFA is the actual 
cleavage agent. 
 
Likely, if deprotection of Mmt was taking place, oligomeric subproducts, 
not visible in the UV-chromatograms due to the intensity of Mmt as 
fluorophore, were actually generating. Therefore two more steps to the 
synthetic strategy were added, consisting of hydrolyze the final Mmt and 
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coupling a non hydrolizable group, e.g. benzylbromide, before the final 
cleavage, (Fig. 4.45).  
 
Fig. 4.45: Improved synthetic strategy to avoid partial Mmt 
deprotection (DTT treatments omitted). 
 
The same procedure was repeated several times and aliquots were taken 
for cleavage after the first, the second and the fourth coupling (Fig. 4.46). 
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Fig. 4.46: Crude profiles of compounds 81-83, UV210 (Conds: 
20-50% CH3CN in H2O with 0.1% TFA in 17 min, UV210). 
 
The products were purified by semi-preparative HPLC and obtained in 
the following final yields: 81 (33%), 82 (21%) and 83 (12%) (see 
Appendix, Figs. A4.2-A4.4).  
 
According to HPLC chromatograms in Fig. 4.46, conversion at each step 
was ≥75%. Therefore all intermediate products were identified as minor 
peaks in crude compound 83. 
 
The coupling yield might be improved by repeating the coupling step for 
a second time after DTT treatment. However, in view of the easy 
purification of the final product and the synthetic difficulty of preparing BB 
18, a single coupling followed by a capping step was preferred. 
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Alternatively, we tried to recover it from the reaction mixture, but ESI(+) 
and 1H-NMR analysis of the final reaction mixture showed that the content 
of non reacted BB 18 was smaller than expected. Part of BB 18 hydrolyses 
in the reaction mixture to its OH precursor 73 and partially reacts with 
DMF, thus generating a mixture of similar compounds whose separation is 
cumbersome (see Appendix Fig. A4.5).  
 
To evaluate if the overall strategy was still worthwhile, several 
parameters were taken into account: yields of the reactions, consumption of 
starting material, time investment, ease and reproducibility of the protocols 
and last but not least, adaptability of the synthetic result to the final goal. In 
this case non complete coupling and non recovery of excess BB 18 was 
balanced by the feasibility of the protocols and the short time investment. 
Furthermore, semipreparative purification protocols enabled the isolation of 
strands of different length from the same cleavage crude. Thus this strategy 
may be suited to generate, in a short time, a series of oligoguanidiniums for 
their preliminary evaluation as internalizing vectors, whereby optimized 
conditions would be needed for large scale synthesis of the most promising 
candidates. 
 
However, a building block endowed with two subunits of bicyclic 
guanidiniums would be convenient to grow faster towards longer 
oligoguanidiniums. Therefore a diguanidinium BB was synthesized, by 
applying to the diguanidinium mesyl derivative 85 the same conditions as 
for compound 54, Fig. 4.47 (37).  
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Fig. 4.47: Synthetic scheme of BB 19. 
 
Preliminary coupling of BB 19 was assayed on a resin functionalized with 
a tetraguanidinium oligomer and nucleophilic conditions were kept the 
same (Fig. 4.48). 
 
 
 
 
 
 
 
 
 
4.2.3 Attempts with bifunctionalized BBs  
 
 243 
a)
NH2
O
HN O
S
N
H
N
N
H
S
N
H
N
N
H
S
N
H
N
N
H4
H3CO
H3CO N
H
O
NH
S
HN
N
HN
SMmt
H3CO
H3CO N
H
O
S
HN
N
HN
SBn
4 6
87
NH
i) 5% TFA, 5% TIS, CH2Cl2. ii) BB 19, K
tBuO. iii) BnBr, Et3N. iv) = i). v) = iii). vi) 100% TFA.
SBn
O O
O
CF3
O O
CF3
OO
CF3
O
i) - v)
vi)
 
b) 
 
min0 2.5 5 7.5 10 12.5 15 17.5 20
mAU   
-400
-200
0
200
400
600
800
81
82
83
87
75
 
Fig. 4.48: (a) Reaction sheme of compound 87 (DTT treatments 
are omitted) and (b) anal. HPLC chromatogram obtained after 
cleavage (Conds: 20-45% CH3CN in H2O with 0.1% TFA in 17 
min, UV210). 
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The hexaguanidinium derivative was obtained from the tetraguanidinium 
precursor as confirmed by ESI(+), (see Appendix, Fig. A4.6). Apparently, 
coupling of BB 19 was less efficient as compared to coupling of BB 18. 
However, BB 19 should be considered in the future as an alternative to BB 
1 for longer oligomers. 
 
So far, elongation of a bicyclic guanidinium was achieved on the 
proposed solid phase system. According to this strategy, anchorage of 
cargos should take place before vector elongation, as Fmoc is not 
compatible as a semipermanent protection of the cysteine α-amino group, 
because it does not survive the couping conditions. 
 
However, introduction of the cargo should take place more conveniently 
at the end of the chain elongation to avoid incompatibilities with the vector 
synthesis. Alternatively, Alloc, which is orthogonal to Mtt and Rinkamide 
resin, and stable to the basic conditions used for the elongation step, was 
attempted.  
 
Alloc-L-Ala-OH, obtained in two steps from H-Ala-OtBu*HCl was 
introduced at the Cys resin prior to incorporation of BB 1. Once attached, 
Mmt was removed and nucleophilic coupling of BB 18 was performed (Fig. 
4.49b and c). This Alloc-Ala-OH residue was introduced to further separate 
the cargo from the vector, which could facilitate cargo anchorage without 
disrupting the biological process. 
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Fig. 4.49: (a) incorporation of 88 to the synthetic scheme (DTT 
treatments are omitted), and (b) analytical HPLC profile of 
crude compound 88 (Conds: 20→50% CH3CN in H2O with 
0.1% TFA in 17 min, UV210). 
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Figure 4.49 shows only one peak, demonstrating the stability of the Alloc 
protection. Finally compound 88 was purified by semipreparative HPLC 
(40% yield, see Appendix Fig. A4.7). 
 
Furthermore, removal of Alloc from the solid support has been reported 
under inert conditions in the presence of phenyl-silane and 
tetrakis(triphenylphosphine)palladium, which is compatible with the 
guanidinium oligomer (64). This should allow the introduction of the cargo 
at any step of the synthetic process. 
 
In fact, in the next section deprotection of NHAlloc in the presence of a 
bicyclic guanidinium unit will be described.  
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4.2.4. Attempt with amino acid-type BB 
 
4.2.4.1 Objectives 
 
Going a step further towards the mimicking of Merrifield’s peptide 
synthesis, we considered replacing the thioether bond between bicyclic 
subunits with an amide bond, in collaboration with Dr. Pilar Castreño 
(ICIQ). We have already demonstrated that bicyclic guanidinium unit 
anchorage through formation of an amide bond was possible (Fig. 4.16). 
Next, we targeted a bifunctionalized BB with a carboxylic function on one 
terminus and a protected amine on the other (Fig. 4.50). 
 
 
Fig. 4.50: Representation of the searched bicyclic guanidinium 
unit. 
 
Synthesis of amino acid type bicyclic guanidinium 20 
 
As amino-protecting groups three different moeties were evaluated: 
Fmoc, Mmt and Alloc. However, only BB 20, bearing an Alloc moiety, was 
successfully obtained. Starting from the readily available mesyl compound 
54, a primary amine was incorporated by nucleophilic substitution in 
aqueous ammonia (91). Next, the free amine was functionalized with Alloc 
with allylchloroformate reagent and precursor 90 was obtained (65). 
Thereafter the silyl group (OTBDPS) was removed to activate the alcohol 
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again as mesyl. Finally the mercaptoacetic acid moiety was linked through 
nucleophilic substitution, which led to final compound 20 (Fig. 4.51). 
 
 
Fig. 4.51: Synthetic scheme for BB 20. 
 
4.2.4.2 Results and discussion 
 
The Alloc-protected BB 20 was successfully coupled to NH2-Cys(Mmt)-
Rink amide-MBHA resin with DIPCDI/HOBt as coupling agents, while 
amide under HATU/PyBOP conditions failed (data not shown). Removal of 
the Alloc group was performed as described (24) and monitored by the 
ninhydrine test. Next, classical acetylation of primary amines and final 
cleavage of the product, led to the crude profile represented in Fig. 4.52. 
Finally compound 92 was purified by semi-preparative HPLC (see 
Appendix Fig. A4.8). 
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Fig. 4.52: (a) Synthesis of 92 (top) and (b) anal. HPLC profile 
of crude compound 92 (bottom) (Conds: 5-60% CH3CN in H2O 
with 0.1 % TFA in 17 min, 60-95% in 3 min, UV210). 
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Finally compound 92 was purified by semi-preparative HPLC (see 
Appendix, Fig. A4.8). 
This attempt shows that classical procedures from Fmoc synthesis, such 
as amide coupling, NHAlloc deprotection and amine capping by 
acetylation, are compatible with bicyclic guanidinium scaffolds. This opens 
the possibility to prepare guanidinium containing oligomers through amino 
acid building blocks (Fig. 4.53) and/or branched oligomers through two 
different chemistries. 
 
 
Fig. 4.53: New strands of bicyclic guanidinium based on amino 
acid BB 20. 
 
Compared to strands bound by thioether bridges, these chains have more 
flexible linkers. In the context of GRTs, flexibility is associated to 
increased internalization rates (66), so these new bicyclic guanidinium 
oligomers constitute promising targets for drug delivery. 
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4.3 Conclusions and outlook 
 
In this chapter we have described the solid phase synthesis of 
polythioether oligomers based on bicyclic guanidinium subunits, with the 
ultimate goal to design libraries of diverse bicyclic GRTs.  
 
The iterative coupling of thioether-bound bicyclic guanidniniums was 
assayed with different molecules, supports and reactions. The first attempt 
was useful to tune cleavage and analytical conditions for the bicyclic 
guanidinium scaffold. However, this strategy was hampered by several 
obstacles that prompted the use of new strategies, based on difunctionalized 
building blocks 17 and 18.  
 
Iterative anchorage of BB 17 on commercially available thiol 4-
methoxytrityl resin failed, probably due to partial anchorage and high initial 
functionalization of the starting resin. Better results may be achieved by 
lowering the initial number of exposed thiols with, i.e. via acylation -which 
has been reported to form thioesters with quantitative yield- (67), and by 
improving nucleophilic coupling conditions.  
 
The third strategy, based on an Cys(Mmt)-Rink amide-MBHA support, 
provided for both the guanidinium moiety coupling via thioether formation 
and cargo attachment through the α-amino group. The key of this strategy 
was the use of a BB with a protected function, in combination with the 
presence of another function carrying a semipermanent protecting group for 
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the incorporation of the cargo, as well as a compatible resin as a permanent 
protecting group.  
 
So far, high, but not quantitative yields, have been achieved with a 
reaction sequence which includes: i) reduction treatments with dithiothreitol 
before nucleophilic coupling to ensure the reduced state of the thiols, ii) a 
capping reaction based on benzyl bromide incorporation and iii) NHAlloc 
as semipermanent group for α-amino protection.  
 
To the best of our knowledge, this constitutes the first example of solid-
phase synthesis of thioethers conceptually following the Merrifield 
approach, in just two steps by removal of a protecting group and 
incorporation of the building block. So far, this synthesis is suited to 
generate a versatile series of bicyclic guanidinium strands, varying in 
linkage, oligomer length and chemical nature of the cargo, to be evaluated 
in future preliminary transfection assays.  
 
Furthermore, we tested standard SPPS protocols for their use on an amino 
acid type bicyclic guanidinium scaffold. Preliminary results are promising 
and point to the development of new oligomeric compounds based on more 
flexible amide linkers. Interestingly, BB 20 and related compounds may be 
applied to any SPPS. In fact, their incorporation in artificial peptides could 
provide with new chemical properties affording strands with non natural 
amino acids. 
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4.4 Experimental part  
 
4.4.1 Solution phase synthesis  
 
General procedures: See section 2.8, except for:  
Thiol-4-methoxytrityl resin purchased in Novabiochem, Novabiochem 
cat. number: 01-64-0077. 
SHMmt was first purchased by Novabiochem (cat number: 01-63-0092) 
but it was recently discontinued. Since then it is synthesized in our lab as 
described herein. 
 
(2R,8R)-2-tert-butyldiphenylsilanoxymethyl-8-hydroxymethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (55). 
 
A solution of 56 (6.00 g, 10.20 mmol) in H2O/AcOH/THF (1:3:1, 150 
mL) was stirred for 20 h at rt. After removing the solvent, the crude was 
dissolved in CH2Cl2 (150 mL) and washed subsequently with saturated 
solutions of Na2CO3 (100 mL) and NH4Cl (3 × 100 mL). The organic phase 
was dried (Na2SO4) and after evaporating the solvent, the remaining oil was 
triturated with toluene/diethyl ether at 4 °C, resulting in 55 as a colorless 
solid in a 98% yield. Mp: 130-132 °C. [α]20D - 42 (c = 0.85, CHCl3). 1H 
NMR (CDCl3) δ 9.23 (s, 1H, NH), 7.78 (s, 1H, NH), 7.67-7.63 (m, 4H, 
ArH), 7.46-7.40 (m, 6H, ArH), 3.83 (dd, J = 3.5, 12.5 Hz, 1H, CH2OSi), 
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3.73 (dd, J = 5.2, 12.5 Hz, 1H, CH2OSi), 3.63-3.47 (m, 4H, CH2O, CHα), 
3.36-3.21 (m, 4H, CH2γ), 2.13-1.86 (m, 5H, OH, CH2β), 1.07 (s, 9H, 
C(CH3)3). 13C NMR (CDCl3) δ 151.2 (CGuan) 135.5, 135.4 (CAr), 132.6, 
129.8, 128.9, 127.8 (CHAr), 65.3, 63.7 (CH2O), 50.6, 49.3 (CHα), 45.6, 
44.6 (CH2γ), 26.7 (C(CH3)3), 22.7 (CH2β), 19.1 (C(CH3)3). ESI(+) m/z [M + 
H - HCl] : 474.5. Anal. Calcd. for C25H36N3O2SiCl: C 62.9, H 7.7, N 8.5; 
found C 63.3, H 7.65, N 8.9. 
The chloride anion of the resulting product could be changed into the 
hexafluorophosphate by dissolving 4 g (1.7 mmol) in CH2Cl2 (100 mL) and 
washing with a 2M KOH solution (2 × 50 mL) and subsequently with 0.1M 
NH4PF6 (2 × 50 mL). 
 
(2R,8R)-2-tert-butyldiphenylsilanoxymethyl-8-
methanesulfonyloxymethyl-3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]-
pyrimidin-1-ium hexafluorophosphate (54). 
 
 
To a solution of alcohol 55 (400 mg, 0.75 mmol) in dry CH2Cl2 (20 mL) 
was added methanesulfonic anhydride (Ms2O, 336 mg, 1.88 mmol) in dry 
THF (5 mL). The mixture was treated with N-methylmorpholine (NMM: 
330 µL, 3.00 mmol) and stirred for 2 h at rt. The organic solution was 
washed with a 0.1M NH4PF6 solution (2 × 30 mL), filtered over cotton and 
concentrated in vacuo. Purification by column chromatography on silica gel 
(eluent: CH2Cl2/CH3OH, 98:2) afforded 54 as a colorless solid in a 98% 
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yield. Mp 60-63 °C. [α]25D - 43 (c = 0.5, CHCl3). 1H NMR (CDCl3) δ 7.63 
(m, 4H, ArH), 7.62 (m, 6H, ArH), 6.24 (s, 1H, NH), 6.08 (s, 1H, NH), 4.30 
(m, 1H, CH2OMs), 4.17 (m, 1H, CH2OMs), 3.80 (m, 1H, CHα), 3.65 (m, 
2H, CH2OSi), 3.57 (m, 1H, CHα), 3.33 (m, 4H, CH2γ), 3.08 (s, 3H, CH3-
OMs), 2.05-1.89 (m, 4H, CH2β), 1.06 (s, 9H, C(CH3)3). 13C NMR (CDCl3) 
δ 150.6 (CGuan), 135.5 (CAr), 132.5, 130.0, 128.9 (CHAr), 69.5 
(CH2OMs), 66.2 (CH2OSi), 50.1, 47.7 (CHα), 45.3, 44.9 (CH2γ), 37.1 
(CH3), 26.7 (C(CH3)3), 22.4, 21.9 (CH2β), 19.1 (C(CH3)3). Exact Mass m/z 
[M + H - HPF6]+: calc.: 516.2352 uma; found 516.2354 uma. 
 
(2R,8R)-2-tert-butyldiphenylsilanoxymethyl-8-
carboxymethylsulfanylmethyl-3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-
a]pyrimidin-1-ium chloride (15). 
 
 
To a stirred solution of 54 (680 mg, 1.03 mmol) in dry THF (50 mL) was 
added a solution of sodium mercaptoacetic acid (363 mg, 3.08 mmol) and 
KtBuO (341 mg, 2.88 mmol) in CH3OH (20 mL). The resulting mixture 
was stirred for 4 h at rt. The solvent was removed, and the solid residue 
dissolved in CH2Cl2 (100 mL), washed with 1N NaHCO3 (100 mL), water 
(100 mL), 1M HCl (100 mL) and then dried over Na2SO4. After filtration 
and evaporation the residue was triturated in EtAcO to afford 15 as a 
colorless solid in a 82% yield. Mp: 166-168 °C. [α]25D - 50 (c = 0.5, 
CH3OH). 1H NMR (CDCl3) δ 8.27 (s, 1H, NH), 8.16 (s, 1H, NH), 7.65-7.60 
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(m, 4H, ArH), 7.41-7.39 (m, 6H, ArH), 3.77 (dd, J = 4.0, 11.0 Hz, 1H, 
CH2OSi), 3.59 (m, 3H, CH2OSi, CHα), 3.43 (d, J = 15.0 Hz, 1H, SCH2CO), 
3.36 (d, J = 15.0 Hz, 1H, SCH2CO), 3.28-3.23 (m, 4H, CH2γ), 2.95-2.71 
(m, 2H, CH2S), 2.12-1.85 (m, 4H, CH2β), 1.07 (s, 9H, C(CH3)3). 13C NMR 
(CDCl3) δ 171.9 (CO), 150.9 (CGuan), 135.5, 135.4 (CAr), 132.6, 129.8, 
127.8 (CHAr), 65.3 (CH2OSi), 49.3, 48.0 (CHα), 45.1, 44.7 (CH2γ), 36.7 
(CH2S), 34.5 (SCH2CO), 26.7 (C(CH3)3) 24.8, 22.5 (CH2β), 19.1 
(C(CH3)3). ESI(+) m/z [M + H - Cl]: 512.4. Anal. Calcd. for 
C27H38N3O3SSiCl·H2O: C 57.1, H 7.1, N 7.4, S 5.6; found C 57.5, H 6.8, N 
7.3, S 5.5. 
 
(2R,8R)-2-tert-butyldiphenylsilanyloxymethyl-8-acetylsulfanylmethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido-[1,2-a]-pyrimidin-1-ium 
hexafluorophosphate (16). 
 
 
A solution of compound 54 (60 mg, 0.09 mmol) and potassium 
thioacetate (32 mg, 0.27 mmol) in CH3CN (4 mL) was placed in a 6 mL 
sealed tube. The reaction mixture was stirred and heated with microwaves 
at 140 ºC for 10 min (200 W, max. 300 PSI). After cooling to rt the solvent 
was evaporated. The resulting crude was dissolved in CH2Cl2 and washed 
with 0.1M NH4PF6 (2 × 10 mL). The organic phase was filtered over cotton 
and concentrated in vacuo to give a crude residue which was purified by 
column chromatography on silica gel (eluent: CH2Cl2/CH3OH, 
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99.5:0.5→98:2), affording 16 as a colorless solid in a 97% yield. Mp: 98-
100 °C. [α]25D - 42 (c = 0.3, CHCl3). 1H NMR (CDCl3) δ 7.61-7.58 (m, 4H, 
ArH), 7.40-7.35 (m, 6H, ArH), 6.10 (s, 1H, NH), 6.08 (s, 1H, NH), 3.63-
3.62 (m, 2H, CH2O), 3.52-3.50 (m, 2H, CHα), 3.38-3.25 (m, 4H, CH2γ), 
3.04 (dd, J = 6.1, 14.3 Hz, 1H, CH2S), 2.98 (dd, J = 6.7, 14.3 Hz, 1H, 
CH2S), 2.34 (s, 3H, CH3CO), 2.07-1.96 (m, 2H, CH2β), 1.89-1.81 (m, 2H, 
CH2β), 1.04 (s, 9H, C(CH3)3). 13C NMR (CDCl3) δ 195.8 (CO), 150.8 
(CGuan), 135.6, 134.4 (CAr), 132.6, 130.1, 127.9 (CHAr), 65.4 (CH2O), 
49.7, 48.5 (CHα), 45.1, 45.0 (CH2γ), 32.5 (CH2S), 30.5 (CH3CO), 26.8 
(C(CH3)3), 24.5, 22.7 (CH2β), 19.2 (C(CH3)3). Exact Mass m/z [M + H - 
HPF6]+: calc.: 496.2454; found 496.2429 uma. 
 
(2R,8R)-2-tert-butyldiphenylsilanyloxymethyl-8-chloromethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido-[1,2-a]-pyrimidin-1-ium 
hexafluorophosphate (66). 
 
 
A solution of alcohol 55 (133.5 mg, 0.282 mmol) in SOCl2 (3.0 mL) and 
pyridine (0.5 mL)
 
was refluxed under for 3 h. Thereafter the solvent was 
eliminated and the resulting oil was dissolved in CH2Cl2 (20 mL) and 
washed with a saturated solution of NaHCO3 (20 mL) and with 0.1 M 
NH4PF6 (20 mL). The organic layer was dried, concentrated and purified by 
column chromatography on silica gel (eluent: CH2Cl2/CH3OH, 
97.5:2.5→95:5) to obtain pure product 67 as a colorless solid with almost 
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quantitative yield. Mp: 79-82 ºC. 1H NMR (CDCl3): δ  7.60-7.53 (m, 4H, 
ArH), 7.42-7.28 (m, 6H, ArH), 6.43 (bs, 1H, NH), 6.22 (bs, 1H, NH), 3.76-
3.39 (m, 6H, CH2O, CH2Cl, CHα), 3.30-3.13 (m, 4H, CH2γ), 2.09-1.77 (m, 
4H, CH2β), 1.00 (s, 9H, C(CH3)3). 13C NMR (CDCl3): 150.7 (CGuan), 
135.1 (CAr), 132.2, 129.5, 127.5 (CHAr), 64.9 (CH2O), 48.9 CH2Cl), 45.0 
(CHα), 44.3 (CH2γ), 26.4 (C(CH3)3), 23.0, 22.3 (CH2β), 18.7 (C(CH3)3). 
ESI(+) m/z: [M + H - HCl]: 456.2 uma. 
 
 
(2R,8R)-2-tert-butyldiphenylsilanyloxymethyl-8-bromomethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido-[1,2-a]-pyrimidin-1-ium 
hexafluorophosphate (67). 
 
 
Procedure A: 
A solution of alcohol 55 (0.14 g, 0.3 mmol), P(Ph)3 (0.2 g, 0.76 mmol) 
and CBr4 (0.25 g, 0.46 mmol) was stirred under for 24 h in dry CH2Cl2 (6 
mL). The reaction was quenched by washing the organic phase with water 
(1 x 5 mL) and with 0.1 M NH4PF6 (2 x 5 mL). Next the organic layer was 
dried over Na2SO4 and concentrated under vaccum. The residue was 
purified by column chromatography on silica gel (eluent: 100% 
EtOAc→CH2Cl2/CH3OH: 97.5:2.5→95:5) and pure product 67 was 
obtained as a colorless solid in a 89% yield.  
Procedure B: 
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Alcohol 55 (30 mg, 0.063 mmol) and Cu(OTf)2 (2% mol) were dissolved 
in 0.5 ml THF and N, N’-dicyclohexylcarbodiimide (CDI, 20 µL, 0.127 
mmol) was added. The solution was stirred at rt for 3 h and the same 
amount of CDI was added again. The reaction was further stirred at rt for 2 
h. Next, N-bromosuccinimide (43 mg, 0.254 mmol) was added dissolved 
THF (2 mL), and the reaction was refluxed for 10 h. Next, the solvent was 
evaporated and the crude dissolved in CH2Cl2 (1 mL). The organic phase 
was washed with 0.1 M NH4PF6 (2 x 1 mL), dried with Na2SO4, filtered 
and concentrated in vacuo. Next, the crude was purified by column 
chromatography on silica gel (eluent: CH2Cl2/CH3OH: 97.5:2.5→95:5). 
Finally, 67 was obtained as a colorless solid in a 50% yield. Mp: 60-64 ºC. 
1H NMR (CD3Cl): δ 7.71-7.60 (m, 4H, CHAr), 7.45-7.35 (m, 6H, CHAr), 
6.42 (s, 1H, NH), 6.21 (s, 1H, NH), 3.80 (dd, J = 13.4, 6.7 Hz, 1H, CH2O), 
3.72-3.53 (m, 5H, CH2O, CH2Br, CHα), 3.32-3.20 (m, 4H, CH2γ), 2.21-
1.88 (m, 2H, CH2β), 1.06 (s, 9H, C(CH3)3). 13C NMR: δ 150.7 (CGuan), 
135.3, 135.2 (CAr), 132.3, 129.7, 127.6 (CHAr), 65.0 (CH2O), 49.1, 48.8 
(CHα), 44.5, 44.4 (CH2γ), 33.2 (CH2Br), 26.2 (C(CH3)3), 24.0, 22.4 (CH2β), 
18.8 (C(CH3)3). ESI(+): m/z [M + H - PF6]+ : 502.2 uma. 
 
(2R,8R)-2-hydroxymethyl-8-acetylsulfanylmethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido-[1,2-a]-pyrimidin-1-ium hexafluorophosphate 
chloride (68). 
 
A solution of compound 16 (20 mg, 0.03 mmol) was stirred for 1 h at -5 
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ºC in 3% HCl-CH3CN (1:2, 1.87 ml). The solvent was evaporated and the 
residue was dissolved in distilled water (8 mL). Thereafter, the aqueous 
phase was washed with CH2Cl2 (2 x 8 mL) and evaporated. Finally the 
residue was dried thouroughly, affording pure compound 68 as a colorless 
solid in a 21 % yield. 1H NMR (CH3OD): δ 3.66 (dd, J = 10.5, 3.8 Hz, 1H, 
CH2O), 3.57-3.55 (m, 1H, CH2O), 3.48-3.35 (m, 8H, CHα, CH2γ), 3.11 (d, 
J = 6.1 Hz, 2H, CH2S), 2.39 (s, 3H, CH3COS), 2.15-2.01 (m, 2H, CH2β), 
1.91-1.76 (m, 2H, CH2β). Exact Mass (ESI+) m/z [M + H - HCl]+: calc.: 
258.1276 uma, found: 258.1284 uma. 
 
(2R,8R)-2-tert-butyldiphenylsilyloxymethyl-8-benzoylthiomethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (69). 
 
 
Mesyl precursor 54 (150 mg, 0.227 mmol) was dissolved in CH3CN (3 
mL) and introduced into a microwave tube to which potassium thiobenzoate 
(0.06 mg, 0.34 mmol) was added. The reaction was heated at 140 ºC (200 
W, max. 300 PSI) for 10 min. Thereafter salts were filtered and solvent was 
evaporated. The resulting solid was dissolved in CH2Cl2 (5 mL) and the 
organic phase was washed with water (2 x 5 mL) and 0.1M NH4PF6 (2 x 5 
mL). The organic layer was filtered over cotton and the solvent was 
concentrated in vacuo. Column chromatography on silica gel (eluent: 
CH2Cl2/ CH3OH, 100:0→96:4) afforded pure product 69 as a colorless 
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solid in a 86% yield. [α]20D: + 20.1 (c = 0.5, CH3CN, st. dev.: 0.7). Mp: 70-
72 ºC. 1H NMR (CH3OD): δ 7.96 (d, J = 8.2 Hz, 2H, ArH-COS), 7.66-7.62 
(m, 4H, ArH-Si), 7.59 (d, 1H, J = 7.6 Hz, ArH-COS), 7.49-7.39 (m, 8H, 
ArH-COS, ArH-Si), 6.42 (s, 1H, NH), 6.21 (s, 1H, NH), 3.74-3.64 (m, 3H, 
CH2O, CHα), 3.62-3.54 (m, 1H, CHα), 3.50-3.42 (m, 1H, CH2γ), 3.38-3.29 
(m, 4H, CH2γ, CH2S), 3.24 (dd, J = 5.6, 14.0 Hz, 1H, CH2S), 2.16-2.06 (m, 
1H, CH2β), 2.06-1.98 (m, 1H, CH2β), 1.97-1.87 (m, 2H, CH2β), 1.07 (s, 9H, 
CH3tBu). 13C NMR (CH3OD): δ 150.4 (CGuan), 135.6 (CAr), 135.5, 134.0 
(CHAr), 133.6 (CAr), 130.1, 128.8, 128.0, 127.5 (CHAr), 65.5 (CH2O), 
50.1 (CHαCH2O), 49.1 (CHαCH2S), 45.4, 45.3 (CH2γ), 32.2 (CH2S), 26.8 
(C(CH3)3), 24.4, 22.6 (CH2β), 19.2 (C(CH3)3). Exact Mass m/z [M + H - 
HPF6]+: calc.: 558.2611 uma, found: 558.2585 uma. 
 
(2R,8R)-2-methylsulfonyloxymethyl-8-benzoylthiomethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate 
(17). 
 
To a solution of compound 69 (331 mg, 0.470 mmol) in THF (25 mL) at 
0 ºC, was added dropwise HF-Pyridine (2.2 mL). The reaction was stirred 
for 10 h at rt. The solvent was removed and the remaining residue was 
dissolved in CH2Cl2 (10 mL). Next, the organic layer was washed with 
water (2 x 10 mL) and with 0.1M NH4PF6 (2 x 10 mL). The organic layer 
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was dried over anhydrous Na2CO3, filtered and evaporated in vacuo. Next, 
the remaining solid was dissolved in CH2Cl2 (10 mL), and NMM (0.205 
mL, 1.88 mmol) and Ms2O (205 mg, 1.18 mmol) were added. After stirring 
at rt for 2 h, the organic layer was washed with water (2 x 5 mL) and with 
0.1M NH4PF6 (2 x 5 mL). Finally, the residue was precipitated in CHCl3 
and pure compound 17 was obtained as a colourless solid in a 61% yield. 
[α]20D: - 90.94 (c = 0.5, CH3CN, stand. dev.: 0.5). Mp: 170-174 ºC. 1H 
NMR (CD3CN): δ 8.02 (d, J = 8.4 Hz, 2H, ArH-S), 7.71 (tr, J = 7.3 Hz, 1H, 
ArH-S), 7.57 (tr, J = 7.9 Hz, 2H, ArH-S), 6.24 (d, J = 13.9 Hz, 2H, NH), 
4.29 (dd, J = 4.3, 10.5 Hz, 1H, CH2O), 4.13 (dd, J = 7.3, 10.3 Hz, 1H, 
CH2O), 3.83-3.76 (m, 1H, CHαCH2O), 3.74-3.67 (m, 1H, CHαCH2S), 3.47-
3.27 (m, 6H, CH2γ, CH2S), 3.09 (s, 3H, CH3), 2.19-2.06 (m, 2H, CH2β), 
2.00-1.85 (m, 2H, CH2β). 13C NMR (CD3CN): δ 191.1 (CO), 150.6 
(CGuan), 136.6 (CAr), 134.3, 129.1, 127.3 (CHAr), 70.8 (CH2O), 48.6 
(CHαCH2O), 47.6 (CHαCH2S); 44.5 (CH2γ); 36.8 (CH3SO3), 32.6 (CH2S), 
24.2, 21.7 (CH2β). Exact Mass (ESI+) m/z [M + H - HPF6]+ : calc.: 
398.1208 uma, found: 398.1208 uma. 
 
General procedure for the synthesis of compounds 70-72. 
To a solution of 0.25 M NaOCH3 (25 eq.), the appropriate mercaptane 
(2.5 eq.) was added and stirred for 20 min. Thereafter, compound 54 (1 eq.) 
was added dissolved in CH3OH and the reaction mixture was stirred at rt 
for 5 h. After evaporation of the solvent, the remaining residue was 
dissolved in CH2Cl2 and the organic phase was washed with water and with 
0.1M NH4PF6, dried over anhydrous Na2CO3, filtered and concentrated at 
reduced pressure. Purification of the crudes was achieved by column 
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chromatography on silica gel with the respective eluents. 
 
(2R,8R)-2-tert-butyldiphenylsilanoxymethyl)-8-benzylthiomethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (70). 
 
Prepared following the described procedure in 0.25M NaOMe (3 mL), 
with benzylmercaptane (9 µl, 0.076 mmol) and compound 54 (20 mg, 0.03 
mmol), dissolved in CH3OH (0.5 mL). Purification by column 
chromatography on silica gel (eluent: CH2Cl2/CH3OH, 100:0→98:2) 
afforded 70 as a light yellow oil in a 48% yield. 1H NMR (CD3Cl): δ 7.68-
7.62 (m, 4H, CHArSiO), 7.49-7.40 (m, 6H, CHArSi), 7.36-7.31 (m, 4H, 
CHAr-BnS), 7.25 (m, 1H, CHAr-BnS), 6.21 (s, 1H, NH), 6.07 (s, 1H, NH),  
3.75 (m,  2H, SCH2Ph), 3.73-3.63 (m, 2H, CH2O), 3.57-3.49 (m, 1H, CHα), 
3.41-3.33 (m, 1H, CHα), 3.31-3.20 (m, 4H, CH2γ), 2.68 (dd, J = 4.4, 13.7 
Hz, 1H, CH2S), 2.56 (dd, J = 7.6, 13.7 Hz, 1H, CH2S), 2.10-1.94 (m, 2H, 
CH2β), 1.94-1.77 (m, 2H, CH2β), 1.08 (s, 9H, C(CH3)3). 13C NMR (CD3Cl): 
δ 149.8 (CGuan), 135.5 (CAr), 134.9 (CAr), 134.4, 130.6, 130.3, 129.6, 
129.6, 128.7, 128.0, 127.3 (CHAr), 65.5 (CH2O), 48.1 (CHαCH2O), 47.9 
(CHαCH2S), 45.4, 45.0 (CH2γ), 36.9 (CH2S), 35.8 (SCH2Ph), 26.8 
(C(CH3)3), 24.8, 22.6 (CH2β), 19.2 (C(CH3)3). ESI(+) m/z [M + H - HPF6]+: 
544.2. 
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(2R,8R)-2-tert-butyldiphenylsilyloxymethyl-8-tritylthiomethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (70). 
 
Prepared following the described procedure in 0.25M NaOMe (15 mL), 
with tritylmercaptane (TrtSH, 104 mg, 0.38 mmol) and compound 54 (100 
mg, 0.15 mmol), dissolved in CH3OH (2 mL). Purification by column 
chromatography on silica gel (eluent: CH2Cl2/CH3OH, 100:0→99.5:0.5) 
afforded 70 as a yellow solid in a 60% yield. 1H NMR (CD3Cl): δ 7.62-7.57 
(m, 4H, CHArSiO), 7.44-7.35 (m, 11H, CHArSiO, CHAr-Trt), 7.32-7.19 
(m, 10H, CHAr-Trt), 6.17 (s, 1H, NH), 5.99 (s, 1H, NH), 3.69-3.58 (m, 2H, 
CH2O), 3.53-3.46 (m, 1H, CHα), 3.25-3.16 (m, 2H, CH2γ), 3.12-3.03 (m, 
2H, CH2γ), 2.86-2.78 (m, 1H, CHα), 2.53-2.46 (dd, J = 5.5, 13.7 Hz, 1H, 
CH2S), 2.43-2.35 (dd, J = 8.4, 13.7 Hz, 1H, CH2S), 2.00-1.81 (m, 3H, 
CH2β), 1.76-1.66 (m, 1H, CH2β), 1.08 (s, 9H, (C(CH3)3). 13C NMR 
(CDCl3): δ 150.2 (CGuan), 144.7, 144.6, 136.5, 135.8 (CAr), 133.1), 130.8, 
130.3, 129.3, 127.9, 127.5, 126.9, 113.7 (CHAr), 67.5 (C), 65.5 (CH2O), 
49.7 (CHαCH2O), 48.0 (CHαCH2S), 45.2, 45.1 (CH2γ), 35.6 (CH2S), 26.8 
(C(CH3)3), 24.6, 22.5 (CH2β), 19.2 (C(CH3)3). ESI(+) m/z [M + H - HPF6]+: 
696.4 uma. 
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(2R,8R)-2-tert-butyldiphenylsilyloxymethyl-8-(4-
methoxyphenyldiphenylmethylthiomethyl)-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate (72). 
 
 
Prepared following the described procedure in 0.25M NaOMe (45 mL), 
with MmtSH (208 mg, 0.9 mmol) and compound 54 (400 mg, 0.6 mmol), 
dissolved in CH3OH (5 mL). Purification by column chromatography on 
silica gel (eluent: CH2Cl2/CH3OH, 100:0→99.5:0.5) afforded 72 as a 
yellow solid (85%). Mp: 98-100 ºC. [α]20D: - 45.7 (c = 0.37, CH3CN, 
stand. dev.: 1.3). 1H NMR (CDCl3): δ 7.68-7.61 (m, 4H, CHAr-Si), 7.48-
7.38 (m, 10H, CHAr-Si, CHAr-Mmt), 7.36-7.28 (m, 6H, CHAr-Mmt), 
7.26-7.20 (m, 2H, CHAr-Mmt), 6.86 (d, J = 9.0 Hz, 2H, CHAr-Mmt), 6.14 
(s, 1H, NH),  5.99 (s, 1H, NH), 3.81 (s, 3H, CH3O), 3.71-3.60 (m, 2H, 
CH2O), 3.53-3.46 (m, 1H, CHα), 3.29-3.16 (m, 2H, CH2γ), 3.12-3.06 (m, 
2H, CH2γ), 2.94-2.85 (m, 1H, CHα), 2.55-2.47 (dd, J = 5.3, 13.1 Hz, 1H, 
CH2S), 2.46-2.39 (dd, J = 8.4, 13.1 Hz, 1H, CH2S), 2.00-1.81 (m, 3H, 
CH2β), 1.76-1.66 (m, 1H, CH2β), 1.08 (s, 9H, C(CH3)3).13C NMR (CDCl3): 
δ 158.4 (CO), 150.2 (CGuan), 144.6, 144.5, 136.1, 135.6, 132.6 (CAr), 
130.8, 130.1, 129.4, 128.1, 128.0, 126.9, 113.7 (CHAr), 67.1 (C), 65.5 
(CH2O), 55.3 (CH3O), 49.9 (CHαCH2O), 48.1 (CHαCH2S), 45.2, 45.0 
(CH2γ), 35.7 (CH2S), 26.8 (C(CH3)3), 24.6, 22.5 (CH2β), 19.2 (C(CH3)3). 
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Exact Mass ESI(+): m/z [M + H - HPF6]+: calc.: 726.3550, found: 
726.3515. 
 
(2R,8R)-2-methanesulfonyloxymethyl-8-(4-
methoxyphenyldiphenylmethylthiomethyl)-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate (18).  
 
 
Alcohol 73 (250 mg, 0.39 mmol) was dissolved in CH2Cl2 (20 mL) and 
NMM (0.204 ml, 1.87 mmol) and then Ms2O (0.204 g, 1.17 mmol) were 
sequentially added. The reaction was stirred at rt for 3 h. Next, the organic 
phase was washed with water (2 x 8 mL) and with 0.1 M NH4PF6 (2 x 8 
mL). After drying the organic phase over Na2CO3 and filtering over cotton, 
the solvent was removed and the oily residue was purified by column 
chromatography on silica gel (eluent: 100% CH2Cl2→CH2Cl2/CH3OH, 
99.5:0.5) and pure compound 18 was obtained as a yellow solid in a 90% 
yield. Mp: 98-100 ºC. [α]20D: - 12.2 (c = 4.42 mg/mL in CH3CN; St. 
Deviation: 0.67). 1H NMR (CD3Cl): δ 7.45-7.41 (m, 4H, ArH), 7.36-7.30 
(m, 6H, ArH), 7.28-7.21 (m, 2H, ArH), 6.86 (d, J = 9.0 Hz, 1H, NH), 6.24 
(s, 1H, NH), 6.0 (s, 1H, NH), 4.29 (dd, J = 4.3, 10.5 Hz, 1H, CH2O), 4.13 
(dd, J = 7.3, 10.3 Hz, 1H, CH2O), 3.82-3.76 (m, 1H, CHα), 3.81 (s, 3H, 
CH3O), 3.37-3.29 (m, 2H, CH2γ), 3.27-3.18 (m, 1H, CHα), 3.17-3.10 (m, 
1H, CH2γ), 3.10 (s, 3H, CH3O), 2.94-2.85 (m, 1H, CH2γ), 2.46 (d, J = 5.3 
Hz, 2H, CH2S), 2.12-2.00 (m, 1H, CH2β), 1.99-1.87 (m, 2H, CH2β), 1.80-
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1.67 (m, 1H, CH2β). 13C NMR (CDCl3): δ 158.4 (CO), 150.5 (CGuan), 
144.6, 144.6, 136.2 (CAr), 130.7, 129.3, 128.1, 126.8, 113.4 (CHAr), 69.7 
(CH2O), 67.1 (C), 55.3 (CH3O), 47.9 (CHαCH2O), 47.4 (CHαCH2S), 44.9 
(CH2γ), 37.2 (CH3O), 35.8 (CH2S), 24.4, 22.1 (CH2β). Exact Mass (ESI+) 
m/z [M + H - HPF6]+ calc.: 566.2147 uma, found: 566.2133 uma. 
 
(2R,8R)-2-hydroxymethyl-8-(4-
methoxyphenyldiphenylmethylthiomethyl)-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate (73). 
 
N
H
N
N
H
S OH
MeO
PF6
N
H
N
N
H
MsO OTBDPS
PF6
NaOMe, MmtSH,
rt-50º C
85%
54 73
 
To a solution of 0.25 M NaOMe (42 ml, 10.6 mmol) was added MmtSH 
(280 mg, 0.91 mmol) and stirred at rt for 5 min. Thereafter, mesyl precursor 
54 (280 mg, 0.42 mmol) was added dissolved in CH3OH (5 mL) and the 
reaction mixture was stirred at rt for 1 h. Next, reaction was heated at 50 ºC 
overnight. After evaporation of the solvent, the remaining residue was 
dissolved in CH2Cl2 (15 mL) and the organic phase was washed with water 
(10 mL) and with NH4PF6 (3 x 10 mL), dried over anhydrous Na2CO3, 
filtered over cotton and concentrated at reduced pressure. Purification of the 
crude was performed by column chromatography on silica gel (eluent: 
100% CH2Cl2→CH2Cl2/CH3OH, 97:3). The product 73 was obtained as a 
colourless solid in a 85% yield. Mp: 85-95 ºC. 1H NMR (CDCl3): δ 7.42-
7.40 (m, 4H, ArH), 7.35-7.7.27 (m, 6H, ArH), 7.26-7.20 (m, 2H, ArH), 6.85 
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(d, J = 8.3 Hz, 2H, ArH), 6.30 (s, 1H, NH), 6.00 (s, 1H, NH), 3.79 (s, 3H, 
CH3O), 3.64-3.59 (m, 1H, CHα), 3.56-3.41 (m, 2H, CH2O), 3.39-3.32 (m, 
1H, CH2γ), 3.21-3.11 (m, 3H, CH2γ), 2.86-2.78 (m, 1H, CHα), 2.51-2.40 
(m, 2H, CH2S), 1.88-1.78 (m, 2H, CH2β), 1.69-1.59 (m, 2H, CH2β). 13C 
NMR (CDCl3): δ 158.4 (CAr), 150.4 (CGuan), 144.7, 136.2 (CAr), 130.8, 
129.4, 128.1, 127.0, 113.4 (CHAr), 66.9 (C), 64.8 (CH2), 55.3 (CH3), 49.9 
(CHαCH2O), 47.8 (CHαCH2S), 45.4, 44.7 (CH2γ), 36.6 (CH3O), 25.2, 22.2 
(CH2β). Exact Mass (ESI+) m/z [M + H - HPF6]+: calc.: 488.2364 uma, 
found: 488.2372 uma. 
 
(4-Methoxyphenyl)diphenylmethanethiol. 
 
The hydrated salt NaSH (1 g, aprox. 12.3 mmol) was dissolved in water 
(12 mL) and acetone (12 mL) under argon atmosphere and the solution was 
buBBled for some minutes with argon. Then, a solution of 4-Methoxytrityl 
chloride (1g, 3.5 mmol) was added with a canula rapidly at rt. Almost 
instantly a white precipitate appeared. After 45 min stirring, the solid was 
filtered and washed with water under inert atmosphere. After drying in 
vacuo, the product was obtained as a slightly pink solid (40% yield). 1H 
NMR (CDCl3): δ 7.34-7.25 (m, 10H, ArH), 7.21 (d, J = 8.8 Hz, 2H, ArH), 
6.84 (d, J = 8.8 Hz, 2H, ArH), 3.83 (s, 3H, CH3). 13C NMR (CDCl3): δ 
158.3, 147.5, 139.5 (CAr), 130.6, 129.4, 127.8, 126.8, 113.1 (CHAr), 62.6 
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(C), 55.3 (CH3). Exact Mass m/z [M - H]-: calc.: 305.1000 uma, found: 
305.1015 uma 
 
(2R,8R)-8-[(2R,8R)-2-hydroxymethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-2-ylmethylsulfanylmethyl-1-ium 
hexafluorophosphate]-8-tert-butyldiphenylsilanyloxymethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate 
(86). 
A solution of mesyl compound 54 (253 mg, 0.38 mmol) and potasium 
thioacetate (222 mg, 1.90 mmol) in a mixture THF/H2O (3:1, 20 mL) was 
refluxed for 7 h. After cooling it to rt, MsOH (246 µL, 3.8 mmol) was 
added and the mixture was refluxed for 16 h. After cooling to rt, Et2O (10 
mL) were added to the solution and the aqueous phase was extracted and 
washed with CHCl3 (2 × 20 mL) and finally with Et2O (20 mL). After 
concentration of about 50% of aqueous layer, KHCO3 (456 mg, 4.56 mmol) 
was added and the solvent evaporated to dryness. Then, CH3OH (50 mL) 
was added to the residue, the precipitate was removed by filtration and the 
solvent evaporated under reduced pressure. This procedure was repeated 
several times increasing the amount of CH2Cl2 in the solvent mixture until 
pure CH2Cl2, resulting in a slightly yellow solid. To a solution of this 
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product, Cs2CO3 (111 mg, 0.34 mmol) in CH3OH (20 mL) and n-PBu3 
(53.6 µL, 0.20 mmol) was added and the mixture was stirred for 40 min. 
Then a solution of 86 (225 mg, 0.34 mmol) in THF (5 mL) was added and 
the mixture was stirred for 2 h. After evaporation of the solvent, the crude 
residue was dissolved in CH2Cl2 (20 mL) and washed with a 0.1M NH4PF6 
solution (2 × 30 mL). The organic layer was filtered over cotton and 
concentrated in vacuo. Purification by column chromatography on silica gel 
(eluent: CH2Cl2/CH3OH, 96:4→94:6) afforded 54 as a colorless solid in a 
92% yield. Mp: 100-104 °C. [α]25D -93 (c = 0.4, CHCl3). 1H NMR (CDCl3) 
δ 7.64-7.24 (m, 4H, ArH), 7.43-7.38 (m, 6H, ArH), 6.47 (s, 1H, NH), 6.35 
(s, 2H, NH), 6.23 (s, 1H, NH), 3.72-3.23 (m, 16H, CH2O, CHα, CH2γ), 2.86 
(dd, J = 3.5, 13.7 Hz, 1H, CH2S), 2.82 (dd, J = 4.0, 13.4 Hz, 1H, CH2S), 
2.65-2.63 (m, 2H, CH2S), 2.54 (dd, J = 3.8, 13.6 Hz, 1H, CH2S), 2.12-1.81 
(m, 8H, CH2β), 1.05 (s, 9H, C(CH3)3). 13C NMR (CDCl3): δ 150.7, 150.3 
(CGuan), 135.2 (CAr), 132.7, 132.5, 129.8, 127.7 (CHAr), 65.4, 65.2 
(CH2OSi, CH2O), 50.1, 49.8, 47.7, 47.6 (CHα), 45.3, 44.8 (CH2γ), 36.0, 
35.7 (CH2S), 26.7 (C(CH3)3), 26.5, 25.8, 22.4, 22.2 (CH2β), 19.1 (C(CH3)3). 
Exact Mass m/z [M + 2H - 2HPF6]2+: calc.: 318.1821 uma; found 318.1816 
uma. 
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(2R,8R)-8-[(2R,8R)-2-methanesulfonyloxymethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-2-ylmethylsulfanylmethyl-1-ium 
hexafluorophosphate]-8-tert-butyldiphenylsilanyloxymethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate (85). 
 
 
To a solution of alcohol 86 (107 mg, 0.11 mmol) and NMM (93.4 µL, 
0.88 mmol) in dry CH2Cl2 (10 mL) was added a solution of Ms2O (100 mg, 
0.55 mmol) in CH2Cl2 (4 mL) and the mixture was stirred for 4 h. The 
solvent was evaporated under reduced pressure and the resulting crude 
dissolved in CH2Cl2 (4 mL) and washed successively with 0.1M NH4PF6 (2 
× 30 mL). The organic layer was dried over anhydrous Na2CO3, filtered and 
concentrated in vacuo. Purification by column chromatography on silica gel 
(eluent: CH2Cl2/CH3OH, 96:4) afforded 85 as colorless solid in a 97% 
yield. Mp: 76-80 °C. [α]25D - 83 (c = 0.5, CHCl3). 1H NMR (CDCl3) δ 7.68-
7.66 (m, 4H, ArH), 7.43-7.38 (m, 6H, ArH), 6.37 (s, 1H, NH), 6.28 (s, 2H, 
NH), 6.22 (s, 1H, NH), 4.22-4.01 (m, 2H, CH2O), 3.72-3.68 (m, 2H, 
CH2O), 3.47-3.23 (m, 12H, CHα, CH2γ), 3.02 (s, 3H, CH3O), 2.84-2.80 (m, 
1H, CH2S), 2.68-2.63 (m, 2H, CH2S), 2.56-2.52 (m, 1H, CH2S), 2.13-1.79 
(m, 8H, CH2β), 1.06 (s, 9H, C(CH3)3). 13C NMR (CDCl3) δ 151.4, 151.2 
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(CGuan), 135.8 (CAr), 132.7, 132.8, 130.3, 127.7 (CHAr), 68.4, 65.6 
(CH2OSi, CH2O), 50.1, 49.8, 47.7, 47.4 (CHα), 45.7, 44.8 (CH2γ), 37.5 
(CH2S), 37.0 (CH3O) 36.9 (CH2S), 26.7 (C(CH3)3), 26.5, 25.9, 22.6, 22.4 
(CH2β), 19.2 (C(CH3)3). Exact Mass m/z [M + H - HPF6]+: calc.: 859.3059 
uma; found 859.3067 uma. 
 
(2R,8R)-8-[(2R,8R)-2-(4-methoxyphenyldiphenylmethylthiomethyl)-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-2-
ylmethylsulfanylmethyl-1-ium hexafluorophosphate]-8-hydroxymethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (84). 
 
 
MmtSH (66 mg, 0.194 mmol) was dissolved in a solution of 0.25 M 
NaOCH3 (13 ml, 3.23 mmol) and stirred at rt for 5 min under inert 
atmosphere Next, a solution of precursor 85 (280 mg, 0.42 mmol) in dry 
CH3OH (2 mL) was added with a syringe. The reaction was stirred at rt for 
1 h and then heated at 50 ºC for 18 h. After removal of the solvent, the 
remaining residue was dissolved in CH2Cl2 (6 mL) and the organic phase 
4.4 Experimental part  
 
 273 
was washed with water (5 mL) and with 0.1M NH4PF6 (3 x 5 mL). After 
drying the organic layer with anhydrous Na2CO3, it was filtered and 
concentrated. Purification of the crude was performed by silica flash 
chromatography (eluent:
 
CH2Cl2/CH3OH, 99.5:0.5→97:3). Pure compound 
84 was obtained as a colorless solid in a 79% yield. Mp: 92-96 ºC. 1H NMR 
(CD2Cl2): δ 7.48-7.43 (m, 4H, ArH), 7.38-7.32 (m, 6H, ArH), 7.30-3.25 (m, 
2H, ArH), 6.88 (d, J = 8.7 Hz, 2H, ArH), 6.38 (bs, 1H, NH), 6.30 (bs, 1H, 
NH), 6.17 (bs, 1H, NH), 5.92 (bs, 1H, NH), 6.00 (bs, 1H, NH), 3.82 (s, 3H, 
CH3O), 3.80-3.74 (m, 1H, CHα), 3.62-3.51 (m, 4H, CHα, CH2γ), 3.49-3.40 
(m, 2H, CH2γ), 3.40-3.28 (m, 3H, CHα, CH2S), 3.26-3.10 (m, 2H, CH2γ), 
2.95-2.85 (m, 3H, CHα, CH2S), 2.66-2.57 (m, 2H, CH2S ), 2.53-2.44 (m, 
2H, CH2S), 2.22-2.09 (m, 1H, CH2β), 2.08-2.00 (m, 1H, CH2β), 1.99-1.80 
(m, 4H, CH2β), 1.76-1.65 (m, 1H, CH2β).13C NMR (CD2Cl2): δ 158.5 
(CAr), 150.8, 150.1 (CGuan), 144.7, 136.2 (CAr), 130.8, 129.4, 128.1, 
126.9, 113.3 (CH2Ar), 66.9 (C), 64.3 (CH2O), 55.3 (CH3O), 50.7, 48.2, 
47.8, 47.6 (CHα), 45.7, 45.5, 45.1 (CH2γ), 36.5, 36.2, 35.9 (CH2S), 26.0, 
25.7, 24.8, 22.4 (CH2β). Exact Mass m/z [M + H - HPF6]+ calc.: 685.3358 
uma, found: 685.3345 uma. 
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(2R,8R)-8-[(2R,8R)-8-(4-methoxyphenyldiphenylmethylthiomethyl)-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-2-
ylmethylsulfanylmethyl-1-ium hexafluorophosphate]-2-
methanesulfonyloxymethyl-3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-
a]pyrimidin-1-ium hexafluorophosphate (20). 
 
 
To a solution of alcohol 84 (150 mg, 0.15 mmol) and NMM (0.62 µl, 
0.597 mmol) in dry CH2Cl2 (10 mL), Ms2O (63 mg, 0.374 mmol) was 
added dissolved in dry CH2Cl2 (2 mL). The reaction was stirred at rt for 3 h. 
The solvent was removed, and after addition of CH2Cl2 (5 mL), the organic 
phase was washed with 0.1M NH4PF6 (2 x 5 mL). Next, the organic layer 
was dried over anhydrous Na2CO3, filtered and concentrated. Finally the 
crude was purified by column chromatography in silica gel (eluent: CH2Cl2/ 
CH3OH,  98:2) affording pure 20 as a colorless solid in a 83% yield. Mp: 
96-100 ºC. [α]20D: - 80.8 (c = 1, CH3CN, stand. dev.: 0.12). 1H NMR 
(CD2Cl2): δ 7.49-7.43 (m, 4H, ArH), 7.39-7.31 (m, 8H, ArH), 6.88 (d, J = 
9.4 Hz, 2H, ArH), 6.47 (bs, 1H, NH), 6.43 (bs, 1H, NH), 6.24 (bs, 1H, NH), 
6.00 (bs, 1H, NH), 4.32 (dd, J = 4.4, 10.2 Hz, 1H, CH2O), 4.17 (dd, J = 6.6, 
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10.5 Hz, CH2O), 3.82 (s, 3H, CH3O), 3.64-3.51 (m, 2H, CHα), 3.51-3.26 
(m, 7H, CHα, CH2γ), 3.24-3.12 (m, CHα, CH2γ), 3.11 (s, 3H, CH3O), 2.97-
2.84 (m, 3H, CHα, CH2S), 2.67-2.58 (m, 2H, CH2S ), 2.51-2.46 (m, 2H, 
CH2S), 2.22-2.10 (m, 2H, CH2β), 2.02-1.80 (m, 4H, CH2β), 1.74-1.65 (m, 
1H, CH2β). 13C NMR (CD2Cl2): δ 158.4 (CAr), 150.5, 150.0 (CGuan), 
144.7, 136.2 (CAr), 130.8, 129.5, 128.1, 127.0, 113.4 (CHAr), 69.9 (C), 
67.0 (CH2), 55.4 (CH3), 48.2, 47.9, 47.8 (CHα), 45.7, 45.5, 45.0, 44.9 
(CH2γ), 37.1 (CH3O), 36.4, 36.3, 36.0 (CH2S), 25.7, 25.6, 24.5, 22.0 
(CH2β). Exact Mass (ESI+) m/z [M + H - HPF6]+ calc.: 763.3134 uma, 
found: 763.3161 uma. 
 
L-Alloc-Ala-OH. 
N
H
O
HO
O
O
L-Alloc-Ala-OH
81%
NH3
O
O
H-Ala-OtBu*HCl
Cl
a) Allylchloroformate,
DiPEA
b) TES, TFA
 
To a stirred solution of H-Ala-OtBu*HCl (0.1 g, 0.55 mmol) and 
allylchloroformate (0.1 µL, 0.83 mmol) in dry CH2Cl2 (1.5 mL) at 0 ºC, 
DiPEA (0.29 µL, 1.7 mmol) was added dropwise. Stirring was continued 
for 4 h. Thereafter, reaction was quenched by washing the organic phase 
with 1M HCl solution (3 x 1.5 mL) and H2O (2 x 1.5 mL). Next, the 
organic phase was dried over anhydrous Na2SO4 and filtered over cotton. 
The solvent was removed by evaporation and the residue was dried prior to 
performing tert-butyl removal. Next, CH2Cl2 (11 mL) triethylsilane (TES) 
(0.14 g, 0.611 mmol) and TFA (30.5 mmol, 2.27 mL) were sequentially 
added to the residue. The reaction was stirred at rt for 5 h. Thereafter the 
solvent was evaporated and the remaining residue was dissolved in CH2Cl2 
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(2 mL) and extracted from the organic phase with distilled water (6 x 2 
mL). Finally the aqueous phase was evaporated and final oil was obtained 
with 81% overall yield. [α]20D: -27.1 (c = 1, CH3OH, stand. dev.: 0.3). 1H 
NMR (CH3OD): δ 5.93 (sex, J = 5.3 Hz, 1H, CH-Alloc), 5.32 (d, J = 19.3 
Hz, 1H, CH-Alloc), 5.20 (d, J = 11.04 Hz, 1H, CH-Alloc), 4.90 (bs, 1H, 
NH), 4.55 (d, J = 5.3 Hz, 2H, CH2-Alloc), 4.19 (q, J = 7.2 Hz, 1H, CHα), 
1.39 (d, J = 7.2 Hz, 3H, CH3). 13C NMR (CH3OD): δ 175.3, 157.1 (C), 
133.0 (CH), 116.3, 65.5 (CH2), 49.6 (CH), 16.7 (CH3). Exact Mass (ESI+): 
m/z [M + Na]+: calc.: 196.0586 uma, found: 196.0585 uma. 
 
(2R,8R)-2-tert-butyldiphenylsilanyloxymethyl-8-aminomethyl-
3,4,6,7,8,9,-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
hexafluorophosphate (91). 
 
 
To a solution of compound 54 (0.54 g, 0.82 mmol) in CH3OH (10 mL) 
was added a solution of 30% aq. ammonia (12 mL). The reaction was 
stirred at rt for 10 min, thereafter CH3OH/CH2Cl2 (1:1, 2 mL) was added in 
order to aid solubilization. After 40 min, the CH3OH was evaporated 
without heating the reaction. Next, the aqueous phase was extracted with 
CH2Cl2 (4 mL). The organic layer was further washed with 0.1M NH4PF6 
(2 x 4 mL) and finally dried with anhydrous Na2CO3, filtered and 
evaporated to dryness. The product 91 was obtained as colorless foaming 
oil with quant. yield. 1H NMR (CDCl3): δ 7.66-7.60 (m, 4H, 1H, ArH), 
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7.41-7.31 (m, 6H, ArH), 4.02 (bs, 2H, NH), 3.85-3.53 (m, 4H, CH2O, 
CHα), 3.28-3.02 (m, 6H, CH2N, CH2γ), 2.15-1.83 (m, 4H, CH2β), 1.05 (s, 
9H, C(CH3)3). 13C NMR (CH3OD): δ 150.6 (CGuan), 135.0 (CAr), 132.2, 
129.5, 127.9, 127.4 (CHAr), 64.9 (CH2O), 48.9 (CHα), 44.7 (CH2N), 44.2 
(CH2γ), 26.4 (C(CH3)3), 19.1 (C(CH3)3). ESI(+): m/z [M + H - HPF6]+: 
437.3 uma. 
 
(2R,8R)-2-tert-butyldiphenylsilanyloxymethyl-8- 
allyloxycarbonylaminomethyl-3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-
a]pyrimidin-1-ium hexafluorophosphate (90). 
 
 
To a solution of amine 91 (186 mg, 0.319 mmol) in dioxane/water 1:1 (4 
mL), cooled down to 0 ºC, was added NaHCO3 (67 mg, 0.799 mmol) and 
allylchloroformate (58 mg, 0.479 mmol). The reaction was stirred at rt for 2 
h. Next, the dioxane was evaporated and the product was extracted from 
water with EtOAc (5 mL) and the organic layer was further washed with 
0.1M NH4PF6 (2 x 5 mL). Next, the organic phase was dried with 
anhydrous Na2CO3, filtered and eliminated in vacuo. The crude compound 
was purified by silica flash chromatography (eluent: CH2Cl2/CH3OH, 
2:98→4:98) and 90 was obtained as a colorless solid in a 93% yield. Mp: 
86-89 ºC. 1H NMR (CDCl3): δ 7.63 (m, 4H, ArH), 7.62 (m, 6H, ArH), 6.24 
(s, 1H, NH), 6.08 (s, 1H, NH), 6.06-5.96 (sex, J = 5.2 Hz, 1H, CH-Alloc), 
5.37 (d, J = 17.2 Hz, 1H, CH-Alloc), 5.25 (d, J = 10.4 Hz, 1H, CH-Alloc), 
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4.54 (d, J = 5.2 Hz, 3.74-3.67 (m, 1H, CH2O), 3.62-3.50 (m, 3H, CH2O, 
CHα), 3.51-3.44 (m, 4H, CH2γ), 3.32 (d, J = 6.2 Hz, CH2NH2), 2.17-2.05 
(m, 2H, CH2β), 1.94-1.84 (m, 2H, CH2β), 1.04 C(CH3)3. ESI(+): m/z [M + 
H - HPF6]+: 521.7 uma. 
 
(2R,8R)-2-hydroxymethyl-8-allyloxycarbonylaminomethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium hexafluorophosphate 
(89). 
 
To a solution of compound 90 (0.87 g, 1.31 mmol) in THF (18 mL) 
cesium fluoride (CsF) (0.59 g, 3.92) was added, and the reaction was stirred 
at rt for 2 days. The solvent was evaporated and the residue dissolved in 
EtOAc (9 mL). Next, the organic layer was extracted with water (4 x 5 
mL). The aqueous phase was evaporated and the residue was dissolved in a 
mixture of CH3OH/CH2Cl2 (9:1). A precipitate was filtered and the filtrate 
was recovered and concentrated in vacuo. This procedure was repeated 
several times with increasing amount of CH2Cl2, until reaching 
CH3OH/CH2Cl2 (1:4). Solvent was evaporated to dryness and product 89 
was obtained with quantitative yield. 1H NMR (CH3OD): δ 6.07-5.97 (sex, 
J = 5.2 Hz, 1H, CH-Alloc), 5.39 (d, J = 17.2 Hz, 1H, CH-Alloc), 5.27 (d, J 
= 10.4 Hz, 1H, CH-Alloc), 4.56 (d, J = 5.2 Hz, 3.74-3.67 (m, 1H, CH2O), 
3.62-3.52 (m, 3H, CH2O, CHα), 3.51-3.44 (m, 4H, CH2γ), 3.32 (d, J = 6.2 
Hz, CH2NH2), 2.17-2.07 (m, 2H, CH2β), 1.94-1.84 (m, 2H, CH2β). 13C 
NMR (CH3OD): δ 156.3 (CO), 149.5 (CGuan), 131.5 (CH), 114.6, 63.7, 
62.1 (CH2), 48.8, 47.1 (CHα), 43.5, 43.2, 42.5 (CH2N, CH2γ), 21.5, 21.0 
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(CH2β). ESI(+): m/z [M + H - HF]+: 283.2 uma. 
 
(2R,8R)-2-carboxymethylsulfanylmethyl-8-
allyloxycarbonylaminomethyl-3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-
a]pyrimidin-1-ium chloride (20). 
N
H
N
N
H
AllocHN OH
N
H
N
N
H
AllocHN S
O
OH
a) MsCl, DIEA
b) NaSCH2CO2H, K
tBuO
Cl Cl
54%
2089
 
To a solution of compound 89 (0.4 g, 0.93 mmol) in dry CH2Cl2 (7 mL) 
and under inert atm, freshly distilled Et3N (0.39 mL, 2.8 mmol) was added. 
The suspension was cooled to 0 ºC and MsCl (0.22 mL, 2.8 mmol), 
previously dissolved in CH2Cl2 (1 mL), was added dropwise. The reaction 
was warmed to rt. After 0.5 h, dry THF (3 mL) was added and the reaction 
was stirred overnight. Thereafter the solvent was evaporated to dryness. 
Next, dry THF (20 mL) was added dropwise as well as a solution of sodium 
mercaptoacetic acid (363 mg, 3.08 mmol) and KtBuO (341 mg, 2.88 mmol) 
in CH3OH (10 mL). The resulting mixture was stirred at rt for 4 h. 
Thereafter the reaction was filtered and the filtrate was evaporated. Then, a 
solution of CH3OH/CH2Cl2 (9:1, 10 mL) was added, the precipitate was 
removed by filtration and the solvent evaporated under reduced pressure. 
This procedure was repeated several times increasing the amount of CH2Cl2 
in the solvent mixture until pure CH2Cl2 was employed. Finally, product 20 
was passed through a Cl-anion exchange column and was obtained as a 
colorless solid in a 54% yield. [α]20D -31.3º (c = 1, CH3OH, stand. dev.: 
0.31). Mp: 85-90 ºC. 1H NMR (CH3OD): δ 5.95-5.86 (sex, J = 5.2 Hz, 1H, 
Solid Phase Synthesis of bicyclic Guanidinium Oligomers 
 280 
CHAlloc), 5.32 (d, J = 17.3 Hz, 1H, CHAlloc), 5.20 (d, J = 10.0 Hz, 1H, 
CHAlloc), 4.56 (bs, 2H, CH2-Alloc), 3.67-3.60 ( m, 1H, CHα), 3.58-3.49 
(m, 1H, CHα), 3.46-3.37 (m, 4H, CH2γ), 3.35 (d, J = 4.1 Hz, 2H, CH2SCO), 
3.26 (d, J = 6.2 Hz, CH2NH2), 2.93 (dd, J = 5.3, 14.1 Hz, 1H, CH2S), 2.75 
(dd, J = 8.0, 14.1 Hz, 1H, CH2S), 2.21-2.14 (m, 1H, CH2β), 2.11-2.04 (m, 
1H, CH2β), 1.96-1.79 (m, 2H, CH2β). 13C NMR (CH3OD): δ 158.2 (CO), 
151.2 (CGuan), 132.8 (CH), 117.6, 66.0 (CH2), 51.5, 48.3 (CHα), 44.9, 
39.3, 36.8, 36.3 (CH2N, CH2γ, CH2S), 25.1 (CH2β). Exact Mass: m/z [M + 
H - HCl]+: calc.: 357.1597 uma, found: 357.1588 uma. 
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4.4.2 Solid phase synthesis  
 
General procedures.  
 
Initial swelling of resins. 
p-Methylbenzhydrylamine (MBHA): 
Table 3.8: Standard protocol for initial swelling of MBHA resin. 
Reagent Operation times min 
60% TFA in 
CH2Cl2 
swelling 2 1, 20 
CH2Cl2 washings 5 1 
5% DiPEA in 
CH2Cl2 
neutralization 3 3 
CH2Cl2 washings 5 1 
DMF washings 5 1 
 
Thiol 4 methoxytrityl resin:  
Treatments with DMF (3 × 1 min), CH2Cl2 (3 × 1 min), DMF (3 × 1 min). 
 
Synthesis. Reagent calculations were done following the scheme:  
Number of eq. x mmol of functional groups/g of resin x g of resin 
employed x MW (mg/mmol) (x density-1). Generally ~ 6 ml of solvent were 
used per gram of resin. Before reaction, resin was swelled in the solvent of 
the reaction, generally DMF. Fmoc deprotection was performed twice (1 x 
1 min, 1 x 15 min) using a 20% piperidine solution in DMF. Capping of 
amines was carried out using a standard capping reagent consisting in the 
mixture of acetic anhydride (5 eq.) and DiPEA (5 eq.) in CH2Cl2 (20 min). 
Mmt deprotection was performed employing a solution of DTT (8 eq.) in 
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DMF (3 x 20 min).  
On-bead analysis. The presence of primary amines was checked by the 
Kaiser test (ninhydrine test) (68). After reaction resin was washed: 3 x 1 
min with the reactions’s solvent, 3 x 1 min with CH2Cl2, 3 x 1 min with 
CH3OH, 3 x 1 min with CH2Cl2. The presence of free thiols was checked by 
the Ellman test (69) after DTT treatment to assure for disulfide reduction. A 
tiny amount of resin was introduced into a vial were it was irst treated fwith 
a solution of 0.5 % DTNB in DMF (150 µl) and then with some drops of 
DiPEA.. Subsequent orange coloration of the solution embedding the beads 
indicate the presence of free thiols, whereas no colour change indicates full 
nucleophilic functionalization of the thiols.  
Standard cleavage protocol. A minimum of 0.01 g of resin were cleaved 
in a syringe with a cold solution of 5% H2O in TFA at rt for 1h. The 
cleavage filtrate was recovered and the solution evaporated by applying 
nitrogen current.  
HPLC-ESI(+) analysis for compounds 57-61. the recovered filtrates were 
dried by applying nitrogen current. The samples were dissolved in 100 µL 
H2O, CH3CN or CH3OH, HPLC grade, depending on the solubility, and 
were analyzed by HPLC-ESI(+) with RP Symmetry column 3.9 x 150 X-
Terra C18 3.5 µm (4.6 x 100 mm); with as eluent CH3CN in H2O with 0.1 
% HCOOH; UV220, inj.: 5 µL; flow: 1 mL/min. The samples were injected 
into a Waters Alliance 2696 system. Flow proceeded from the column 
through a Waters 996 photodiode array (PDA) detector, which monitored 
wavelengths from 210 to 400 nm. From the PDA, the 1 mL/min flow was 
split using a flow splitter (0.5 mL/min each) to the Waters 2420 ELS 
detector (ELSD) and the electrospray Waters Micromass ZQ MS detector.  
HPLC analysis and purification for compounds 74-80, 88, and 92: the 
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recovered filtrates were dried by applying nitrogen current. The samples 
were dissolved in 100 µL CH3CN/CH3OH (1:1), HPLC grade, and analysed 
on RP-C18 column Symmetry300TM C18 5µm 4.6 x 150 mm, UV210-220, 5 µl 
inj., 1 ml/min flux, on HPLC: Agilent Technologies Serie 1200. 
Semipreparative-HPLC purification was performed on Waters HPLC 600 
equipment with a quaternary pump (0.01-20 mL/min). 
 
NHR-BAL-MBHA resin (R = Butylamine or 3-Methylbutylamine). 
 
 
To MBHA resin (0.5 g, 0.34 mmol) swollen in DMF (3 mL) was added a 
solution of BAL (0.182 g, 0.68 mmol), HOBt (0.105 mg, 0.68 mmol), 
DIPCDI (0.102 mL, 0.68 mmol) dissolved in the minimum amount of 
DMF. The syringe was placed on a shaker overnight at rt. The reaction was 
checked by ninhydrine test and aldehyde test (70). Next, the primary amine 
coupling was performed with Butylamine or 3-Methylbutylamine by adding 
to the resin, embedded in a solution of 1% AcOH in DMF, first the amine 
(1 mmol) and then NaCNBH3 (63 mg, 1 mmol). The reaction was shaken 
on an orbital shaker at rt for 4 h. Finally it was again checked by ninhydrine 
and aldehyde test. 
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(2R,8R)-2-hydroxymethyl-8-(3-
methylbutyl)amidomethylsulfanylmethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (57). 
 
To Methylbutylamine-BAL-MBHA (0.4 g, 0.27 mmol) resin swollen in 
DMF was added a solution of 15 (0.44 g , 0.81 mmol), HOBt ( 0.121 g, 
0.81 mmol) and DIPCDI (0.125, 0.81 mmol). The syringe was shaken for 2 
days at rt. After washes, the reaction was checked by ninhydrine test. 
Acetylation was performed to cap any remaining free amine groups with a 
solution of Ac2O (1.36 mmol) and DiPEA (1.36 mmol). The resin was 
washed and cleaved according to general procedure. Analytical HPLC was 
employed to detect product 57 in the cleavage crude: Conds: 0→100 % 
CH3CN in H20 with 0.1% HCOOH in 15 min, ESI (+) m/z [M + H - TFA]: 
343.2 uma. Compound 7 was not further purified.  
 
 
 
 
 
 
 
 
 
 
4.4 Experimental part  
 
 285 
(2R,8R)-2-benzylsulfanylmethyl-8-butylamidomethylsulfanylmethyl-
3,4,6,7,8,9-hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium 
trifluoroacetate (58). 
 
O
S
N
H
N
N
H
S
N
H
58
TFA
 
Coupling of 15, deprotection of OTBDPS and electrophilic activation was 
performed as described for compounds 57 and 58 on Butylamine-BAL-
MBHA resin (0.05 g, 0.034 mmol). Thereafter, in the minimum amount of 
DMF under inert atmosphere, was added a solution of benzylthiol (12 µL, 
0.102 mmol) and Cs2CO3 (39 mg, 0.102 mmol) in DMF (0.5 mL). The 
reaction was shaken at rt for 24 h on an orbital stirrer. After washes, 
standard cleavage was performed and the crude was analyzed by HPLC: 
0→100% CH3CN in H20 with 0.1% HCOOH in 15 min, ESI(+) m/z [M + H 
- TFA]+: 435.2 uma. Compound 58 was not further purified. 
 
(2R,8R)-2-methanesulfonyloxymethyl-8-
butylamidomethylsulfanylmethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (59). 
 
 
Coupling of 15 proceeds as described for compound 57 on Butylamine-
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BAL-MBHA resin (0.1 g, 0.068 mmol). Therafter the resin was embedded 
in THF (0.4 mL) to which were added 1M TBAF-THF (0.34 mL, 0.34 
mmol), the syringe was shaken at rt for 3 h. Next, a solution of MsCl (40.5 
µL, 0.53 mmol), DiPEA (115 µL, 0.7 mmol) and 4% DMAP (40 mg in 1 
mL dry THF) in THF:CH2Cl2 (2 mL) was added to the resin swollen in the 
minimum amount of THF. After washes, standard cleavage was performed 
and the cleavage crude was analyzed by HPLC: 0→100% CH3CN in H20 
with 0.1% HCOOH in 15 min, ESI(+) m/z [M + H - TFA]+: 407.2 uma. 
Compound 9 was not further purified. 
 
(2R,8R)-8-[(2R,8R)-8-hydroxymethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-2-ylmethylsulfanylmethyl-1-ium 
hexafluorophosphate]-2-butylamidomethylsulfanylmethyl-3,4,6,7,8,9-
hexahydro-2H-pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (60). 
 
 
Coupling of 15, deprotection of OTBDPS and electrophilic activation was 
performed as described for compound 59 on Butylamine-BAL-MBHA resin 
(0.05 g, 0.034 mmol). Next a solution of 16 (65.4 mg, 0.034 mmol) and 
Cs2CO3 (39 mg, 0.102 mmol) in DMF (0.5 mL), was added to the resin 
swollen in the minimum amount of DMF under inert atmosphere. The 
reaction was shaken at rt for 72 h. After washes, standard cleavage was 
performed and the cleavage crude was analyzed by HPLC; Conds: 
0→100% CH3CN in H20 with 0.1% HCOOH in 15 min; ESI(+) m/z [M + H 
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- TFA]+: 640.2 uma and  [M + H + HPF - 2TFA]+: 672.2 uma. Compound 
60 was not further purified.  
 
Tri(bicyclic guanidinium) oligomer 61. 
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Coupling of 15 was performed as described for compound 57 on 
Butylamine-BAL-MBHA resin (0.05 g, 0.034 mmol). Removal of 
OTBDPS, electrophilic activation and BB 16 coupling protocols, according 
to compound 60, were repeated twice. After washes, standard cleavage was 
performed and the crude was analyzed by HPLC; Conds: 0→100% CH3CN 
in H20 with 0.1% HCOOH in 15 min; ESI(+) m/z [M + H - TFA]+: 838.4 
uma. Compound 61 was not further purified. 
 
(2R,8R)-2-benzoylthiomethyl-8-sulfhydril-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (74) 
 
 
Swelled Thiol 4-methoxytrityl resin (0.06 g, 0.11 mmol) was embedded 
in the minimum amount of DMF and a solution with Cs2CO3 (106 mg, 0.33 
mmol) and BB 17 (180 mg, 0.33 mmol) in DMF (1 mL) was added. The 
syringe was shaken on an orbital stirrer at rt for 24 h. Next, the resin was 
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washed and cleaved with a solution of 8% TFA and 5% Triisopropylsilane 
(TIS) in CH2Cl2 (1 mL). Next, the cleavage crude was analyzed on HPLC 
(Conds: 0→100 % CH3CN in H20 with 0.1% HCOOH in 15 min, UV214) 
and the final compound was identified by LC-MS. The product 74 was not 
further purified. ESI(+) m/z [M + H - TFA]+: 336.12 uma. 
 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin. 
 
Prior to coupling, MBHA resin (1 g, 0.68 mmol) was washed with DMF 
(5 x 1 min). Thereafter Rink amine linker was anchored by adding a 
solution of Rink amine (1.1 g, 2.04 mmol), HOBt (304.2 mg, 2.04 mmol) 
and DIPCDI (314 µl, 2.04 mmol) dissolved in DMF (6 mL) to a syringe 
placed on a shaker at rt for 18 h. After washes, anchored Fmoc group was 
deprotected. Next, amino acid Fmoc-Cys(Mmt)-OH (1.26 g, 2.04 mmol) 
was coupled under the same conditions. 
On 0.1 g of resin (0.068 mmol), additional Fmoc deprotection, acetylation 
and cleavage in 100% TFA at rt for 1h, were performed. After evaporating 
and drying in vacuo, loading of the resin was approximated to 80% (0.054 
mmol). 
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(R)-2-acetamido-3-(benzylthio)propanamide (75). 
 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.04 g, 0.027 mmol) was 
deprotected and capped at its α amine group. Next, SMmt was removed, 
followed by treatment with DTT. Prior to coupling, the resin was washed 
under inert atmosphere with dry DMF (3 x 1 min). Thereafter a solution of 
Et3N (12 µl, 0.027 mmol) and BnBr (16 µl, 0.027 mmol) in dry DMF was 
added, and the syringe was placed on a shaker for 3 h at rt. Thereafter the 
resin was cleaved (TFA 100%, rt, 1 h). The cleaved product 75 was 
analyzed by anal HPLC (5→95% CH3CN in H2O, 0.1% TFA, in 15 min, 
UV220) and obtained as a colorless oil without further purification in a 65% 
yield. 1H NMR (CH3OD): δ 7.39-7.29 (m, 4H, CHAr), 7.27-7.20 (m, 1H, 
CHAr), 4.67 (t, 1H, CHα), 3.8 (m, 2H, CH2Bn), 2.87 (dd, J = 5.8,13.8 Hz 
1H, CH2S), 2.67 (dd, J = 8.2, 13.8 Hz, 2H, CH2S), 2.03 (s, 3H, CH3O), 
1.81-1.71 (m, 2H, CH2β). ESI(+) m/z [M + H]+: 253.1 uma. 
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(2R,8R)-2-(4-methoxyphenyldiphenylmethylthiomethyl)-8-(1-
acetamido-1-carboxamidoethylsulfanylmethyl)-3,4,6,7,8,9-hexahydro-
2H-pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (76).  
 
 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.05 g, 0.034 mmol) was 
deprotected and capped at its α amino terminus. Next, SMmt was 
deprotected, followed by treatment with DTT. Prior to nucleophilic 
coupling, the resin was washed under inert atm with dry DMF (3 x 1 min). 
Next, a solution of KtBuO (11 mg, 0.102) and BB 18 (72 mg, 0.102 mmol) 
in dry DMF (0.4 mL) was added, and the syringe was placed at rt on a 
shaker for 3 h. Thereafter washes and DTT treatment were performed. 
Capping of the resin were carried out following the same nucleophilic 
coupling conditions of BnBr, described for compound 75. Finally, 100% 
TFA cleavage afforded a crude compound which was analyzed by anal. 
HPLC (5→95% CH3CN in H2O with 0.1% TFA in 15 min, UV220) and 76 
was obtained as colorless oil without further purification in a 41% yield. 1H 
NMR (CH3OD): δ 7.43-7.39 (m, 4H, ArH), 7.32-7.2 (m, 8H, ArH), 6.87-
6.84 (d, J = 8.9 Hz, 2H, ArH), 4.55-4.51 (s, 1H, CHα), 3.8 (s, 3H, CH3O), 
3.54-3.47 (m, 1H, CH2α), 3.45-3.37 (m, 2H, CH2γ), 3.20-3.10 (m, 1H, 
CH2S), 3.06-2.96 (m, 2H, CH2S, CH2γ), 2.94-2.85 (m, 3H, CH2S, CH2γ, 
CH2α), 2.76-2.69 (m, 2H, CH2S), 2.59-2.49 (m, 1H, CH2S), 2.21-2.14 (m, 
1H, CH2β), 2.02 (s, 3H, CH3CONH), 2.02-1.94 (m, 1H, CH2β), 1.92-1.83 
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(m, 1H, CH2β), 1.79-1.69 (m, 1H, CH2β). ESI(+): m/z [M + H - TFA]+: 
632.2 uma. 
 
(2R,8R)-2-benzylsulfanylmethyl-8-(1-acetamido-1-
carboxamidoethylsulfanylmethyl)-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (81). 
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Synthesis of compound 81 was performed as for product 76 starting from 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.05 g, 0.034 mmol). Before 
final cleavage additional SMmt deprotection and BnBr capping were 
performed. Finally, 100% TFA cleavage afforded a crude compound which 
was analyzed by anal. HPLC (Conds: 5-95% CH3CN in H2O with 0.1% 
TFA in 20 min, UV210). Further semipreparative purification (20→90% 
CH3CN in H2O with 0.1% TFA in 17 min, UV210) yielded pure product 81 
as colorless oil in a 33% yield. 1H NMR (CD3CN): δ 7.39-7.34 (m, 4H, 
ArH), 7.33-7.28 (m, 1H, ArH), 7.14 (bs, 1H, NH), 7.11 (bs, 1H, NH), 7.03 
(bs, 1H, NH), 6.68 (bs, 1H, NH), 6.08 (bs, 1H, NH), 3.80 (s, 2H, SCH2Ph), 
3.54-3.47 (m, 1H, CHα), 3.46-3.38 (m, 1H, CHα), 3.37-3.27 (m, 4H, CH2γ), 
3.08-2.98 (m, 2H, CH2S ), 2.76-2.68 (m, 2H, CH2S), 2.58-2.51 (m, 2H, 
CH2S), 2.12-2.04 (m, 2H, CH2β), 2.03 (s, 3H, CH3O), 1.81-1.71 (m, 2H, 
CH2β). 13C NMR (CD3CN): δ 150.86 (CGuan), 138.4 (CAr), 128.9, 128.6, 
127.2 (CHAr), 48.5, 47.6, 45.5 (CHα), 45.0 (CH2γ), 37.1, 35.9 (CH2S), 25.8 
(CH2β), 25.4 (CH3). Exact Mass (ESI+): m/z [M + H - TFA]+: calc.: 
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450.1997 uma, found: 450.1993 uma. 
 
(2R,8R)-8-[(2R,8R)-8-benzylsulfanylmethyl-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-2-ylmethylsulfanylmethyl-1-ium 
hexafluorophosphate]-2-(1-acetamido-1-
carboxamidoethylsulfanylmethyl)-3,4,6,7,8,9-hexahydro-2H-
pyrimido[1,2-a]pyrimidin-1-ium trifluoroacetate (82). 
 
 
The same procedure as for product 81 was carried out starting from 0.08 g 
of Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.08 g, 0.054), repeating the 
steps between the first Mmt deprotection and capping twice with BnBr. 
100% TFA cleavage afforded a crude compound which was analyzed by 
anal. HPLC (Conds: 20→40% CH3CN in H2O with 0.1% TFA in 17 min, 
UV210). Further semipreparative purification under the same conditions 
yielded pure product 82 as colorless oil in a 21% yield. 1H NMR (CH3OD): 
δ 7.44-7.36 (m, 4H, ArH), 7.36-7.29 (m, 1H, ArH), 4.64-4.60 (q, J = 5.3 
Hz, 1H, CHα), 3.87 (s, 2H, SCH2Ph), 3.71-3.61 (m, 3H, CHα), 3.58-3.37 
(m, 1H, CHα, CH2γ), 3.12 (dd, J = 5.3, 14.0 Hz, 1H, CH2S), 3.00-2.92 (m, 
3H, CH2S),  2.85 (dd, 1H, J = 8.9, 14.0 Hz, CH2S), 2.80-2.71 (m, 4H, 
CH2S), 2.64 (dd, J = 7.5, 13.8 Hz, 1H, CH2S), 2.28-2.17 (m, 2H, CH2β), 
2.10 (s, 3H, CH3O), 1.99-1.85 (m, 2H, CH2β). 13C NMR (CD3CN): δ 150.8 
(CGuan), 138.2 (CAr), 128.7, 128.3, 126.9 (CHAr), 52.8, 47.9, 47.7, 47.6, 
45.1 (CHα), 45.0, 44.9 (CH2γ), 36.4, 36.1, 35.6, 34.0, 30.7, 30.6 (CH2S), 
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25.3, 26.2 (CH2β), 21.2 (CH3). Exact Mass (ESI+): m/z [M + H - TFA]+: 
calc.: 647.2984 uma, found: 647.2984 uma. 
 
Tetra(bicyclic guanidinium) oligomer 83. 
 
 
The same procedure as for product 81 was followed starting from 
Fmoc-Cys(Mmt)-Rink-amide-MBHA (0.08 g, 0.054 mmol), repeating 
four times the steps between the first Mmt deprotection and capping with 
BnBr. 100% TFA cleavage afforded a crude compound which was 
analyzed by anal. HPLC (Conds: 20→50% CH3CN in H2O with 0.1% 
TFA in 17 min, UV210). Further semipreparative purification (Conds: 25% 
CH3CN in H2O with 0.1% TFA for 17 min, then in 3 min from 25→28%, 
UV210) yielded pure product 83 as colorless oil in a 12% yield. 1H NMR 
(CH3OD): δ 7.46-7.36 (m, 4H, CHAr), 7.35-7.30 (m, 1H, CHAr), 4.65-
4.59 (m, 1H, CHα), 3.76-3.60 (m, 8H, CHα), 3.58-3.42 (m, 16H, CHγ), 
3.12 (dd, J = 5.3, 14.0 Hz, 2H, SCH2Ph), 3.01-2.90 (m, 7H, CH2S), 2.87-
2.70 (m, 9H, CH2S), 2.63 (dd, J = 7.7, 13.7 Hz, 2H, CH2S), 2.29-2.18 (m, 
8H, CH2β), 2.11 (s, 3H, CH3O), 2.04-1.89 (m, 8H, CH2β). Exact Mass 
(ESI+): m/z [M + Na]+: calc.: 1519.4492 uma, found: 1519.4525 uma. 
 
 
Solid Phase Synthesis of bicyclic Guanidinium Oligomers 
 294 
Hexa(bicyclic guanidinium) oligomer 87. 
 
 
The same procedure as for compound 81 was repeated with 0,04 g Fmoc-
Cys(Mmt)-Rink-amide-MBHA starting resin (0.04 g, 0.027 mmol), until 
incorporating four times BB 1 and capping with BnBr. Next, BB 19 was 
anchored after DTT treatment, under the same coupling conditions 
described before. After 100% TFA cleavage, the crude compound 87 was 
analyzed by anal. HPLC (Conds: 20→45% CH3CN in H2O with 0.1% TFA 
in 17 min, UV210) and ESI(+). The product 87 was identified among several 
oligomer precursors (see Fig. 3.45, Fig. A3.2), but not further purified. 
ESI(+) m/z [M + 2H - 2TFA]2+: 946.3 uma. 
 
Compound 88. 
 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.035 g, 0.024 mmol) was 
deprotected at its amino terminus and coupling of L-Alloc-Ala-OH was 
performed as described earlier for Rink amine to MBHA resin. Next, the 
SMmt was removed, BB 18 anchored through nucleophilic substitution and 
the thiol end capped with BnBr, following protocols described before. 
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Finally, crude compound 88 was analyzed by anal. HPLC (20→50% 
CH3CN in H2O with 0.1% TFA in 17 min, UV210) and further purified by 
semi preparative HPLC (Conds: 20→50% CH3CN in H2O with 0.1% TFA 
in 15 min, 50-95% in 4 min, UV210), although yield could not calculated, as 
a not enough amount of final compound was recovered. 1H NMR (CH3OD): 
δ  7.46-7.23 (m, 5H, CHArS), 6.01-5.89 (m, 1H, CH-Allyl), 5.33 (d, J = 
17.5 Hz, 1H, CH
-
Allyl), 5.21 (d, J = 11.7 Hz, CH-Allyl), 3.81 (s, 2H, 
SCH2Ph), 3.59-3.36 (m, 6H, CH2α, CH2γ), 3.25-3.06 (m, 1H, CH2S), 3.01-
2.94 (m, 2H, CH2S), 2.87-2.80 (m, 1H, CH2S),  2.73-2.68 (m, 1H, CH2S), 
2.63-2.53 (m, 1H, CH2S), 2.23-2.08 (m, 2H, CH2β), 1.90-1.77 (m, 2H, 
CH2β), 1.38 (d, J = 7.0 Hz, 3H, CH3-Ala). Exact Mass (ESI+): m/z [M + H - 
TFA]+ calc.: 563.2474 uma, found: 563.2477 uma. 
 
Compound 92. 
 
 
Fmoc-Cys(Mmt)-Rink-amide-MBHA resin (0.035 g, 0.024 mmol) was 
deprotected at its amino terminus. Next, a solution of BB 20 (36 mg, 
0.072 mmol), HOBt (11 mg, 0.072 mmol) and DIPCDI (11 µL, 0.072 
mmol) dissolved in DMF (0.4 mL) was added to the resin and the syringe 
was shaken at rt for 18 h. Alloc deprotection was performed as reported 
(70), with treatments of 0.05 eq. of Pd(P(Ph)3)4 and 5 eq. of PhSiH3 under 
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inert atm (3 x 15 min) at rt. Thereafter the free primary amine was 
acetylated. Before final cleavage the thiol group (SMmt) was deprotected 
and capped with BnBr as described before. The crude compound 92 was 
analyzed by HPLC (5→60% CH3CN in H2O with 0.1 % TFA in 17 min, 
60→95% in 3 min, UV210) and further purified by semipreparative HPLC 
(15→30% CH3CN in H2O with 0.1 % TFA in 20 min, UV210), but yield 
could not be calculated as a very tiny amount of product was recovered. 
Exact Mass (ESI+) m/z [M + H - TFA]+ calc.: 507.2212 uma, found: 
507.2216 uma.
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Fig. A4.1: a) HPLC profile of pure compound 75: 5-95% 
CH3CN in H2O with 0,1% TFA in 17 min, UV220, 5µL, 1 
mL/min and b) 1H-NMR spectrum in CH3OD. 
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Fig. A4.2: a) HPLC profile of pure compound 81: 5-95% 
CH3CN in H2O with 0,1% TFA in 15 min, UV210, 5µL, 1 
mL/min and b) 1H-NMR spectrum in CD3CN. 
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Fig. A4.3: a) HPLC profile of pure compound 82: 20-60% 
CH3CN in H2O with 0,1% TFA in 15 min, UV210, 5 µL, 1 
ml/min;  b) 1H-NMR spectrum in CH3OD. 
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Fig. A4.4: a) HPLC profile of pure compound 83: 20-50% 
CH3CN in H2O with 0,1% TFA in 17 min, UV210, 5µL, 1 
mL/min and b) 1H-NMR spectrum in CH3OD. 
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Fig. A4.5: ESI(+)-MS of crude compound 18 recovered 
by filtration from coupling reaction. 
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Fig. A4.6: ESI(+)-MS of crude compound 87; 761.2 uma: [82 + H - 
TFA]+, 845.3 uma: [Triguanidinium oligomer + H - 3TFA]+, 946.3: [87 
+ 2H - 2TFA]2+, 1072.3: [Triguanidinium oligomer + H - TFA]+, 
1383.4: [83 + H - TFA]+. 
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Fig. A4.7: HPLC profile of pure compound 88 (20-50% CH3CN 
in H2O with 0.1% TFA in 17 min, UV210, 5 µL, 1 mL/min). 
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Fig. A4.8: HPLC profile of pure compound 92 (20-50% CH3CN 
in H2O with 0.1% TFA in 17 min, UV210, 5µL, 1 mL/min) 
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Summary 
 
This thesis deals with the combination of preorganized scaffolds and 
guanidnium-based recognition elements to give rise on one hand to specific 
protein surface ligands and on the other to transfection agents. 
 
In Chapter 1 we introduce the concepts of non covalent biomolecular 
recognition and multivalency, both at the basis of biological surface 
interactions. Supramolecular chemistry, which deals with the self-assembly 
and recognition of molecules via non covalent interactions, contributes to 
the understanding and mimicry of these biological events. Preorganized 
multivalent scaffolds, grafted with recognition elements, such as guanidine, 
are paving new ways for biomolecular recognition and drug discovery (1).  
Moreover, we describe in this first Chapter the specific objectives of the 
thesis as well as the main compounds employed. 
 
Chapter 2 deals with the recognition of the surface of protein p53. P53 is 
an oligomeric transcription factor, of crucial role for cell cycle and genomic 
integrity. Its activity is dependent on its tetrameric state, therefore 
association-deffective mutants of its tetramerization domain (p53TD) 
constitute valuable therapeutic targets. Designed calix[4]arene ligands 1a 
and 1b, described in Chapter 2, both bind p53TD and stabilize its naturally 
occuring mutant p53R337H, as assessed by biophysical techniques. The 
association takes place, as predicted by molecular dynamics simulations, 
via hydrophobic and guanidinium-oxoanion interactions (2). Differences in 
the affinity constants between compounds 1a and 1b rely on their overall 
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distinct flexibility: Higher flexibility, both in the protein and in the ligand, 
afford in this case for enhanced association (3).  
 
Chapter 3 provides a general introduction to the function, the structure as 
well as to the pharmacological interest of K+ channels. Thereafter, the 
synthesis of a series of calix[4]arene ligands as potential blockers of the 
voltage dependent Kv1 family, is described. Binding according to a conical 
C4 symmetry design is predicted by molecular modeling and the effects on 
channel function are assessed. Non toxic, reversible inhibition is observed 
for compounds 3, 6 and 11, tetraacylguanidinium or tetraarginine members 
of the series with small lower rim O-substituents. Moreover, 
electrophysiological evaluation of their binding mode is in keeping with 
expectations for docking in the central pore and interaction with the pore 
domain “turret” (4). 
 
Molecular and drug transporters across cell membranes are most often 
functionalized with guanidinium groups as these polycations have shown to 
be crucial for interaction with phosphate and other anionic moieties on the 
liposomal cell surface. In Chapter 4 we present a family of molecular 
transporters that internalize into mitochondria, based on thioether-bound 
bicyclic guanidinium subunits (5). For the purpose of preparing a series of 
these oligomers, several synthetic strategies on solid support are described. 
The best approach is based on Merrifield-like peptide synthesis: A 
difunctionalized bicyclic guanidinium synthon, compound 18, bearing both 
electrophile (OMs) and protected nucleophile (SMmt) groups, is repeatedly 
grafted via nucleophilic substitution. The sequence requires removal of 
methoxytrityl, reduction with 1,4-dithiothreitol, as well as coupling and 
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capping with benzyl bromide. Moreover, a bicyclic guanidinium monomer 
containing an amino group and a carboxylic acid function is evaluated as an 
alternative building block for novel amide-bridged strands (6).  
 
1.  Martos V, Castreño P, Valero J, de Mendoza J (2008) Binding to protein surfaces by 
supramolecular multivalent scaffolds. Curr Op Chem Biol 12:698-706. 
 
2.  Gordo S, Martos V, Santos E, Menéndez M, Bo C, Giralt E, de Mendoza J (2008) 
Stability and structural recovery of the tetramerization domain of p53-R337H mutant 
induced by a designed templating ligand. Proc Natl Acad Sci USA 105:16426-16431.  
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Las interacciones no covalentes entre superficies de macromoléculas 
biológicas constituyen la base de numerosos mecanismos celulares 
esenciales, como el reconocimiento, la internalización y la señalización 
celular. El desarrollo de moléculas capaces de simular o inhibir dichas 
interacciones constituye un reto, dadas las características de las superficies 
de unión implicadas, que carecen de una topología característica, y por otra 
parte son extensas, planas y discontinuas, además de flexibles y dinámicas 
(1). Otra característica que dificulta el diseño de ligandos pequeños con 
fines terapéuticos, es la solvatación de las superficies, expuestas al medio 
acuoso, ya que las moléculas de agua compiten por muchas de las 
interacciones no covalentes de naturaleza polar (2).  
La química supramolecular es la química de las interacciones débiles y 
estudia el reconocimiento entre moléculas mediante interacciones no 
covalentes generando sistemas de mayor estabilidad y complejidad. Por 
ello, con frecuencia los químicos supramoleculares se inspiran en la 
naturaleza para diseñar sistemas capaces de establecer asociaciones 
reversibles y al mismo tiempo fuertes y específicas, incluso en disolventes 
tan polares como el agua (3). En este sentido, el fenómeno de la 
multivalencia, ampliamente representado en la naturaleza, ha inspirado un 
gran número de sistemas basados en esqueletos preorganizados (como 
porfirinas, calix[4]arenos, dendrímeros, rotaxanos etc.), dotados de 
múltiples elementos de reconocimiento, cuyas interacciones son débiles 
consideradas de forma aislada pero que en su conjunto proporcionan 
afinidad y especificad de unión (4).  
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La naturaleza emplea frecuentemente el grupo funcional guanidina, como 
por ejemplo el presente en la cadena lateral del aminoácido arginina, porque 
permite establecer pares iónicos fuertes con grupos carboxilato, fosfato o 
sulfato presentes en los sistemas biológicos (5). De esa forma, la 
combinación de esqueletos semirígidos o preorganizados con elementos de 
reconocimiento con estructura de guanidina ha permitido el desarrollo de 
numerosos receptores de biomoléculas (6), así como de transportadores 
moleculares (7).  
En esta memoria se describen, por un lado, el diseño, la síntesis y la 
evaluación de ligandos con estructura de calix[4]areno dotados de grupos 
funcionales guanidinio para el reconocimiento de superficies proteicas 
específicas y, por otro, el desarrollo de estrategias de síntesis en fase sólida 
para la obtención de vectores celulares basados en oligómeros de guanidina 
bicíclica. 
 
 
La proteína p53 es un factor de transcripción, a veces denominado 
“guardián del genoma”, por su papel crucial en el ciclo celular y en la 
integridad genómica. Cuando el ADN se ve dañado, p53 interrumpe el ciclo 
celular y simultáneamente induce la expresión de la maquinaria de 
reparación del ADN. Si el daño es irreversible, la misma proteína 
desencadena el proceso de apoptosis. Estructuralmente, es un 
homotetrámero que da lugar a varios dominios de regulación, de unión a 
ADN y de tetramerización, y se encuentra mutado en aproximadamente un 
50% de cánceres humanos (8). Aunque la mayoría de las mutaciones 
afectan al dominio de unión a ADN, unas pocas se producen en el dominio 
de tetramerización. Es el caso de la mutación p53R337H que desestabiliza 
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el tetrámero y en consecuencia aumenta la probabilidad de aparición de 
tumores en el organismo (9). 
En el capítulo 2 describimos el diseño racional, la síntesis y el estudio de 
dos ligandos 1a y 1b concebidos para mantener unidos los cuatro 
monómeros de la proteína mutada p53-R337H y recuperar así la integridad 
tetramérica de la proteína nativa. 
Ambos ligandos están basados en un esqueleto de calix[4]areno cónico, 
dotado de cuatro grupos catiónicos metilguanidinio en el borde más ancho y 
de cadenas hidrofóbicas en el cerco inferior (propilos en el caso de 1a y 
puentes de dietilenglicol en el caso de 1b). Del estudio realizado se han 
extraido las siguientes conclusiones (10, 11): 
 
 La estructura de los complejos formados por la asociación entre 
los ligandos 1a y 1b y los tetrámeros de la proteína p53 nativa y el 
mutante p53R337H se predijo correctamente por dinámica molecular y 
se confirmó mediante técnicas biofísicas (CD, DSC, NMR, MS-ESI(+)).  
 Las interacciones hidrofóbicas juegan un papel esencial en dichos 
complejos, si bien las interacciones guanidino-carboxilato, contribuyen 
a fortalecerlos. 
 Ambos ligandos 1a y 1b estabilizan y se asocian de manera 
cooperativa al tetrámero mutado p53R337H, además de ser más afines a 
éste que al tetrámero nativo. 
 El ligando 1a establece asociaciones más fuertes con ambos 
tetrámeros que su análogo 1b, además de causar una ligera distorsión en 
la estructura tetramérica original.  
 La flexibilidad, tanto de la biomolécula como del ligando, 
contribuye en este caso a una mejor adaptación y en consecuencia a una 
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mayor fortaleza de la asociación.  
 El estudio pone de relieve y demuestra que una deficiencia 
estructural que impide la oligomerización de determinadas proteínas, 
como p53R337H, puede corregirse mediante una pequeña molécula 
que, al fijarse sobre la superficie proteica, actúa a modo de molde 
(chaperón) molecular, restituyendo su estructura nativa.  
 
 
Los canales de potasio constituyen los canales iónicos más difundidos y 
están presentes en prácticamente todas las células eucariotas y procariotas. 
Conducen cationes potasio de forma selectiva a través de la membrana 
celular y controlan procesos esenciales como la excitabilidad, la 
homeostasis y la secreción (12). La relación estructura atómica-función de 
dichos canales fue elucidada por R. McKinnon, que fue galardonado en el 
año 2003 con el premio Nobel de química por dicho descubrimiento. Dado 
que las deficiencias en los canales de K+ causan múltiples patologías, éstos 
constituyen importantes objetivos farmacológicos, sobre todo los 
correspondientes a la familia de canales dependientes de voltaje Kv1 (13). 
En el capítulo 3 de la presente memoria describimos el diseño y la síntesis 
de una serie de ligandos de calix[4]areno (3-14), y su evaluación como 
bloqueantes de canales Kv1, a los que se unen sobre la entrada del poro. Las 
conclusiones de este estudio fueron (14): 
 
 La estrategia sintética empleada permite una fácil variación de los 
sustituyentes del cerco superior y da acceso a una amplia gama de 
potenciales ligandos, con diversa funcionalización. 
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 El diseño de unión a los dominios del poro extracelulares, según una 
simetría cuaternaria cónica, se ha confirmado a nivel teórico mediante 
cálculos de dinámica molecular. 
 La funcionalidad celular se valoró por métodos electrofisiológicos 
(two electrode voltage clamp y voltage clamp fluorometry) in vitro 
sobre oocitos de Xenopus laevis, lo que permitió demostrar una 
inhibición no tóxica y reversible para los compuestos 3, 6 y 11, 
funcionalizados con grupos tetraacilguanidinio o tetraarginina en su 
cerco superior y O-sustituyentes cortos en su cerco inferior. 
 Las constantes de asociación aparentes para el ligando 6 se 
encuentran en un rango micromolar bajo y muestran coeficientes de Hill 
de 1, consistentes con un único sitio de unión.  
 La disminución de corriente inducida por 6 se ve acompañada de un 
desplazamiento, dependiente del voltaje, hacia voltajes más positivos de 
la apertura de los canales.  
 Asímismo se observa una ralentización tanto en el movimiento del 
dominio sensor de voltaje (S4), como en la velocidad de apertura de los 
canales, inducida por la unión de 6.  
 Ambas conclusiones indican que la unión de 6 con Kv1 implica una 
interacción con el dominio turret de Kv1, que se transmite al dominio 
S4, modificando así la cinética de apertura del canal, así como su 
respuesta a los cambios de voltaje. 
 Los calix[4]arenos funcionalizados con grupos guanidinio 
constituyen por tanto un punto de partida para el desarrollo de ligandos 
reversibles, no tóxicos, específicos y afines a distintos canales de Kv1+.  
 
 
 320 
La eficacia terapéutica de un fármaco depende de su capacidad para llegar 
a su diana en tejidos, células u orgánulos. Sin embargo, una de las 
principales limitaciones actuales en el desarrollo de fármacos eficaces con 
estructuras químicas polares sigue siendo el traspasar la barrera constituída 
por las membranas celulares. Por ello, la unión de los fármacos a 
determinados compuestos que ayuden a franquear dichas barreras, y 
denominados por ello con frecuencia caballos de Troya, supone un 
importante avance al respecto. Los transportadores moleculares están 
dotados generalmente de grupos guanidinio porque dichas moléculas 
policatiónicas interaccionan fácilmente con los grupos fosfato y demás 
oxoaniones de la superficie celular (7). 
En nuestro grupo de investigación se describió recientemente una nueva 
familia de transportadores guanidínicos basados en oligómeros de 
guanidina bicíclica unidos mediante enlaces de tipo tioéter (15, 16). La 
necesidad de establecer estudios sistemáticos de estructura-función ha 
motivado el desarrollo de estrategias sintéticas en fase sólida, es decir 
resinas de poliestireno convencionales.  
Las estrategias sintéticas descritas a lo largo del capítulo 4 parten de 
diferentes sintones de subunidades de guanidina bicíclica (15-20), los 
cuales condicionan el uso de resinas poliméricas y reacciones diferentes. El 
desarrollo de estas estrategias ha permitido llegar a las conclusiones 
siguientes (17): 
 
 La formación de puentes disulfuro durante la reacción de 
acoplamiento, así como la baja reactividad del anión tiolato creado in 
situ, dificultan la síntesis de oligómeros sobre la resina NHR-BAL-
MBHA a partir de los sintones 15 y 16. 
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 El empleo de subunidades de guanidina bicíclica dotadas, en uno de 
sus brazos, de buenos grupos salientes y en el otro de un nucleófilo de 
tipo tiol, covenientemente enmascarado, como los compuestos 17, 18 y 
19, constituyen el sintón ideal ya que reducen la secuencia sintética de 
cada ciclo de introducción de guanidina a dos reacciones acoplamiento 
y desprotección. 
 La formación de puentes disulfuro durante la reacción de 
acoplamiento entre grupos tiol de la propia resina impide el 
acoplamiento eficaz de subunidades de guanidina bicíclica 17, 
probablemente debido a la alta funcionalización inicial de la resina 
empleada (4-metoxitritiltiol). 
 La combinación del sintón 18 y el soporte basado en la resina Cys-
Rinkamide-MBHA, permite la introducción iterativa del sintón 18 con 
un rendimiento de aprox. 80% para cada acoplamiento.  
 La neutralización de los grupos tiol sin reaccionar con bromuro de 
bencilo y los tratamientos reductores previos a las reacciones de 
acoplamiento, mejoran el rendimiento de los compuestos finales y 
facilitan la purificación final. 
 El empleo del grupo alloc como protector semipermanente permite 
el anclaje en esta secuencia sintética de moléculas o fármacos en 
cualquier momento de la síntesis del oligómero. 
 El sintón 20 puede emplearse como un sucedáneo de un amino 
ácido en una síntesis convencional de péptidos modificados y abre la 
puerta a nuevos oligómeros de guanidina bicíclica unidos por enlaces 
amida.  
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